Microbial aggregates used to treat vaginal disorders

By combining lactobacillus isolates with different functions and genomic characteristics, such as Lactobacillus janniae and Lactobacillus curvature, the problem of vaginal microbiota imbalance was solved, achieving effective implantation in the female urogenital tract and restoration of microbiota balance, reducing vaginal inflammation and infection.

CN123124982APending Publication Date: 2026-11-17FREYA BIOSCIENCES LTD
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
CN202480084767.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-15
Filing Date
2024-11-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively identify and utilize specific bacteria and bacterial colonies that can colonize the human female urogenital tract, and cannot effectively solve the problems of inflammation and infection caused by vaginal microbiota imbalance.

Method used

A microbial conglomerate is provided, comprising lactobacillus isolates with different functions and genomic characteristics, such as Lactobacillus janniae and Lactobacillus curvature. By combining these isolates to adapt to the vaginal environment of different subjects, the implantation effect is enhanced, and the use of antibiotic pretreatment is avoided.

Benefits of technology

Successfully implanted into the urogenital tracts of different subjects, it restores or maintains the balance of vaginal flora, reduces or eliminates symptoms of vaginal inflammation and infection, such as bacterial vaginosis, without relying on antibiotic pretreatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124982A_ABST
    Figure CN123124982A_ABST
Patent Text Reader

Abstract

Compositions comprising defined populations of isolated lactobacilli are provided, said defined populations being configured to facilitate implantation into the female urogenital tract of a subject. Methods for applying the microbial confluents to the urogenital tract of a subject are also provided herein.
Need to check novelty before this filing date? Find Prior Art

Description

Related applications

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 599,555, filed November 15, 2023, entitled “Vaginal Bacterial Composition,” pursuant to 35 USC §119(e), the contents of which are incorporated herein by reference.

[0002] Reference to the electronic sequence list The contents of the electronic serial number (F089570001WO00-SEQ-GJM.xml; size: 42,018 bytes; creation date: November 15, 2024) are incorporated herein by reference in their entirety. Background Technology

[0003] The vagina is a fibromuscular tubular passage within the female body that connects the uterus to the outside. A healthy vagina is home to a symbiotic flora of microorganisms (especially lactobacilli), which protect the host from vaginal infections. The acidity of a healthy vagina in women of reproductive age (pH approximately 3.5-4.5) is believed to be due to lactobacilli breaking down their secreted glycogen / glucose into lactic acid. Acidic conditions are unfavorable to the growth of many pathogenic microorganisms and pathogens, including bacteria, protozoa, and viruses. However, an imbalance in the vaginal microbiota can lead to the overgrowth of pathogenic microorganisms and pathogens, resulting in dysbiosis, inflammation, and / or infection.

[0004] Products containing lactobacilli (such as Lactobacillus acidophilus, Lactobacillus rhamnosus, or Lactobacillus gasseri) for vaginal or oral use have been on the market for many years. These products include vaginal suppositories containing lyophilized Lactobacillus acidophilus or other human-derived lactobacillus species (such as Lactobacillus rhamnosus or Lactobacillus gasseri), as well as various nutritional supplements.

[0005] It is necessary to identify specific bacteria and bacterial colonies that can colonize the human female urogenital tract, and to better understand the internal environment of the urogenital tract and the overall health profile of subjects who receive such isolates. Summary of the Invention

[0006] This article provides compositions of microbial aggregates comprising two or more bacterial isolates capable of being implanted into the human female urogenital tract (e.g., implanted into the human female urogenital tract of a female subject exhibiting, for example, urogenital dysbiosis).

[0007] In some embodiments, the microbial conglomerates of this disclosure are designed to include specific Lactobacillus isolates with different functional and genomic characteristics (e.g., Lactobacillus crispatus and / or Lactobacillus jans isolates). For example, the microbial conglomerates of this disclosure may include two or more Lactobacillus isolates, each with different functional properties (e.g., different growth rates, different acidification rates, different carbohydrate utilization profiles, different implantation rates). Furthermore, the two or more Lactobacillus isolates may also contain different genomic characteristics. This difference in genomic characteristics allows the microbial conglomerates containing two or more Lactobacillus isolates to cover a pre-selected portion of the species-level pan-genome (e.g., all genes of the species-level pan-genome associated with implantation), although any single Lactobacillus isolate itself may not cover the pre-selected portion.

[0008] Microbial aggregates with different functional and genomic characteristics, as described herein, can be implanted into the female urogenital tracts of different groups of subjects, each subject having a different vaginal environment (e.g., different resident microbiota, such as different dysbiotic resident microbiota). Subjects differ in age, ethnicity and nationality, hormone levels (e.g., different stages of the menstrual cycle, menopause), presence of comorbidities, lifestyle, diet, and geographic factors. Each of these differences among subjects can affect the resident microbiota (e.g., including the composition of dysbiotic microbiota and bacterial species) and local environment (e.g., pH, H2O2 levels, glycogen levels, estrogen levels, etc.) within the urogenital tract. The inventors of this disclosure have determined that microbial aggregates with different functional and genomic characteristics, as described herein, are highly adaptable to such different environments present in different groups of subjects and can be successfully implanted into the urogenital tracts of these different subjects. In some embodiments, the microbial aggregates of this disclosure can be successfully implanted without the use of antibiotics such as metronidazole (e.g., as a pretreatment step prior to administration of the microbial aggregates).

[0009] Some aspects of this disclosure provide a microbial aggregate comprising a defined population of isolated lactobacilli, the defined population including: (a) Lactobacillus japonicus obtained from a bacterial sample deposited with DSM accession number 34770 (Lactobacillus jensenii) isolates; (b) Lactobacillus curlis isolate obtained from a bacterial sample deposited under DSM accession number 34772; (c) Lactobacillus curlis isolates obtained from a bacterial sample deposited under DSM accession number 34771, and (d) Lactobacillus curlis isolate obtained from a bacterial sample deposited under DSM accession number 34773.

[0010] Some aspects of this disclosure provide a microbial aggregate comprising a defined population of isolated lactobacilli, the defined population including: (a) The percentage of Lactobacillus janniae isolates whose genomes are greater than or equal to a threshold when compared with the genomes of bacterial samples deposited in DSM 34770. (b) The percentage of Lactobacillus curlis isolates whose genomes are identical to the genomes of bacterial samples deposited in DSM 34771 when compared with a threshold. (c) The percentage of genome identity of Lactobacillus curlis isolates when compared with the genome of bacterial samples deposited in DSM 34772 that is greater than or equal to a threshold; and (d) The percentage of Lactobacillus curlis isolates whose genomes are identical to the genomes of bacterial samples preserved in DSM 34773 with a threshold greater than or equal to the threshold.

[0011] Some aspects of this disclosure provide a method for increasing the relative abundance of lactobacilli in the female urogenital tract of a subject, the method comprising applying any of the microbial aggregates described herein to the subject's urogenital tract.

[0012] Some aspects of this disclosure provide a composition comprising an isolate of *Lactobacillus japonicus* obtained from a bacterial sample deposited under DSM accession number 34770.

[0013] Some aspects of this disclosure provide a composition comprising a *Lactobacillus curvatureii* isolate obtained from a bacterial sample deposited under DSM accession number 34772.

[0014] Some aspects of this disclosure provide a composition comprising a *Lactobacillus curvatureii* isolate obtained from a bacterial sample deposited under DSM accession number 34771.

[0015] Some aspects of this disclosure provide a composition comprising a *Lactobacillus curvatureii* isolate obtained from a bacterial sample deposited under DSM accession number 34773.

[0016] Some aspects of this disclosure provide a composition comprising two or more lactobacilli selected from the following: (a) An isolate of Lactobacillus janniae obtained from a bacterial sample deposited under DSM accession number 34770; (b) Lactobacillus curlis isolate obtained from a bacterial sample deposited under DSM accession number 34772; (c) Lactobacillus curlis isolates obtained from a bacterial sample deposited under DSM accession number 34771, and (d) Lactobacillus curlis isolate obtained from a bacterial sample deposited under DSM accession number 34773.

[0017] Some aspects of this disclosure provide a composition comprising a Lactobacillus japonicus isolate whose genome has a percentage of identity greater than or equal to a threshold when compared with the genome of a bacterial sample deposited in DSM 34770.

[0018] Some aspects of this disclosure provide a composition comprising a Lactobacillus curvature isolate whose genome has a percentage of identity greater than or equal to a threshold when compared with the genome of a bacterial sample deposited in DSM 34771.

[0019] Some aspects of this disclosure provide a composition comprising a Lactobacillus curvature isolate whose genome has a percentage of identity greater than or equal to a threshold when compared with the genome of a bacterial sample deposited in DSM 34772.

[0020] Some aspects of this disclosure provide a composition comprising a Lactobacillus curvature isolate whose genome has a percentage of identity greater than or equal to a threshold when compared with the genome of a bacterial sample deposited in DSM 34773.

[0021] Some aspects of this disclosure provide a composition comprising two or more lactobacilli selected from the following: (a) The percentage of Lactobacillus janniae isolates whose genomes are greater than or equal to a threshold when compared with the genomes of bacterial samples deposited in DSM 34770. (b) The percentage of Lactobacillus curlis isolates whose genomes are identical to the genomes of bacterial samples deposited in DSM 34771 when compared with a threshold. (c) The percentage of genome identity of Lactobacillus curlis isolates when compared with the genome of bacterial samples deposited in DSM 34772 that is greater than or equal to a threshold; and (d) The percentage of Lactobacillus curlis isolates whose genomes are identical to the genomes of bacterial samples preserved in DSM 34773 with a threshold greater than or equal to the threshold.

[0022] In one embodiment, this disclosure provides a microbial aggregate comprising (i) an isolate of Lactobacillus janniae and (ii) at least two phenotypic Lactobacillus curvature isolates.

[0023] In another embodiment, this disclosure provides a microbial aggregate comprising (i) Lactobacillus janniae isolate and (ii) at least three phenotypic Lactobacillus curvature isolates.

[0024] In yet another embodiment, this disclosure provides a microbial aggregate comprising (i) an *Lactobacillus japonicus* isolate and (ii) at least two phenotypic *Lactobacillus curvaturei* isolates, wherein each of the at least two phenotypic *Lactobacillus curvaturei* isolates is characterized by a different carbon substrate utilization profile. In various embodiments, the at least two phenotypic *Lactobacillus curvaturei* isolates are characterized by utilizing both mannitol and glucose. In some embodiments, the first phenotypic *Lactobacillus curvaturei* isolate is characterized by utilizing mannitol to a lesser extent than the second phenotypic *Lactobacillus curvaturei* isolate.

[0025] In another embodiment, this disclosure provides a microbial conglomerate comprising (i) an *Lactobacillus janniae* isolate and (ii) at least three phenotypic *Lactobacillus curvaturei* isolates, wherein at least two phenotypic *Lactobacillus curvaturei* isolates are each characterized by different carbon substrate utilization profiles. In various embodiments, the at least three phenotypic *Lactobacillus curvaturei* isolates are characterized by utilizing both mannitol and glucose. In some embodiments, the first phenotypic *Lactobacillus curvaturei* isolate is characterized by utilizing mannitol to a lesser extent than the second phenotypic *Lactobacillus curvaturei* isolate.

[0026] In other embodiments, this disclosure provides a microbial aggregate comprising (i) an *Lactobacillus japonicus* isolate and (ii) at least two phenotypic *Lactobacillus curvaturei* isolates, wherein the at least two phenotypic *Lactobacillus curvaturei* isolates exhibit different growth rates and / or acidification rates during the logarithmic growth phase on a medium with mannitol or glucose as the carbon substrate. In some embodiments, the growth rate is determined according to the steps in Table 7. In other embodiments, the acidification rate is determined according to the steps in Table 8.

[0027] In various embodiments, each isolate of the microbial conglomerate has implantation potential in a recipient subject. Implantation potential can be assessed according to various methods, including methods for detecting the implantation potential of the microbial conglomerate in a recipient subject, said methods including detecting the presence of at least one bacterial isolate in the recipient at least 24 hours after administration of the microbial conglomerate to the recipient (e.g., vaginal cavity). In various embodiments for measuring implantation, the microbial conglomerate includes (i) *Lactobacillus jenny* isolates and (ii) at least two phenotypic *Lactobacillus curvaturei* isolates. In other embodiments, the microbial conglomerate comprises (i) *Lactobacillus jenny* isolates and (ii) at least three phenotypic *Lactobacillus curvaturei* isolates. In some embodiments, measuring implantation may include detecting at least two or three bacterial isolates at least 24 hours after administration of the microbial conglomerate to the recipient. In other embodiments, the detection step may also be at least 48 hours, 72 hours, 7 days, 4 weeks, 8 weeks, and 16 weeks after administration of the microbial conglomerate to the recipient.

[0028] In various implementations, the detection step may include nucleic acid sequencing of at least one bacterial isolate, including nucleic acid molecules, the genome, or a region of the genome. Sequencing may be whole-genome sequencing.

[0029] In some implementations, when detecting implantation, the detection may include measuring the relative abundance of at least 1%, 5%, 10%, 15%, or 20% of the isolates collected from the vaginal cavity after administration of the microbial conglomerate.

[0030] In various implementation schemes, the relative abundance of each isolate in the microbial aggregate is proportionally equal.

[0031] In other embodiments, the relative abundance percentage of Lactobacillus in the aggregate is Lactobacillus japonicus in the range of 15%-60% and the remaining Lactobacillus is Lactobacillus curvifolius. In yet another embodiment, the percentage of Lactobacillus in the aggregate is Lactobacillus japonicus in the range of 25% to 40% and the remaining Lactobacillus is Lactobacillus curvifolius. In still another embodiment, the percentage of Lactobacillus in the aggregate is Lactobacillus japonicus in the range of 20% to 30% and the remaining Lactobacillus is Lactobacillus curvifolius.

[0032] In various embodiments, the lactobacillus isolates are derived from vaginal secretions obtained from at least two or at least three female donors. In various embodiments, the vaginal secretions contain microorganisms from a balanced vaginal microbiota.

[0033] In other embodiments of the microbial aggregate, the Lactobacillus janniae isolate is derived from a balanced vaginal microbiota containing Lactobacillus janniae and Lactobacillus curvature, wherein a first Lactobacillus curvature isolate is derived from a balanced vaginal microbiota containing Lactobacillus janniae and Lactobacillus curvature, and wherein a second Lactobacillus curvature isolate is derived from a balanced vaginal microbiota containing Lactobacillus curvature but lacking detectable Lactobacillus janniae.

[0034] In the embodiments, at least two of the at least three phenotypic Lactobacillus curlis isolates exhibit different growth rates and / or acidification rates to one or more carbon substrates during the logarithmic growth phase. In various embodiments, the growth rate is determined according to the steps in Table 7, and the acidification rate is determined according to the steps in Table 8.

[0035] In various embodiments, at least two of the *Lactobacillus* microbial aggregates possess different carbon utilization profiles. The carbon utilization profiles may be selected from: glycogen utilization profiles; glucose utilization profiles; fructose utilization profiles; mannose utilization profiles; maltodextrin utilization profiles; and mannitol utilization profiles. In some embodiments, the carbon utilization profile is a glycogen utilization profile. In some other embodiments, the carbon utilization profile is a mannitol utilization profile.

[0036] In other embodiments, at least two types of *Lactobacillus* in the microbial aggregate have different growth rates, acidification rates, lactic acid production rates, and / or carbon utilization profiles. The carbon utilization profile may be selected from: glycogen utilization profiles; glucose utilization profiles; fructose utilization profiles; mannose utilization profiles; maltodextrin utilization profiles; and mannitol utilization profiles. In some embodiments, the carbon utilization profile is a glycogen utilization profile. In some other embodiments, the carbon utilization profile is a mannitol utilization profile. In some embodiments, when grown in modified MRS medium, modified MRS + maltodextrin, modified MRS + fructose, modified MRS + mannose, or modified MRS + mannitol, the growth rate of the microbial aggregate is higher than that of the lowest-performing individual isolate in the aggregate. In other embodiments, when grown in modified MRS medium, modified MRS + maltodextrin, or modified MRS + glycogen, the acidification rate of the microbial aggregate is higher than that of the lowest-performing individual isolate in the microbial aggregate.

[0037] In various implementation schemes, the total bacterial content in the microbial aggregates is 10 6 Up to 10 11 Within the range of CFU. In other embodiments, the total bacterial content in the aggregate is 10. 7 Up to 10 9 Within the range of CFU. In other embodiments, the total content of at least one lactobacillus isolate present in the microbial aggregate is 2.0 x 10⁻⁶.6 -3.0 X 10 6 Up to 2.0 x 10 11 -3.0 X 10 11 Within the range of CFU. In other embodiments, the total content of at least one Lactobacillus isolate present in the aggregate is within 2.0 x 10⁻⁶. 7 -3.0 X 10 7 Up to 2.0 x 10 9 -3.0 X 10 9 Within the range of CFU. At least one lactobacillus isolate may be *Lactobacillus japonicus*.

[0038] In some embodiments, the aggregate has a greater growth rate than that of a two-membered aggregate comprising any one of *Lactobacillus japonicus* isolates and at least two *Lactobacillus curvature* isolates. The aggregate may also have a greater acidification rate than that of a two-membered aggregate comprising any one of *Lactobacillus japonicus* isolates and at least two *Lactobacillus curvature* isolates.

[0039] In other respects, this disclosure provides a composition comprising the microbial aggregates described herein, and pharmaceutically acceptable buffers, diluents, or excipients. The composition may be in a dosage form, such as a suppository, tablet, capsule, film, gel, or cream. In one embodiment, the dosage form is a capsule.

[0040] The composition in various embodiments may be contained in 10 6 Up to 10 11 The total bacterial content in the microbial aggregates within the range of CFU. In other embodiments, the total bacterial content in the aggregates is 10. 7 Up to 10 9 Within the range of CFU. In other embodiments, the total content of at least one lactobacillus isolate present in the microbial aggregate is 2.0 x 10⁻⁶. 6 -3.0 X 10 6 Up to 2.0 x 10 11 - 3.0 X 10 11 Within the range of CFU. In other embodiments, the total content of at least one Lactobacillus isolate present in the aggregate is within 2.0 x 10⁻⁶. 7 -3.0 X 10 7 Up to 2.0 x 10 9 -3.0 X 10 9 Within the range of CFU. At least one lactobacillus isolate may be *Lactobacillus japonicus*.

[0041] On the other hand, this disclosure relates to a kit containing the microbial aggregates described herein or a composition containing the microbial aggregates described herein, and further comprising a device or applicator suitable for delivering the microbial aggregates or composition into the vaginal cavity, and optionally instructions for use. In some embodiments, the kit may include an antibacterial wash and / or cleansing solution, which may be included in a device, such as, but not limited to, a syringe or pre-soaked gauze. In one embodiment, the antibacterial wash and / or cleansing solution may contain chlorhexidine.

[0042] On the other hand, this disclosure provides a method comprising applying a microbial conglomerate to the urogenital tract of a subject, for example, a subject with an dysbiotic vaginal microbiota. The microbial conglomerate or composition may be administered in capsule form. In embodiments, the method may flood the subject's urogenital tract with lactobacilli and / or increase the relative abundance of lactobacilli in the subject's female urogenital tract, both of which can be assessed by detecting the presence of at least one bacterial isolate of the microbial conglomerate in the subject at least 24 hours after administration of the microbial conglomerate. In other embodiments, the detection step may be performed at least 48 hours, 72 hours, 7 days, 4 weeks, 8 weeks, and 16 weeks after administration of the microbial conglomerate to the subject. In other embodiments, the detection step may include nucleic acid sequencing of the nucleic acid molecule, genome, or genomic region of at least one bacterial isolate. Sequencing may be whole-genome sequencing. In some embodiments, the subject does not exhibit vaginal clinical symptoms such as vaginal discharge, vaginal itching, vaginal irritation, and / or vaginal odor. In other implementations, subjects did not exhibit clinical symptoms of bacterial vaginosis (BV) as diagnosed by the Amsel criteria or Nugent score.

[0043] On the other hand, this disclosure provides a method comprising applying a microbial conglomerate to the urogenital tract of a subject, for example, a subject with an dysbiotic vaginal microbiota, which, after application of the microbial conglomerate, transforms into a balanced vaginal microbiota. In embodiments, the balanced vaginal microbiota remains stable for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or at least up to 1 year after application of the microbial conglomerate. In yet other embodiments, the balanced vaginal microbiota remains stable for at least 1 menstrual cycle, at least 2 menstrual cycles, at least 3 menstrual cycles, at least 4 menstrual cycles, at least 5 menstrual cycles, at least 6 menstrual cycles, at least 7 menstrual cycles, at least 8 menstrual cycles, at least 9 menstrual cycles, at least 10 menstrual cycles, at least 11 menstrual cycles, and at least 12 menstrual cycles after application of the microbial conglomerate.

[0044] In other respects, this disclosure provides a method for preparing microbial aggregates, the method comprising: (i) obtaining Lactobacillus jenny isolates; (ii) obtaining at least two phenotypic Lactobacillus curvature isolates; and (iii) combining the Lactobacillus jenny isolates and at least two phenotypic Lactobacillus curvature isolates into a mixture to form microbial aggregates.

[0045] In some embodiments, the method for preparing a microbial aggregate includes: (i) obtaining an *Lactobacillus jenny* isolate; (ii) obtaining at least three phenotypic *Lactobacillus curvaturei* isolates; and (iii) combining the *Lactobacillus jenny* isolate and at least three phenotypic *Lactobacillus curvaturei* isolates into a mixture to form a microbial aggregate. In some embodiments, the formed microbial aggregate is a 3-isolated microbial aggregate comprising the *Lactobacillus jenny* isolate and two phenotypic *Lactobacillus curvaturei* isolates. In other embodiments, the formed microbial aggregate is a 4-isolated microbial aggregate comprising the *Lactobacillus jenny* isolate and three phenotypic *Lactobacillus curvaturei* isolates.

[0046] In the embodiments, the prepared polymers of *Lactobacillus japonicus* isolates and each *Lactobacillus curvatureus* isolate are expressed in equal proportions in the mixture. The polymers in various embodiments may contain 10... 6 Up to 10 11 The total bacterial count is within the range of CFU. In other embodiments, the total bacterial count in the aggregate is 10... 7 Up to 10 9 Within the range of CFU. In other embodiments, the total content of at least one lactobacillus isolate present in the microbial aggregate is 2.0 x 10⁻⁶. 6 -3.0 X 10 6 Up to 2.0 x 10 11 - 3.0 X 10 11 Within the range of CFU. In other embodiments, the total content of at least one Lactobacillus isolate present in the aggregate is within 2.0 x 10⁻⁶. 7 -3.0 X 10 7 Up to 2.0 x 10 9 -3.0 X 10 9 Within the range of CFU. At least one lactobacillus isolate may be *Lactobacillus japonicus*.

[0047] In various implementation schemes, the Lactobacillus janniae isolate is derived from a first vaginal donor with balanced microbiota as an Lactobacillus janniae isolate implanted in the recipient subject after SCVMP vaginal microbiota transfer; and at least one Lactobacillus curvature isolate is derived from a second vaginal donor with balanced microbiota as an Lactobacillus curvature isolate implanted in the recipient subject after SCVMP vaginal microbiota transfer.

[0048] In some embodiments, the Lactobacillus janniae isolate contains one or more carbohydrate utilization genes, which contain nucleotide sequences selected from SEQ ID NO: 9-10, or contain nucleotide sequences having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or up to 100% of the nucleotide sequences selected from SEQ ID NO: 9-10.

[0049] In other embodiments, the first of the Lactobacillus curlis isolates comprises one or more carbohydrate utilization genes, which contain nucleotide sequences selected from SEQ ID NO: 11-14, or contain nucleotide sequences having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or up to 100% of the nucleotide sequences selected from SEQ ID NO: 11-14.

[0050] In another embodiment, the second type of Lactobacillus curlis isolate comprises one or more carbohydrate utilization genes, which contain nucleotide sequences selected from SEQ ID NO: 15-18, or contain nucleotide sequences having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or up to 100% of the nucleotide sequences selected from SEQ ID NO: 15-18.

[0051] In yet another embodiment, the third type of Lactobacillus curlis isolate comprises one or more carbohydrate utilization genes, which contain nucleotide sequences selected from SEQ ID NO: 19-22, or contain nucleotide sequences having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or up to 100% selected from SEQ ID NO: 19-22.

[0052] On the other hand, this disclosure provides a method for treating a subject suffering from vaginal flora imbalance, the method comprising administering a therapeutically effective amount of a microbial conglomerate, a composition described herein, or a kit described herein, thereby treating the vaginal flora imbalance. In one embodiment, the microbial conglomerate is a 3-isolated microbial conglomerate comprising *Lactobacillus jenny* isolate and two phenotypically different *Lactobacillus curvaturei* isolates. In other embodiments, the microbial conglomerate is a 4-isolated microbial conglomerate, namely, *Lactobacillus jenny* isolate and three phenotypically different *Lactobacillus curvaturei* isolates.

[0053] In another aspect, this disclosure provides a method for treating a subject suffering from bacterial vaginosis (BV), the method comprising administering a therapeutically effective amount of the microbial conglomerate, the composition described herein, or the kit described herein, thereby treating bacterial vaginosis (BV). In one embodiment, the microbial conglomerate is a 3-isolated microbial conglomerate comprising *Lactobacillus jenny* isolate and two phenotypically different *Lactobacillus curvaturei* isolates. In other embodiments, the microbial conglomerate is a 4-isolated microbial conglomerate, namely, *Lactobacillus jenny* isolate and three phenotypically different *Lactobacillus curvaturei* isolates.

[0054] On the other hand, this disclosure provides a method for manufacturing the microbial aggregates described herein, the method comprising independently culturing each isolate of the microbial aggregate in a bioreactor, harvesting the isolates, and combining the isolates in equal proportions to obtain the microbial aggregate. The bioreactor may be a 10L, 50L, 500L, 1000L, or up to 3000L bioreactor. The culturing step may yield at least 1g, 25g, 50g, 500g, 1kg, 10kg, or 50kg lyophilized / dry weight of each isolate.

[0055] In some embodiments, this disclosure provides a microbial conglomerate comprising a defined population of isolated lactobacilli configured to facilitate implantation into the female urogenital tract of a subject, the defined population comprising: a *Lactobacillus japonicus* isolate; a *Lactobacillus curvaturei* isolate that grows well in the presence of *Lactobacillus japonicus*; and at least one additional *Lactobacillus curvaturei* isolate that grows well in the absence of *Lactobacillus japonicus*.

[0056] In some implementations, a *Lactobacillus curvatureensis* isolate that grows well in the absence of *Lactobacillus janniae* can be implanted into the female urogenital tract of a subject for at least a predetermined period of time.

[0057] In some implementations, the defined population of isolated lactobacilli includes: The relative abundance of total viable cells was 15% to 35% of Lactobacillus janniae; the relative abundance of total viable cells was 15% to 35% of Lactobacillus curvaturei growing well in the presence of Lactobacillus janniae; and the relative abundance of total viable cells was 30% to 70% of additional Lactobacillus curvaturei growing well in the absence of Lactobacillus janniae.

[0058] In some implementations, the defined population of isolated lactobacilli includes: Approximately 25% of the total viable cells were Lactobacillus janniae; Approximately 25% of the total viable cells were *Lactobacillus curvaturei*, which grows well in the presence of *Lactobacillus janniae*; and approximately 50% of the total viable cells were additional *Lactobacillus curvaturei*, which grows well in the absence of *Lactobacillus janniae*.

[0059] In some embodiments, wherein: the Lactobacillus janniae isolate comprises multiple Lactobacillus janniae; the Lactobacillus curvature isolate that grows well in the presence of Lactobacillus janniae comprises multiple Lactobacillus curvature isolates that grow well in the presence of Lactobacillus janniae; and the at least one additional Lactobacillus curvature isolate that grows well in the absence of Lactobacillus janniae comprises multiple additional Lactobacillus curvature isolates that grow well in the absence of Lactobacillus janniae.

[0060] Some aspects of this disclosure provide a microbial aggregate comprising a defined population of isolated lactobacilli, the defined population being configured to facilitate implantation into the female urogenital tract of a subject, the defined population comprising: Lactobacillus japonicus isolate; A *Lactobacillus curly-shaped* isolate that grows well in the presence of *Lactobacillus janniae*; and At least two additional Lactobacillus curvature isolates, wherein the at least two additional Lactobacillus curvature isolates have different growth rates, and wherein the at least two additional Lactobacillus curvature isolates grow well in the absence of Lactobacillus janieri.

[0061] In some embodiments, the growth rate of the first of at least two additional *Lactobacillus curvaturei* isolates is 0.27–0.29 h⁻¹ and the growth rate of the second of at least two additional *Lactobacillus curvaturei* isolates is 0.24–0.26 h⁻¹ during an 8-hour period in the culture (initial pH 4.7), wherein the growth rate is calculated using the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time); or, during an 8-hour period in the culture (initial pH 5.2), the growth rate of the first of at least two additional *Lactobacillus curvaturei* isolates is 0.35–0.37 h⁻¹ and the growth rate of the second of at least two additional *Lactobacillus curvaturei* isolates is 0.31–0.33 h⁻¹, wherein the growth rate is calculated using the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time).

[0062] In some implementations, at least two of the Lactobacillus curlis isolates differ in their growth rate, glycogen utilization rate, lactic acid production rate, acidification rate, and / or the time it takes for them to be implanted in the female urogenital tract.

[0063] In some implementations, the defined population of isolated lactobacilli includes: Lactobacillus janniae accounted for 15% to 35% of the total viable cells. The relative abundance of total viable cells was 15% to 35% of *Lactobacillus curlis*, which grows well in the presence of *Lactobacillus janniae*; and The relative abundance of total viable cells is 15% to 35% for additional Lactobacillus curvature.

[0064] In some implementations, the defined population of isolated lactobacilli includes: Approximately 25% of the total viable cells were Lactobacillus janniae; Approximately 25% of the total viable cells were *Lactobacillus curlii*, which grows well in the presence of *Lactobacillus janniae*; and Approximately 50% of the total viable cells were additional Lactobacillus curvature.

[0065] In some implementations, the Lactobacillus janniae isolates contain multiple Lactobacillus janniae strains; The *Lactobacillus curlis* isolates that grow well in the presence of *Lactobacillus japonicus* include multiple *Lactobacillus curlis* strains that grow well in the presence of *Lactobacillus japonicus*; and Each of the at least two additional Lactobacillus curvature isolates contains multiple Lactobacillus curvature strains.

[0066] Some aspects of this disclosure provide a microbial aggregate comprising a defined population of isolated lactobacilli, the defined population being configured to facilitate implantation into the female urogenital tract of a subject, the defined population comprising: Lactobacillus japonicus isolate; A *Lactobacillus curly-shaped* isolate that grows well in the presence of *Lactobacillus janniae*; and At least two additional Lactobacillus curvature isolates, wherein the at least two additional Lactobacillus curvature isolates have different acidification rates, and wherein the at least two additional Lactobacillus curvature isolates grow well in the absence of Lactobacillus janniae.

[0067] In some embodiments, over a 24-hour period in the culture (initial pH 4.7), the acidification rate of the first of at least two additional *Lactobacillus curlis* isolates is approximately -0.006 h⁻¹, and the acidification rate of the second of at least two additional *Lactobacillus curlis* isolates is approximately -0.007 h⁻¹, wherein the acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time); or During a 24-hour period in the culture (initial pH 5.2), the acidification rate of the first of at least two additional Lactobacillus curlis isolates was -0.008 to -0.006 h⁻¹, and the acidification rate of the second of at least two additional Lactobacillus curlis isolates was -0.012 to -0.010 h⁻¹, wherein the acidification rate was calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0068] In some implementations, at least two of the Lactobacillus curlis isolates differ in their growth rate, glycogen utilization capacity, lactic acid production rate, and / or the time to implantation into the female urogenital tract.

[0069] In some implementations, the defined population of isolated lactobacilli includes: Lactobacillus janniae accounted for 15% to 35% of the total viable cells. A relative abundance of 15% to 35% of total viable cells represents *Lactobacillus curvatureensis* that grows well in the presence of *Lactobacillus janniae*. The relative abundance of total viable cells is 30% to 70% of at least two additional Lactobacillus curvature species.

[0070] In some implementations, the defined population of isolated lactobacilli includes: Approximately 25% of the total viable cells were Lactobacillus janniae; Approximately 25% of the total viable cells were *Lactobacillus curlii*, which grows well in the presence of *Lactobacillus janniae*; and Approximately 50% of the total viable cells were Lactobacillus curvature.

[0071] In some implementations, the Lactobacillus janniae isolates contain multiple Lactobacillus janniae strains; The *Lactobacillus cristata* isolates that grow well in the presence of *Lactobacillus japonicus* include various *Lactobacillus cristata* strains that grow well in the presence of *Lactobacillus japonicus*; and Each of the at least two additional Lactobacillus curvature isolates contains multiple Lactobacillus curvature strains.

[0072] In some implementations, a well-grown *Lactobacillus curvatureensis* isolate in the presence of *Lactobacillus janniae* can be implanted into the female urogenital tract of a subject in the presence of *Lactobacillus janniae* and remain there for at least a predetermined period of time.

[0073] In some implementations, each of the lactobacilli is characterized by having different sets of single nucleotide polymorphisms (SNPs), different haplotype characteristics, and / or different sets of single nucleotide variants (SNVs) in its genome.

[0074] In some implementations, different groups of SNPs define SNP maps.

[0075] In some implementations, each lactobacillus contains a core genome, in which different groups of SNVs are contained within the core genome.

[0076] In some implementations, the genome of Lactobacillus contains a number of SNVs such that when the core genome of Lactobacillus is compared with the core genome of control Lactobacillus, it has a greater than a threshold percentage of identity, which defines the difference between two different Lactobacillus isolates.

[0077] In some implementations, the genome of each Lactobacillus curvature isolate contains a number of SNVs such that when the genome of the Lactobacillus curvature isolate is compared with the genome of a reference Lactobacillus curvature isolate, it has a percentage of identity greater than or equal to a threshold, which defines the distinction between two different Lactobacillus curvature isolates.

[0078] In some implementations, the identity percentage is greater than or equal to 99.81%.

[0079] In some implementations, the identity percentage is greater than or equal to 99.90%.

[0080] In some implementations, the identity percentage is greater than or equal to 99.96%.

[0081] In some implementations, at least two of the lactobacilli differ in their growth rates.

[0082] In some implementations, Lactobacillus japonicus and at least one type of Lactobacillus curvature differ in their growth rates.

[0083] In some implementations, at least two types of *Lactobacillus curvatureensis* differ in their growth rates.

[0084] In some implementations, the growth rate is the growth rate in vitro (e.g., in a culture) and / or in vivo.

[0085] In some implementations, the growth rate of *Lactobacillus japonicus* in the culture over an 8-hour period (initial pH 4.7) is 0.32–0.36 h⁻¹, wherein the growth rate is calculated using the formula: (final OD₆₀₀ divided by initial OD₆₀₀) divided by the natural logarithm (Ln) of (final time minus initial time); or the growth rate over the culture over an 8-hour period (initial pH 5.2) is 0.41–0.43 h⁻¹, wherein the growth rate is calculated using the formula: (final OD₆₀₀₀ divided by initial OD₆₀₀) divided by (final time minus initial time).

[0086] In some implementations, the growth rate of *Lactobacillus curlis* isolates that grow well in the presence of *Lactobacillus janniae* is 0.35–0.41 h⁻¹ in the culture over an 8-hour period (initial pH 4.7), wherein the growth rate is calculated using the following formula: the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time); or the growth rate is 0.39–0.41 h⁻¹ in the culture over an 8-hour period (initial pH 5.2), wherein the growth rate is calculated using the following formula: the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time).

[0087] In some embodiments, the first additional *Lactobacillus curvature* isolate exhibits a growth rate of 0.27–0.29 h⁻¹ in the culture over an 8-hour period (initial pH 4.7), wherein the growth rate is calculated using the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time); or a growth rate of 0.35–0.37 h⁻¹ in the culture over an 8-hour period (initial pH 5.2), wherein the growth rate is calculated using the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time).

[0088] In some embodiments, the second additional *Lactobacillus curvature* isolate exhibits a growth rate of 0.24–0.26 h⁻¹ over an 8-hour period in the culture (initial pH 4.7), wherein the growth rate is calculated using the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time); or a growth rate of 0.31–0.33 h⁻¹ over an 8-hour period in the culture (initial pH 5.2), wherein the growth rate is calculated using the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time).

[0089] In some implementations, at least two types of lactobacilli differ in their acidification rates.

[0090] In some implementations, Lactobacillus japonicus and at least one type of Lactobacillus curvature differ in their acidification rates.

[0091] In some embodiments, at least two types of *Lactobacillus curvature* differ in their acidification rates. In some embodiments, the acidification rate is the acidification rate in vitro (e.g., in culture) and / or in vivo.

[0092] In some embodiments, the acidification rate of *Lactobacillus japonicus* in the culture over a 24-hour period (initial pH 4.7) is -0.005 to -0.003, wherein the acidification rate is calculated using the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time); or the acidification rate over a 24-hour period (initial pH 5.2) in the culture is -0.009 to -0.007, wherein the acidification rate is calculated using the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0093] In some embodiments, the acidification rate of *Lactobacillus curlis* isolates that grow well in the presence of *Lactobacillus janniae* in the culture over a 24-hour period (initial pH 4.7) is -0.009 to -0.007, wherein the acidification rate is calculated using the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time); or the acidification rate over a 24-hour period (initial pH 5.2) in the culture is -0.012 to -0.010, wherein the acidification rate is calculated using the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0094] In some embodiments, the acidification rate of the first additional *Lactobacillus curvatureii* isolate in the culture over a 24-hour period (initial pH 4.7) is -0.007 to -0.005 h⁻¹, wherein the acidification rate is calculated using the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time); or the acidification rate in the culture over a 24-hour period (initial pH 5.2) is -0.008 to -0.006 h⁻¹, wherein the acidification rate is calculated using the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0095] In some embodiments, the second additional Lactobacillus curvature isolate exhibits an acidification rate of -0.008 to -0.006 h⁻¹ over a 24-hour period in the culture (initial pH 4.7), wherein the acidification rate is calculated using the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time); or an acidification rate of -0.012 to -0.010 h⁻¹ over a 24-hour period in the culture (initial pH 5.2), wherein the acidification rate is calculated using the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0096] In some embodiments, at least two of the lactobacilli differ in their ability to utilize glycogen. In some embodiments, *Lactobacillus japonicus* and at least one *Lactobacillus curvatureii* differ in their ability to utilize glycogen. In some embodiments, at least two *Lactobacillus curvatureii* species differ in their ability to utilize glycogen. In some embodiments, the ability to utilize glycogen refers to the ability to utilize glycogen in vitro (e.g., in a culture) and / or in vivo.

[0097] In some embodiments, at least two of the lactobacilli differ in their lactic acid production rates. In some embodiments, *Lactobacillus japonicus* and at least one *Lactobacillus curvatureii* differ in their lactic acid production rates. In some embodiments, at least two *Lactobacillus curvatureii* species differ in their lactic acid production rates. In some embodiments, lactic acid production rate refers to the in vitro (e.g., in culture) and / or in vivo lactic acid production rate.

[0098] In some embodiments, at least two of the lactobacilli differ in the time it takes for them to implant into the female urogenital tract. In some embodiments, *Lactobacillus japonicus* and at least one *Lactobacillus curvatureii* differ in the time it takes for them to implant into the female urogenital tract. In some embodiments, at least two *Lactobacillus curvatureii* species differ in the time it takes for them to implant into the female urogenital tract. In some embodiments, the time of implantation into the female urogenital tract is determined in vivo.

[0099] In some embodiments, at least one of the lactobacillus isolates is capable of implanting into the subject's female urogenital tract within 24 hours after administration. In some embodiments, at least one of the lactobacillus isolates is capable of persisting in the subject's female urogenital tract for at least 4 days after administration.

[0100] In some implementations, 2, 3, or 4 Lactobacillus isolates are able to persist in the female urogenital tract of the subject for at least 4, 5, 6, or 7 days after administration, and optionally, 2, 3, or 4 Lactobacillus isolates are able to persist in the female urogenital tract of the subject for at least one menstrual cycle after administration.

[0101] In some implementation schemes, the lactobacilli in the polymer: It can compete with the resident microbiota in the female urogenital tract of the subject, optionally without requiring at least partial removal of the resident microbiota, for example by administering an antimicrobial agent, such as an antibiotic, to the urogenital tract; or it can be implanted in the presence of the resident microbiota.

[0102] In some embodiments, each type of lactobacillus in the aggregate is obtained from a healthy (e.g., lactobacillus-dominant) human donor. In some embodiments, the lactobacillus included in the defined population is obtained from at least two different healthy (e.g., lactobacillus-dominant) human donors, optionally wherein the lactobacillus included in the defined population is obtained from three different healthy (e.g., lactobacillus-dominant) human donors. In some embodiments, *Lactobacillus japonicus* isolates and *Lactobacillus curvatureii* isolates that grow well in the presence of *Lactobacillus japonicus* are obtained from different healthy (e.g., lactobacillus-dominant) human donors. In some embodiments, at least two additional *Lactobacillus curvatureii* isolates are obtained from the same healthy (e.g., lactobacillus-dominant) human donor.

[0103] In some implementations, at least two *Lactobacillus curvatureii* isolates grow well in the absence of *Lactobacillus janniae*, and each of the *Lactobacillus* species in the aggregate can optionally be propagated individually using large-scale culture methods.

[0104] Some aspects of this disclosure provide a microbial aggregate comprising a defined population of isolated lactobacilli, the defined population being configured to facilitate implantation into the female urogenital tract of a subject, the defined population comprising: Lactobacillus japonicus isolates; and Two or three Lactobacillus curvature isolates, wherein at least two of the two or three Lactobacillus curvature isolates have different growth rates, acidification rates and / or lactic acid production rates.

[0105] Some aspects of this disclosure provide a pharmaceutical composition comprising any of the microbial aggregates described herein, as well as a pharmaceutically acceptable buffer, diluent, or excipient.

[0106] Some aspects of this disclosure provide a method for increasing the relative abundance of lactobacilli in the female urogenital tract of a subject, the method comprising applying any of the microbial aggregates described herein to the subject's urogenital tract.

[0107] In some implementations, the subject’s female urogenital tract contains a bacterial community with a relative abundance of less than 90% (e.g., less than 80%, 70%, 60%, 50%, 40%, 30%, or 20%) of the total bacterial community prior to the application of the microbial conglomerate.

[0108] In some implementations, the subject's female urogenital tract contains a bacterial community with a relative abundance of more than 70% (e.g., more than 80%, 85%, 90%, 95%, or 98%) of lactobacilli in the total bacterial community after administration of the microbial aggregate.

[0109] In some implementations, after administration of the microbial aggregate, the relative abundance of lactobacilli in the bacterial population of the female urogenital tract of the subject increases by at least 5 percentage points (e.g., at least 10, 15, 20, 25, 30, 40, 50, or 60 percentage points).

[0110] In some implementations, any of the microbial aggregates described herein may be used for therapy.

[0111] In some embodiments, any of the microbial aggregates described herein are used as a method for treating female urogenital tract dysbiosis in a subject, the method comprising applying the microbial aggregate to the urogenital tract of the subject, optionally wherein the subject is asymptomatic.

[0112] In some embodiments, any of the microbial aggregates described herein are used in a method of treating inflammation of the female urogenital tract of a subject, the method comprising applying the microbial aggregate to the urogenital tract of the subject, optionally wherein the subject is asymptomatic.

[0113] Some aspects of this disclosure provide a method for assembling a microbial aggregate comprising two or more isolates belonging to one or more bacterial species, the method comprising: Obtain gene sequencing data from two or more isolates in a so-called sample; Obtain gene sequencing data from reference samples of each isolate; Use at least one computer processor to: At least the core portion of the gene sequencing data from the so-called sample is compared with the gene sequencing data from the reference sample; Using the aligned gene sequencing data, an identity percentage value is calculated, which represents the percentage of identical sequences in the aligned gene sequencing data; and The inclusion of the same group of bacteria in the claimed sample and the reference sample is determined by setting the identity percentage value to be greater than or equal to the threshold for distinguishing different isolates of the same bacterial species; and Microbial aggregates were assembled using what are called samples.

[0114] In some implementations, the method further includes determining the threshold by: Obtain gene sequencing data from two or more samples of two or more isolates; Using at least one computer processor, at least the core portion of the gene sequencing data obtained from two or more isolates is compared; Using at least one computer processor, calculate the percentage of identity between each pair of paired sequences; and Using at least one computer processor, the threshold is determined by determining the maximum value of the calculated percentage identifier.

[0115] In some implementations, the bacterial species includes Lactobacillus species.

[0116] In some implementations, the bacterial species includes Lactobacillus curvatureii.

[0117] In some embodiments, determining that the claimed sample and the reference sample contain the same group of bacteria includes determining a threshold of identity percentage greater than or equal to 99.81%. In some embodiments, determining that the claimed sample and the reference sample contain the same group of bacteria includes determining a threshold of identity percentage greater than or equal to 99.90%. In some embodiments, determining that the claimed sample and the reference sample contain the same group of bacteria includes determining a threshold of identity percentage greater than or equal to 99.96%. Attached Figure Description

[0118] Figure 1 A schematic diagram is provided showing the isolation of bacteria from the donor's vaginal microbiota.

[0119] Figure 2 An option is provided for identifying individual lactobacilli to be included in an exemplary microbial aggregate.

[0120] Figure 3A -C provides a chart showing that genome assemblies can be used to distinguish one type of Lactobacillus from another based on the percentage of identity of bacterial genome fragments.

[0121] Figure 4A -B shows the relative abundance of *Lactobacillus curvature* in samples collected from the vagina during multiple visits from a single donor. Figure 5A -D shows the relative abundance of Lactobacillus curvature in samples taken from example recipient subjects after application of the material obtained from the donor in Figure 4.

[0122] Figure 6 A schematic diagram of the selection based on pan-genome analysis is shown.

[0123] Figures 7A-7B The growth graph of the test isolates over time is shown. Figure 7A ) and pH chart ( Figure 7B ).

[0124] Figures 8A-8D The growth rate of a single bacterium is shown as a comparison with that of an exemplary 4-membered aggregate (MC-1).

[0125] Figures 9A-9D The comparison of acidification changes (pH changes) between a single bacterium and an exemplary 4-member aggregate (MC-1) is shown.

[0126] Figures 10A-10H The comparison of D-lactic acid and L-lactic acid production between a single bacterium and an exemplary 4-membered polymer (MC-1) is shown.

[0127] Figure 11A-11B The percentage of D- / L-lactic acid produced over time in a single bacterium and in an exemplary 4-membered polymer (MC-1) was compared.

[0128] Figure 12A-12D The abundance of *Lactobacillus curvaturei* and *Lactobacillus janniae* in an exemplary 4-member (MC-1) complex grown on MRS agar plates is shown, along with the relative abundance of the species over time using qPCR.

[0129] Figure 13 This is a flowchart depicting an exemplary process 1300 for assembling microbial aggregates according to some embodiments of the technology described herein.

[0130] Figure 14 An exemplary implementation of a computer system is described, which can be used in conjunction with some implementations of the techniques described herein.

[0131] Figure 15 A schematic diagram of the isolates contained in an exemplary 4-membered aggregate (MC-1) is shown.

[0132] Figure 16A-16L The results showed that the modified maltodextrin (containing 20 mg / mL) was used. Figure 16A -B), glycogen ( Figure 16C -D), glucose ( Figure 16E -F), fructose ( Figure 16G -H), mannose ( Figure 16I -J) or mannitol ( Figure 16K Growth and growth rate of individual isolates and exemplary 4-member aggregates (MC-1) grown in MRS medium (-L)

[0133] Figure 17A-17L The results showed that the modified formulation contained 20 mg / mL maltodextrin ( Figure 17A -B), glycogen ( Figure 17C -D), glucose ( Figure 17E -F), fructose ( Figure 17G -H), mannose ( Figure 17I -J) or mannitol ( Figure 17K Acidification of individual isolates and exemplary 4-member (MC-1) polymers grown in MRS medium (-L)

[0134] Figures 18A-18F The results showed that the modified maltodextrin (containing 20 mg / mL) was used. Figure 18A ), glycogen ( Figure 18B ),glucose( Figure 18C ),fructose( Figure 18D ), Mannose ( Figure 18E ) or mannitol ( Figure 18F The relative abundance of individual isolates of the 4-membered polymer (MC-1) grown in MRS medium over time (measured by qPCR).

[0135] Figures 19A-19D The exemplary 4-member cluster (MC-1) and competing strains are shown in the growth ( Figure 19A -B) and acidification ( Figure 19C Comparison of -D) aspects.

[0136] Figures 20A-20C The growth comparison of individual isolates and the exemplary 4-member cluster (MC-1) is shown. Figure 20A ), and a comparison of the growth of 2-member aggregates and exemplary 4-member aggregates ( Figure 20B ). Figure 20C The growth rates of all individual isolates, 2-member and 4-member aggregates were compared after 8 hours.

[0137] Figures 21A-21C A comparison of acidification was shown between individual isolates and the exemplary 4-member aggregate (MC-1). Figure 21A ), and a comparison of the acidification of 2-member polymers and exemplary 4-member polymers ( Figure 21B ). Figure 21C The acidification rates of all individual isolates, 2-member and 4-member aggregates are compared after 8 hours.

[0138] Figures 22A-22B The growth comparison of a 3-member aggregate and an exemplary 4-member aggregate (MC-1) is shown. Figure 22A ), and a comparison of the growth rates of 3-member aggregates and 4-member aggregates (MC-1) after 8 hours ( Figure 22B ).

[0139] Figures 23A-23B The acidification comparison of the 3-membered polymer and the exemplary 4-membered polymer (MC-1) is shown. Figure 23A ), and a comparison of the acidification rates of 3-membered and 4-membered polymers (MC-1) after 8 hours ( Figure 23B ).

[0140] Figures 24A-24C The relative abundance percentage (based on CFU / ml) of each isolate from the 2-member aggregate is shown, as measured on the plate.

[0141] Figures 25A-25B The relative abundance percentage (based on CFU / ml) of each isolate of the 3-member polymer is shown, as measured by qPCR. Detailed Implementation

[0142] A healthy vaginal microbiota is primarily composed of Lactobacillus species (also known as "lactobacter-dominant"), which protects against harmful pathogens and helps maintain a healthy or "balanced" vaginal environment. For the purposes of this article, a "balanced" vaginal environment or microbiota does not include an dysbiotic vaginal environment or microbiota. An important function of Lactobacillus in the vaginal microbiota is to maintain a healthy acidified state within a range of approximately pH 3.5–4.5, due to the metabolic activity of secreted glycogen / glucose by Lactobacillus within the vagina to produce lactic acid. Acidic conditions are unfavorable to the growth of many pathogenic microorganisms and pathogens, including bacteria, protozoa, and viruses. When vaginal dysbiosis (i.e., a "dysbiotic" vaginal environment) occurs, it is characterized by a decrease in Lactobacillus and an increase in microbial diversity (including, in some cases, vaginal pathogens), which increases the risk of various reproductive tract disorders such as bacterial vaginosis, inflammation, aerobic vaginitis, vulvovaginal candidiasis, sexually transmitted infections, and complications during pregnancy, including preterm birth. If clinical symptoms such as vaginal discharge, vaginal itching, vaginal irritation, and / or vaginal odor occur, antibiotics and antifungal agents are usually the first-line treatment for these conditions; however, these treatments may be ineffective and lead to recurrence.

[0143] In recent years, live biotherapy products have emerged as an alternative class of therapeutic agents with broad applications, including the potential to address vaginal microbiota issues. The U.S. Food and Drug Administration (FDA) defines live biotherapy products as biological products containing live organisms (such as bacteria) intended to prevent, treat, or cure human diseases or ailments, excluding vaccines. Live biotherapy products containing lactobacillus species (such as Lactobacillus acidophilus, Lactobacillus rhamnosus, or Lactobacillus gasseri) for vaginal or oral use have been marketed for many years. These products include vaginal suppositories containing lyophilized Lactobacillus acidophilus or other human-derived lactobacillus species (such as Lactobacillus rhamnosus or Lactobacillus gasseri), as well as various nutritional supplements. However, there is an urgent need for more effective live biotherapy products to improve vaginal health and address vaginal flora imbalances. In particular, there is a need to develop efficient aggregates of bacterial isolates that can be administered as live biotherapy products to treat and address vaginal flora imbalances, vaginal infections, and to improve the overall health profile of subjects receiving such isolates.

[0144] This document provides microbial conglomerates containing a defined population comprising two or more different bacteria capable of implantation into the female urogenital tract of a human subject (e.g., implantation into the female urogenital tract of a female subject exhibiting, for example, urogenital dysbiosis). In some embodiments, the microbial conglomerates of this disclosure include a defined population of isolated lactobacilli configured to facilitate implantation into the female urogenital tract of a subject, the defined population comprising: *Lactobacillus japonicus* isolates; *Lactobacillus curvatureii* isolates that grow well in the presence of *Lactobacillus japonicus*; and at least one additional *Lactobacillus curvatureii* isolate that grows well in the absence of *Lactobacillus japonicus* (e.g., two different *Lactobacillus curvatureii* isolates, such as two different *Lactobacillus curvatureii* isolates with different acidification rates). The urogenital tract includes the reproductive tract, which is considered to be connected between the vaginal and endometrial spaces (e.g., they represent interconnected biogeographical microenvironments), and that there is an exchange of microbes and immune molecules between these microenvironments (Chen C et al., The microbiotacontinuum along the female reproductive tract and its relation to uterine-related diseases, Nature Communications, Vol. 8, 875 (2017)).

[0145] Preparations of lactogenic bacteria (e.g., including Lactobacillus) known in the art are generally insufficiently capable of colonizing and implanting in the body, for example, in the human female urogenital tract of different groups of female subjects (e.g., female subjects exhibiting dysbiosis or infection of the vaginal microbiome). Bacterial intervention strategies in the art have attempted to reverse urogenital dysbiosis by altering the microbiome to be Lactobacillus-dominant, focusing on selecting individual strains of Lactobacillus, formulating them into probiotic supplements or live biotherapy products (LBPs), and then administering them orally or topically, sometimes after antibiotic treatment. However, these strategies lack compelling data showing that the reversal of dysbiosis or infection is partly due to the poor implantation potential of the strains (Vieira-Baptista et al. 2022; van de Wijgert and Verwijs 2020; Thanaboonyawat et al. 2023). Probiotic supplements typically consist of non-vaginal Lactobacillus species (such as Lactobacillus rhamnosus), which are not suitable for persistent vaginal implantation, and most supplements employ a single species or strain approach. Regarding LBPs, the only widely studied vaginal LBP is Lactobacillus curvature CTV-05. In a recent double-blind randomized clinical study, LBPs containing Lactobacillus curvature CTV-05 had no effect on reproductive outcomes in women undergoing assisted reproductive procedures with abnormal vaginal microbiota (Haahr et al., Human Reproduction, Vol. 38, Supplement 1, June 2023), highlighting the ineffectiveness of single-strain products in influencing the resident microbiota of the urogenital tract in different groups of female subjects.

[0146] There are four main problems that hinder the discovery of lactic acid-producing bacteria (e.g., including Lactobacillus) that can colonize and implant in vivo: (1) the source of the bacteria, (2) the process of identifying and isolating suitable bacteria, (3) the route of administration of the bacteria, and (4) combinations of multiple bacteria, such as specific combinations of bacterial isolates.

[0147] The inventors realized that the following conditions are advantageous for identifying lactic acid-producing bacteria (e.g., including lactobacilli) capable of colonizing and implanting in the female reproductive tract: First, the preparations of lactogenic bacteria (e.g., including Lactobacillus) are derived from human female donors exhibiting a healthy (non-dysbiotic) vaginal microbiota; that is, the lactogenic bacteria to be administered to human female subjects are derived from a microbial microenvironment (the donor woman's urogenital microbiota) adapted to survive and thrive in this environment; the lactogenic bacteria are not derived from food or other animal sources. The methods described herein involve using bacterial preparations derived from healthy human female donors.

[0148] Secondly, the bacteria or bacterial isolates capable of colonizing and implanting in human subjects are identified after the donor preparation (containing lactogenic bacteria) has been administered to female recipients (e.g., after a predetermined time period), rather than before administration to the subjects as is typically described in the art. Typically, the methods described in the art involve first collecting a (vaginal) sample from a healthy individual, then isolating and propagating individual isolates in vitro (in cultures), followed by in vitro testing to assess their in vitro colonization ability (e.g., adhesion tests to vaginal epithelial cells (VEC) or HeLa cells, and their ability to produce antimicrobial agents (e.g., hydrogen peroxide), and finally administering the isolates to the recipient. A disadvantage of this is that any in vitro test involves a reductionist simulation of the in vivo environment, and with such an in vitro approach, results vary in the degree of predictability of success.

[0149] The microbial aggregates described herein comprise a defined population of isolated lactobacilli, generated using a method comprising: implanting a bacterial preparation derived from a healthy human female donor into a human woman (e.g., a woman exhibiting dysbiosis); collecting a (vaginal) sample from the female subject after a predetermined time period; determining which species and isolates successfully colonize and implant in vivo into the female subject's urogenital tract, for example, by comparing the composition (bacterial taxonomy and isolates) of the donor woman and the female subject (e.g., by nucleic acid sequencing); and, after identifying isolates that have successfully colonized and implanted into the microbial microenvironment in vivo, returning these isolates to a healthy donor or a stored sample from the donor (or optionally, a recipient sample) to isolate those specific isolates, propagate them, and formulate them into bacterial preparations and / or (pharmaceutical) compositions. These methods thus eliminate the need for cumbersome and labor-intensive in vitro testing procedures and the inherent uncertainty in current methods that must be determined in vitro to predict the ability to colonize in vivo, thereby increasing the likelihood of identifying relevant, highly adapted, and successful isolates capable of colonizing and implanting in vivo. The forward approach first applies a donor sample containing microbial aggregates, then identifies specific species and isolates that can be implanted and improve vaginal flora imbalance in the recipient. This forward approach not only provides a greater chance of identifying therapeutically effective isolates that can improve flora imbalance, but also allows for the identification of isolate aggregates, such as preferred combinations of bacterial isolates representing a subgroup of the donor sample, thereby providing therapeutic efficacy.

[0150] A healthy vaginal flora is characterized by an acidic environment inhabited primarily by lactobacilli (a dominant species of lactobacilli residing in the vaginal microenvironment). The microbial composition in a healthy woman's body may vary, but it is typically dominated by lactobacilli species such as *Lactobacillus curvularia*, *Lactobacillus indolentus*, *Lactobacillus gasseri*, *Lactobacillus japonicus*, and mixtures thereof. It is estimated that a healthy vagina in women of reproductive age contains 10... 6 -109 The vaginal flora is dominated by lactic acid-producing bacteria (e.g., lactobacilli) forming individual colony-forming units. Species distribution varies among women of different geographical backgrounds, ethnicities (e.g., Asian, Caucasian, Black, Hispanic), ages, lifestyles, etc. The composition of the vaginal flora is also influenced by specific isolates inherited from a woman's mother and / or isolates that migrate from her digestive tract to the urogenital tract. In healthy, fertile women, the vaginal pH is approximately 3 to 5.5 (more specifically, between pH 3.5 and 4.5), primarily due to lactic acid production. Vaginal pH undergoes physiological changes from birth to menopause. Increased vaginal pH is unfavorable for the survival of lactobacilli but harmless to other microorganisms. Vaginal lactobacilli are believed to have a protective effect against vaginal colonization by pathogenic microorganisms such as yeast (Candida albicans), Trichomonas vaginalis, Neisseria gonorrhoeae, and Chlamydia trachomatis, as well as viruses such as HIV, HSV-2, and various anaerobic bacteria, and to prevent the establishment of bacteria present in the colon such as Gardnerella vaginalis, Mosclerobacterium, Bacteroides, Prevotella, and Escherichia coli in the vagina.

[0151] Several factors can contribute to vaginal flora imbalance. These factors may include: a) the use of antibiotics to kill pathogenic bacteria, which can lead to a significant decrease in vaginal lactobacillus levels; b) hormonal changes, particularly changes in estrogen levels, which can occur at multiple stages of a woman's life (e.g., puberty, pregnancy, reproductive years, premenopause, and postmenopause); estrogen levels are thought to be associated with (dominant) vaginal lactobacillus levels; c) sexual intercourse, which may be associated with an increase in vaginal pH that disrupts the vaginal flora (semen is typically alkaline), as bacteria other than lactobacillus may begin to proliferate once vaginal pH increases; d) the use of medications, such as chemotherapy drugs or antifungal drugs; e) the use of contraceptive products; f) menstruation; g) poor hygiene (e.g., promoting the unintended spread of microbes from the rectum to the urogenital region); h) general health conditions, such as having comorbidities, such as diabetes; and (i) overuse of hygiene measures, particularly the use of vaginal douches.

[0152] Vaginal flora imbalance can lead to vaginal diseases such as candidiasis and bacterial vaginosis, two common vaginal conditions affecting women worldwide. Bacterial vaginosis is thought to result from the replacement of lactobacilli in the vagina with a range of unwanted species, such as Gardnerella vaginalis, Bacteroides, Moscurvy, Prevotella, and Mycoplasma hominis. Vaginal infections are most commonly associated with one or more of the following: Escherichia coli, Enterococcus, Pseudomonas, Proteus, Klebsiella, Streptococcus, Staphylococcus, Gardnerella vaginalis, Ureaplasma, Bacteroides, Peptococcus, Neisseria, Serratia, Seneca, Megacoccus, Corynebacterium, Clostridium, and Candida.

[0153] The dominance of vaginal lactobacilli is thought to play a significant role in resisting infection by producing lactic acid and acidifying the vagina, as well as by producing other antimicrobial products such as hydrogen peroxide. The presence of vaginal lactobacilli is associated with reduced frequency of bacterial vaginosis, yeast infections, and sexually transmitted pathogens (including Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis) and viruses (such as HIV and HSV). Lactobacillus dominance varies by race (they are thought to be very dominant in Asian and white women, but less so in Black and Hispanic women, although they are still generally majority).

[0154] Studies have shown that depleted lactobacillus colonies can be transient, lasting only a few days, while in other cases, they can persist for weeks. Some women with depleted lactobacillus colonies remain asymptomatic, for example, in terms of vaginal health and general well-being. However, such women may have a higher risk of infection and STDs.

[0155] The female urogenital tract (also known as the urogenital system) consists of interconnected biogeographical microenvironments, such as the vaginal microenvironment and the endometrial microenvironment. Bacteria in the vaginal microbiota can migrate to distant sites of the urogenital tract via the cervix. Dysbiosis in the vaginal microbiota can lead to dysbiosis in distal sites. Dysbiosis in these sites is associated with a range of diseases and disorders, including urinary tract infections (UTI), pelvic inflammatory disease (PID), and bacterial vaginosis (BV). In some embodiments, the application of the microbial community described herein, comprising individual and unique lactobacilli (e.g., *Lactobacillus janniae* and / or *Lactobacillus curvaturei*), to the vagina is intended to address dysbiosis in distal sites of the urogenital tract.

[0156] Lactobacillus japonicus *Lactobacillus janniae* is a Gram-positive, rod-shaped, aerobic species of lactobacillus and a naturally occurring component of the vaginal microbiota. In vitro studies have shown that *Lactobacillus janniae* inhibits the release of pro-inflammatory mediators from vaginal epithelial cells, thereby promoting antimicrobial defense without inducing immune-mediated inflammation (Witkin SS and Linhares IM, Why do lactobacilli dominate the human vaginal microbiota? BJOG 2017; 124:606-611). *Lactobacillus janniae* contains two D-lactate dehydrogenase genes and one L-lactate dehydrogenase gene for lactate production.

[0157] In some embodiments, *Lactobacillus japonicus* isolates were obtained from bacterial samples deposited on October 4, 2023, by DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Inhoffenstr. 7B, D-38124 Braunschweig under DSM accession number 34770 (“DSM 34770”). This deposit was made pursuant to the provisions of the Budapest Treaty, which governs the international recognition of microbial deposits for patent proceedings.

[0158] In some embodiments, the *Lactobacillus janniae* isolate is derived from or propagated from a bacterial sample deposited in DSM 34770. In some embodiments, when compared with the genome of a bacterial sample deposited in DSM 34770, the genome of the *Lactobacillus janniae* isolate has a percentage of identity greater than or equal to a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%).

[0159] In some embodiments, *Lactobacillus janseri* (e.g., *Lactobacillus janseri* isolates) can be obtained from vaginal secretions of a donor (e.g., a human donor). In some embodiments, *Lactobacillus janseri* (e.g., *Lactobacillus janseri* isolates) can be obtained using the method described in International Patent Publication No. WO 2022 / 185121, published September 9, 2022, the contents of which are incorporated herein by reference. For example, vaginal fluid can be collected from a donor, using a menstrual cup or vaginal swab, and plated onto a selective medium (e.g., a diffusion medium, such as broth, and / or a solid medium, such as agar) to allow individual bacterial isolates to colonize and multiply. Non-limiting examples of selective media include De Man–Rogosa–Sharpe (MRS) medium, Rogosa medium, M17 medium, Elliker, and thioglycolate medium. Individual colonies (e.g., bacterial isolates) can then be selected and multiplied by inoculation into large-scale cultures. As used herein, the large-scale culture method refers to a method of amplifying a single bacterial isolate by allowing it to multiply in at least 1 liter of selective diffusion medium (e.g., broth). In some embodiments, the large-scale culture is a selective diffusion medium (e.g., broth) of about 1 L, about 2 L, about 3 L, about 4 L, about 5 L, about 6 L, about 7 L, about 8 L, about 9 L, about 10 L, about 15 L, about 20 L, about 25 L, about 30 L, about 35 L, about 40 L, about 45 L, about 50 L, about 100 L, about 500 L, about 1,000 L, about 2,000 L, about 3,000 L, about 4,000 L, or about 5,000 L or more.In some implementations, large-scale cultures are 1 L – 50 L, 1 L – 45 L, 5 L – 45 L, 5 L – 40 L, 10 L – 40 L, 10 L – 35 L, 15 L – 35 L, 15 L – 30 L, 20 L – 30 L, 20 L – 25 L, 1 L – 5 L, 1 L – 10 L, 5 L – 10 L, 5 L – 15 L, 10 L – 20 L, 15 L – 20 L, 15 L – 20 L, 15 L – 25 L, 20 L – 25 L, 20 L – 30 L, 25 L – 30 L, 25 L – 35 L, 30 L – 40 L, 35 L – 40 L, 35 L – 45 L, 40 L – 45 L, 40 L – Selective diffusion media (e.g., broth) in sizes of 50 L, 45 L – 50 L, 50 L – 250 L, 100 L – 5,000 L, 100 L – 2,000 L, 100 L – 1,000 L, 500 L – 5,000 L, 500 L – 3,000 L, 500 L – 1,500 L, or 1,000 L – 10,000 L.

[0160] In some embodiments, the microbial aggregates of this disclosure may include isolates of *Lactobacillus japonicus*. In some embodiments, the growth rate refers to the in vitro growth rate calculated after 8 hours of bacterial growth in a culture. In some embodiments, the growth rate of a specific bacterium or aggregate is determined after inoculation with MRS broth at 37°C at 5 million CFU / mL. The growth rate can be determined according to the following formula: the growth rate equals the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the growth rate of *Lactobacillus japonicus* included in the microbial aggregates of this disclosure is approximately 0.2 hours over an 8-hour time period in a culture (initial pH 4.7). -1 Approximately 0.25 hours -1 Approximately 0.3 hours -1 Approximately 0.35 hours -1 Approximately 0.4 hours -1 Approximately 0.45 hours -1 or about 0.5 hours -1The growth rate is calculated using the following formula: the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure exhibits a growth rate of 0.2–0.25 h / m² in the culture over an 8-hour period (initial pH 4.7). -1 0.2 – 0.3 hours -1 0.2 – 0.35 hours -1 0.2 – 0.4 hours -1 0.2 – 0.45 hours -1 0.2 – 0.5 hours -1 0.25 – 0.3 hours -1 0.25 – 0.35 hours -1 0.25 – 0.4 hours -1 0.25 – 0.45 hours -1 0.25 – 0.5 hours -1 0.3 – 0.35 hours -1 0.3-0.4 hours -1 0.3 – 0.45 hours -1 0.3 – 0.5 hours -1 0.35 – 0.4 hours -1 0.35 – 0.45 hours -1 0.35 – 0.5 hours -1 0.4 – 0.45 hours -1 0.4 – 0.5 hours -1 Or 0.45 – 0.5 hours -1 The growth rate is calculated using the following formula: the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure exhibits a growth rate of approximately 0.35 h / min over an 8-hour time period in culture (initial pH 4.7). -1 (For example, 0.34 hours) -1 The growth rate is calculated using the following formula: the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time).

[0161] In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure exhibits a growth rate of approximately 0.2 h / m² during an 8-hour culture period (initial pH 5.2) after 8 hours of growth in the culture. -1 Approximately 0.25 hours -1 Approximately 0.3 hours -1 Approximately 0.35 hours -1 Approximately 0.4 hours -1 Approximately 0.45 hours -1 or about 0.5 hours -1 The growth rate is calculated using the following formula: the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure exhibits a growth rate of 0.2–0.25 h⁻¹ within an 8-hour time period in the culture (initial pH 5.2) after 8 hours of growth. -1 0.2–0.3 hours -1 0.2 – 0.35 hours -1 0.2 – 0.4 hours -1 0.2 – 0.45 hours -1 0.2 – 0.5 hours -1 0.25 – 0.3 hours -1 0.25 – 0.35 hours -1 0.25 – 0.4 hours -1 0.25 – 0.45 hours -1 0.25 – 0.5 hours -1 0.3 – 0.35 hours -1 0.3 – 0.4 hours -1 0.3 – 0.45 hours -1 0.3 – 0.5 hours -1 0.35 – 0.4 hours -1 0.35 – 0.45 hours -1 0.35 – 0.5 hours -1 0.4 – 0.45 hours -1 0.4 – 0.5 hours -1 Or 0.45 – 0.5 hours -1The growth rate is calculated using the following formula: the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure has a growth rate of approximately 0.4 h / m² during an 8-hour time period in the culture (initial pH 5.2) after 8 hours of growth. -1 (For example, 0.42 hours) -1 The growth rate is calculated using the following formula: the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time).

[0162] In some embodiments, the acidification rate refers to the in vitro acidification rate calculated after 24 hours of bacterial growth in the culture. In some embodiments, the acidification rate of a specific bacterium or aggregate is determined after inoculating MRS broth at 37°C with 5 million CFU / mL. The acidification rate can be determined according to the following formula: the acidification rate equals the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus japonicus* included in the microbial aggregates of this disclosure is approximately -0.003 hours over a 24-hour time period in the culture (initial pH 4.7). -1 Approximately -0.004 hours -1 Approximately -0.006 hours -1 Approximately -0.007 hours -1 Approximately -0.008 hours -1 Approximately -0.009 hours -1 Approximately -0.010 hours -1 Approximately -0.011 hours -1 Or approximately -0.12 hours -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure is -0.003 to -0.005 h⁻¹ in the culture over a 24-hour period (initial pH 4.7). -1 -0.003 to -0.006 hours -1 -0.003 to -0.007 hours -1 -0.003 to -0.008 hours -1 -0.003 to -0.009 hours -1 -0.003 to -0.010 hours-1 -0.003 to -0.011 hours -1 -0.003 to -0.012 hours -1 -0.004 to -0.006 hours -1 -0.004 to -0.007 hours -1 -0.004 to -0.008 hours -1 -0.004 to -0.009 hours -1 -0.004 to -0.010 hours -1 -0.004 to -0.011 hours -1 -0.004 to -0.012 hours -1 -0.005 to -0.007 hours -1 -0.005 to -0.008 hours -1 -0.005 to -0.009 hours -1 -0.005 to -0.010 hours -1 -0.005 to -0.011 hours -1 -0.001 to -0.012 hours -1 -0.006 to -0.008 hours -1 -0.006 to -0.009 hours -1 -0.006 to -0.010 hours -1 -0.006 to -0.011 hours -1 -0.006 to -0.12 hours -1 -0.007 to -0.009 hours -1 -0.007 to -0.010 hours -1 -0.007 to -0.011 hours -1 -0.007 to -0.012 hours -1 -0.008 to -0.010 hours -1 -0.008 to -0.011 hours -1 -0.008 to -0.012 hours -1 -0.009 to -0.011 hours -1 -0.009 to -0.012 hours -1 Or -0.010 to -0.012 hours -1The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure is approximately -0.004 h over a 24-hour time period in culture (initial pH 4.7). -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0163] In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure exhibits an acidification rate of approximately -0.003 hours over a 24-hour period in the culture (initial pH 5.2). -1 Approximately -0.004 hours -1 Approximately -0.006 hours -1 Approximately -0.007 hours -1 Approximately -0.008 hours -1 Approximately -0.009 hours -1 Approximately -0.010 hours -1 Approximately -0.011 hours -1 Or approximately -0.12 hours -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure is -0.003 to -0.005 h over a 24-hour period in culture (initial pH 5.2). -1 -0.003 to -0.006 hours -1 -0.003 to -0.007 hours -1 -0.003 to -0.008 hours -1 -0.003 to -0.009 hours -1 -0.003 to -0.010 hours -1 -0.003 to -0.011 hours -1 -0.003 to -0.012 hours -1 -0.004 to -0.006 hours -1 -0.004 to -0.007 hours -1 -0.004 to -0.008 hours -1 -0.004 to -0.009 hours -1-0.004 to -0.010 hours -1 -0.004 to -0.011 hours -1 -0.004 to -0.012 hours -1 -0.005 to -0.007 hours -1 -0.005 to -0.008 hours -1 -0.005 to -0.009 hours -1 -0.005 to -0.010 hours -1 -0.005 to -0.011 hours -1 -0.001 to -0.012 hours -1 -0.006 to -0.008 hours -1 -0.006 to -0.009 hours -1 -0.006 to -0.010 hours -1 -0.006 to -0.011 hours -1 -0.006 to -0.12 hours -1 -0.007 to -0.009 hours -1 -0.007 to -0.010 hours -1 -0.007 to -0.011 hours -1 -0.007 to -0.012 hours -1 -0.008 to -0.010 hours -1 -0.008 to -0.011 hours -1 -0.008 to -0.012 hours -1 -0.009 to -0.011 hours -1 -0.009 to -0.012 hours -1 Or -0.010 to -0.012 hours -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus japonicus* contained in the microbial aggregates of this disclosure is approximately -0.008 h over a 24-hour time period in the culture (initial pH 5.2). -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0164] In some embodiments, the *Lactobacillus janniae* of this disclosure grows well. As used herein, the term "growing well" means a bacterium that, when grown under the same conditions, grows or multiplies at a higher rate than a control bacterium (e.g., *Lactobacillus janniae* isolate). For example, the control bacterium could be a different isolate of the same species.

[0165] In some embodiments, a *Lactobacillus japonicus* isolate is described as "growing well" if it is able to grow and multiply in vitro or in vivo. In some embodiments, a *Lactobacillus japonicus* isolate is described as "growing well" if its growth rate is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25% higher than that of a control *Lactobacillus japonicus* (under the same conditions). In some implementations, a *Lactobacillus japonicus* isolate is considered to be "growing well" if its growth rate is 1%-5%, 1%-10%, 5%-10%, 5%-15%, 10%-20%, 15%-20%, 15%-25%, 20%-25%, 1%-25%, 1%-20%, 5%-25%, 5%-20%, or 5%-15% higher than that of the control *Lactobacillus japonicus* (under the same conditions).

[0166] Lactobacillus curvature *Lactobacillus curlai* is a Gram-positive, rod-shaped, aerobic species of lactobacillus and a naturally occurring component of the vaginal microbiota. A vaginal microbiota dominated by *Lactobacillus curlai* is associated with a healthy vagina because *Lactobacillus curlai* has been shown to provide protection against sexually transmitted infections (STIs), bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC) due to its ability to produce lactic acid and bacteriocins (Chee WJY et al., Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health, Microbial Cell Factories, Vol. 19, 203 (2020)). *Lactobacillus curlai* contains two L-lactate dehydrogenase genes and one D-lactate dehydrogenase gene for lactic acid production.

[0167] In some embodiments, the *Lactobacillus curli* isolates of this disclosure are obtained from bacterial samples deposited with DSM accession number 34771 (“DSM34771”). In some embodiments, the *Lactobacillus curli* isolates of this disclosure are obtained from bacterial samples deposited with DSM accession number 34772 (“DSM 34772”). In some embodiments, the *Lactobacillus curli* isolates of this disclosure are obtained from bacterial samples deposited with DSM accession number 34773 (“DSM 34773”). DSM34771, DSM 34772 and DSM 34773 were deposited on October 4, 2023 by DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Inhoffenstr. 7B, D-38124 Braunschweig. The aforementioned deposit was made in accordance with the terms of the Budapest Treaty, which is the international recognition of the deposit of microorganisms for patent proceedings purposes.

[0168] In some embodiments, *Lactobacillus curvaturei* (e.g., *Lactobacillus curvaturei* isolates) can be obtained from vaginal secretions of a donor (e.g., a human donor). In some embodiments, *Lactobacillus curvaturei* (e.g., *Lactobacillus curvaturei* isolates) can be obtained using the method described in International Patent Publication No. WO 2022 / 185121, published September 9, 2022, the contents of which are incorporated herein by reference. For example, vaginal fluid can be collected from a donor, using a menstrual cup or vaginal swab, and plated onto a selective medium (e.g., a diffusion medium, such as broth, and / or a solid medium, such as agar) to allow individual bacterial isolates to colonize and multiply. Non-limiting examples of selective media include De Man–Rogosa–Sharpe (MRS), Rogosa medium, M17 medium, Elliker, and thioglycolate medium. Individual colonies can then be selected and multiplied by inoculation into a large-scale culture. As used herein, the large-scale culture method refers to a method of amplifying individual bacterial isolates by allowing them to multiply in at least 1 liter of selective diffusion medium (e.g., broth). In some implementations, the large-scale culture is a selective diffusion medium (e.g., broth) of about 1 L, about 2 L, about 3 L, about 4 L, about 5 L, about 6 L, about 7 L, about 8 L, about 9 L, about 10 L, about 15 L, about 20 L, about 25 L, about 30 L, about 35 L, about 40 L, about 45 L, about 50 L, about 100 L, about 500 L, about 1,000 L, about 2,000 L, about 3,000 L, about 4,000 L, or about 5,000 L or more.In some implementations, large-scale cultures are 1 L – 50 L, 1 L – 45 L, 5 L – 45 L, 5 L – 40 L, 10 L – 40 L, 10 L – 35 L, 15 L – 35 L, 15 L – 30 L, 20 L – 30 L, 20 L – 25 L, 1 L – 5 L, 1 L – 10 L, 5 L – 10 L, 5 L – 15 L, 10 L – 15 L, 10 L – 20 L, 15 L – 20 L, 15 L – 25 L, 20 L – 25 L, 20 L – 30 L, 25 L – 30 L, 25 L – 35 L, 30 L – 40 L, 35 L – 40 L, 35 L – 45 L, 40 L – 45 L, 40 L – Selective diffusion media (e.g., broth) of 50 L or 45 L–50 L, 50 L–250 L, 100 L–5,000 L, 100 L–2,000 L, 100 L–1,000 L, 500 L–5,000 L, 500 L–3,000 L, 500 L–1,500 L, or 1,000 L–10,000 L.

[0169] In some embodiments, the microbial aggregates of this disclosure may include one or more different *Lactobacillus curvatureii* isolates. In some embodiments, the microbial aggregates of this disclosure may include 1, 2, 3, 4, 5 or more different *Lactobacillus curvatureii* isolates.

[0170] In some embodiments, the growth rate refers to the in vitro growth rate calculated after the bacteria have grown in the culture for 8 hours. In some embodiments, the growth rate of a specific bacterium or aggregate is determined after inoculating MRS broth at 37°C with 5 million CFU / mL. The growth rate can be determined according to the following formula: the growth rate equals the natural logarithm (Ln) of (final OD600 divided by initial OD600) divided by (final time minus initial time).

[0171] In some embodiments, when grown in a selective diffusion medium (e.g., MRS) with an initial pH of 4.7, the growth rate of *Lactobacillus curvatureensis* contained in the microbial aggregates of this disclosure is approximately 0.2 hours. -1 Approximately 0.25 hours -1 Approximately 0.3 hours -1 Approximately 0.35 hours -1 Approximately 0.4 hours -1 Approximately 0.45 hours -1or about 0.5 hours -1 In some embodiments, when grown in a selective diffusion medium (e.g., MRS) at an initial pH of 4.7, the growth rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is 0.2–0.25 hours. -1 0.2 – 0.3 hours -1 0.2 – 0.35 hours -1 0.2-0.4 hours -1 0.2 – 0.45 hours -1 0.2 – 0.5 hours -1 0.25 – 0.3 hours -1 0.25 – 0.35 hours -1 0.25 – 0.4 hours -1 0.25 – 0.45 hours -1 0.25 – 0.5 hours -1 0.3 – 0.35 hours -1 0.3 – 0.4 hours -1 0.3 – 0.45 hours -1 0.3 – 0.5 hours -1 0.35 – 0.4 hours -1 0.35 – 0.45 hours -1 0.35-0.5 hours -1 0.4 – 0.45 hours -1 0.4 – 0.5 hours -1 Or 0.45 – 0.5 hours -1 In some embodiments, the *Lactobacillus curvature* contained in the microbial aggregates of this disclosure grows at a rate of approximately 0.3 hours in a selective diffusion medium (e.g., MRS) with an initial pH of 4.7. -1 (e.g., 0.28 hours) -1 In some embodiments, the *Lactobacillus curvature* contained in the microbial aggregates of this disclosure grows at a rate of approximately 0.4 hours when grown in a selective diffusion medium (e.g., MRS) with an initial pH of 4.7. -1 (e.g., 0.38 hours) -1 In some embodiments, the *Lactobacillus curvature* contained in the microbial aggregates of this disclosure grows at a rate of approximately 0.25 hours in a selective diffusion medium (e.g., MRS) with an initial pH of 4.7. -1 .

[0172] In some embodiments, when grown in a selective diffusion medium (e.g., MRS) with an initial pH of 5.2, the growth rate of *Lactobacillus curvatureensis* contained in the microbial aggregates of this disclosure is approximately 0.2 hours. -1 Approximately 0.25 hours -1 Approximately 0.3 hours -1 Approximately 0.35 hours -1 Approximately 0.4 hours -1 Approximately 0.45 hours -1 or about 0.5 hours -1 In some embodiments, when grown in a selective diffusion medium (e.g., MRS) at an initial pH of 5.2, the growth rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is 0.2–0.25 hours. -1 0.2 – 0.3 hours -1 0.2 – 0.35 hours -1 0.2-0.4 hours -1 0.2 – 0.45 hours -1 0.2 – 0.5 hours -1 0.25 – 0.3 hours -1 0.25 – 0.35 hours -1 0.25 – 0.4 hours -1 0.25 – 0.45 hours -1 0.25 – 0.5 hours -1 0.3 – 0.35 hours -1 0.3 – 0.4 hours -1 0.3 – 0.45 hours -1 0.3 – 0.5 hours -1 0.35 – 0.4 hours -1 0.35 – 0.45 hours -1 0.35-0.5 hours -1 0.4 – 0.45 hours -1 0.4 – 0.5 hours -1 Or 0.45 – 0.5 hours -1 In some embodiments, the growth rate of the *Lactobacillus curlii* of this disclosure is about 0.35 (e.g., 0.36) when grown in a selective diffusion medium (e.g., MRS) with an initial pH of 5.2. In some embodiments, the growth rate of the *Lactobacillus curlii* of this disclosure is about 0.4 hours when grown in a selective diffusion medium (e.g., MRS) with an initial pH of 5.2. -1In some embodiments, the growth rate of the *Lactobacillus curvature* disclosed herein is approximately 0.3 hours when grown in a selective diffusion medium (e.g., MRS) with an initial pH of 5.2. -1 (For example, 0.32 hours) -1 ).

[0173] In some embodiments, the acidification rate refers to the in vitro acidification rate calculated after 24 hours of bacterial growth in the culture. In some embodiments, the acidification rate of a specific bacterium or aggregate is determined after inoculating MRS broth at 37°C with 5 million CFU / mL. The acidification rate can be determined according to the following formula: the acidification rate equals the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0174] In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of the *Lactobacillus curvature* of this disclosure in the culture over a 24-hour period (initial pH 4.7) is approximately -0.003 hours. -1 Approximately -0.004 hours -1 Approximately -0.006 hours -1 Approximately -0.007 hours -1 Approximately -0.008 hours -1 Approximately -0.009 hours -1 Approximately -0.010 hours -1 Approximately -0.011 hours -1 Or approximately -0.12 hours -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is -0.003 to -0.005 h⁻¹ in the culture over a 24-hour period (initial pH 4.7). -1 -0.003 to -0.006 hours -1 -0.003 to -0.007 hours -1 -0.003 to -0.008 hours -1 -0.003 to -0.009 hours -1 -0.003 to -0.010 hours -1 -0.003 to -0.011 hours -1 -0.003 to -0.012 hours -1 -0.004 to -0.006 hours -1 -0.004 to -0.007 hours -1-0.004 to -0.008 hours -1 -0.004 to -0.009 hours -1 -0.004 to -0.010 hours -1 -0.004 to -0.011 hours -1 -0.004 to -0.012 hours -1 -0.005 to -0.007 hours -1 -0.005 to -0.008 hours -1 -0.005 to -0.009 hours -1 -0.005 to -0.010 hours -1 -0.005 to -0.011 hours -1 -0.001 to -0.012 hours -1 -0.006 to -0.008 hours -1 -0.006 to -0.009 hours -1 -0.006 to -0.010 hours -1 -0.006 to -0.011 hours -1 -0.006 to -0.12 hours -1 -0.007 to -0.009 hours -1 -0.007 to -0.010 hours -1 -0.007 to -0.011 hours -1 -0.007 to -0.012 hours -1 -0.008 to -0.010 hours -1 -0.008 to -0.011 hours -1 -0.008 to -0.012 hours -1 -0.009 to -0.011 hours -1 -0.009 to -0.012 hours -1 Or -0.010 to -0.012 hours -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is approximately -0.006 h over a 24-hour time period in culture (initial pH 4.7). -1The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is approximately -0.007 h over a 24-hour time period in culture (initial pH 4.7). -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is approximately -0.008 h over a 24-hour time period in culture (initial pH 4.7). -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is -0.006 to -0.008 h over a 24-hour period in culture (initial pH 4.7). -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0175] In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the *Lactobacillus curvature* contained in the microbial aggregates of this disclosure exhibits an acidification rate of approximately -0.003 hours over a 24-hour period in the culture (initial pH 5.2). -1 Approximately -0.004 hours -1 Approximately -0.006 hours -1 Approximately -0.007 hours -1 Approximately -0.008 hours -1 Approximately -0.009 hours -1 Approximately -0.010 hours -1 Approximately -0.011 hours -1 Or approximately -0.12 hours -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is -0.003 to -0.005 h⁻¹ in the culture over a 24-hour period (initial pH 5.2). -1-0.003 to -0.006 hours -1 -0.003 to -0.007 hours -1 -0.003 to -0.008 hours -1 -0.003 to -0.009 hours -1 -0.003 to -0.010 hours -1 -0.003 to -0.011 hours -1 -0.003 to -0.012 hours -1 -0.004 to -0.006 hours -1 -0.004 to -0.007 hours -1 -0.004 to -0.008 hours -1 -0.004 to -0.009 hours -1 -0.004 to -0.010 hours -1 -0.004 to -0.011 hours -1 -0.004 to -0.012 hours -1 -0.005 to -0.007 hours -1 -0.005 to -0.008 hours -1 -0.005 to -0.009 hours -1 -0.005 to -0.010 hours -1 -0.005 to -0.011 hours -1 -0.001 to -0.012 hours -1 -0.006 to -0.008 hours -1 -0.006 to -0.009 hours -1 -0.006 to -0.010 hours -1 -0.006 to -0.011 hours -1 -0.006 to -0.12 hours -1 -0.007 to -0.009 hours -1 -0.007 to -0.010 hours -1 -0.007 to -0.011 hours -1 -0.007 to -0.012 hours -1 -0.008 to -0.010 hours -1 -0.008 to -0.011 hours -1 -0.008 to -0.012 hours -1 -0.009 to -0.011 hours -1 -0.009 to -0.012 hours -1 Or -0.010 to -0.012 hours-1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is approximately -0.007 h over a 24-hour time period in culture (initial pH 5.2). -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time). In some embodiments, when grown in a selective diffusion medium (e.g., MRS), the acidification rate of *Lactobacillus curvature* contained in the microbial aggregates of this disclosure is approximately -0.0011 h over a 24-hour period in culture (initial pH 5.2). -1 The acidification rate is calculated using the following formula: the natural logarithm (Ln) of (final pH divided by initial pH) divided by (final time minus initial time).

[0176] In some embodiments, the *Lactobacillus curlis* of this disclosure grows well in the presence of *Lactobacillus janniae*. As used herein, the term "growing well" means bacteria that grow or reproduce at a higher rate than control bacteria when grown under the same conditions (e.g., *Lactobacillus curlis* isolates). For example, control bacteria may be different isolates of the same species.

[0177] In some embodiments, a *Lactobacillus curvatureii* isolate is described as "growing well" if it is able to grow and multiply in vitro or in vivo. In some embodiments, a *Lactobacillus curvatureii* isolate is described as "growing well" if its growth rate is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25% higher than that of a control *Lactobacillus curvatureii* (under the same conditions). In some implementations, a *Lactobacillus curvatureii* isolate is considered to be "growing well" if its growth rate is 1%-5%, 1%-10%, 5%-10%, 5%-15%, 10%-20%, 15%-20%, 15%-25%, 20%-25%, 1%-25%, 1%-20%, 5%-25%, 5%-20%, or 5%-15% higher than that of the control *Lactobacillus curvatureii* (under the same conditions).

[0178] In some embodiments, when grown in the presence of Lactobacillus jenny, the growth rate of Lactobacillus curvature that grows well in the presence of Lactobacillus jenny is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25% higher than the growth rate of control Lactobacillus curvature that grows well in the presence of Lactobacillus jenny (under the same conditions). In some embodiments, when grown in the presence of *Lactobacillus japonicus*, the growth rate of *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus japonicus* is 1%-5%, 1%-10%, 5%-10%, 5%-15%, 10%-15%, 10%-20%, 15%-20%, 15%-25%, 20%-25%, 1%-25%, 1%-20%, 5%-25%, 5%-20%, or 5%-15%. In some embodiments, the microbial aggregates of this disclosure comprise one or more *Lactobacillus curvaturei* species that grow well in the presence of *Lactobacillus japonicus*. In some embodiments, the microbial aggregates of this disclosure contain 1, 2, 3, 4, or 5 *Lactobacillus curvaturei* species that grow well in the presence of *Lactobacillus japonicus*.

[0179] In some implementations, *Lactobacillus curvatureensis* isolates that grow well in the presence of *Lactobacillus janniae* are obtained from bacterial samples deposited under DSM accession number 34772.

[0180] In some embodiments, *Lactobacillus curlis* isolates that grow well in the presence of *Lactobacillus jenny* are derived from or propagated from bacterial samples deposited under DSM 34770. In some embodiments, the genome of the *Lactobacillus curlis* isolates that grow well in the presence of *Lactobacillus jenny* has a percentage of identity greater than or equal to a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%) when compared with the genome of a bacterial sample deposited under DSM 34772.

[0181] Various aspects of this disclosure provide a curly-shaped Lactobacillus that grows well in the presence of Lactobacillus janniae, which can be implanted in the female urogenital tract of a subject in the presence of Lactobacillus janniae and persist for at least a predetermined period of time.

[0182] The implantation of *Lactobacillus curli*, which grows well in the presence of *Lactobacillus jenny*, into the female urogenital tract can persist for a predetermined period of time in the presence of *Lactobacillus jenny*. In some embodiments, the implantation of *Lactobacillus curli*, which grows well in the presence of *Lactobacillus jenny*, can persist for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, or longer. In some implementations, the implantation of *Lactobacillus curli* that grows well in the presence of *Lactobacillus japonicus* persists for 1–7 days, 1–2 weeks, 1–3 weeks, 1–4 weeks, 2–4 weeks, 1–2 months, 2–4 months, 4–6 months, 6–8 months, 8–10 months, 10–12 months, 1–6 months, 6–12 months, 3–9 months, 6 months to 1 year, 6 months to 2 years, or 1–2 years. The duration of implantation of *Lactobacillus curli* that grows well in the presence of *Lactobacillus japonicus* depends on several factors known to those skilled in the art, such as the specific medical condition being treated, individual variability (e.g., lifestyle and diet), and the underlying cause of the condition.

[0183] In some embodiments, the *Lactobacillus curlis* isolates of this disclosure can grow well in the absence of *Lactobacillus janieri*. In other words, in some embodiments, the *Lactobacillus curlis* isolates can grow well regardless of the presence or absence of *Lactobacillus janieri*. A bacterium (e.g., *Lactobacillus curlis* isolate) that grows well in the absence of another bacterium (e.g., *Lactobacillus janieri* isolate) refers to a bacterium that maintains a similar growth rate whether or not it is present.

[0184] In some embodiments, *Lactobacillus curvatureii* isolates that grow well in the absence of *Lactobacillus jenny* are obtained from bacterial samples deposited with DSM accession number 34771. In some embodiments, *Lactobacillus curvatureii* isolates that grow well in the absence of *Lactobacillus jenny* are obtained from bacterial samples deposited with DSM accession number 34773.

[0185] In some embodiments, *Lactobacillus curvatureii* isolates that grow well in the absence of *Lactobacillus jenny* are derived from or propagated from bacterial samples deposited under DSM 34771. In some embodiments, the genome of the *Lactobacillus curvatureii* isolates that grow well in the absence of *Lactobacillus jenny* has a percentage of identity greater than or equal to a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%) when compared with the genome of bacterial samples deposited under DSM 34771.

[0186] In some embodiments, *Lactobacillus curlis* isolates that grow well in the absence of *Lactobacillus jenny* are derived from or propagated from bacterial samples deposited in DSM 34773. In some embodiments, the genome of the *Lactobacillus curlis* isolates that grow well in the absence of *Lactobacillus jenny* has a percentage of identity greater than or equal to a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%) when compared with the genome of bacterial samples deposited in DSM 34773.

[0187] In some embodiments, the microbial aggregates of this disclosure comprise one or more *Lactobacillus curvaturei* species that grow well in the absence of *Lactobacillus janieri*. In some embodiments, the microbial aggregates of this disclosure comprise 1, 2, 3, 4, or 5 *Lactobacillus curvaturei* species that grow well in the absence of *Lactobacillus janieri*. In some embodiments, the microbial aggregates of this disclosure comprise two *Lactobacillus curvaturei* species that grow well in the absence of *Lactobacillus janieri* (e.g., two different *Lactobacillus curvaturei* species).

[0188] In some implementations, each type of *Lactobacillus curvatureensis* that grows well in the absence of *Lactobacillus janniae* can be implanted into the female urogenital tract of the subject for at least a predetermined period of time. Implantation of *Lactobacillus curvatureensis* isolates that grow well in the absence of *Lactobacillus janniae* into the female urogenital tract can last for a predetermined period of time. In some implementations, implantation of *Lactobacillus curvatureensis* isolates that grow well in the absence of *Lactobacillus janniae* can last for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, or longer. In some implementations, the implantation of *Lactobacillus curvaturei* isolates that grow well in the absence of *Lactobacillus jenny* can last for 1–7 days, 1–2 weeks, 1–3 weeks, 1–4 weeks, 2–4 weeks, 1–2 months, 2–4 months, 4–6 months, 6–8 months, 8–10 months, 10–12 months, 1–6 months, 6–12 months, 3–9 months, 6 months to 1 year, 6 months to 2 years, or 1–2 years. The duration of implantation of *Lactobacillus curvaturei* isolates that grow well in the absence of *Lactobacillus jenny* depends on several factors known to those skilled in the art, such as the specific medical condition being treated, individual variability (e.g., lifestyle and diet), and the underlying cause of the condition.

[0189] In some embodiments, one or more *Lactobacillus curvatureii* isolates include a first and a second *Lactobacillus curvatureii* isolate. In some embodiments, the first *Lactobacillus curvatureii* isolate has a growth rate of approximately 0.28 hours. -1 (For example, when grown in a selective medium with an initial pH of 4.7). In some embodiments, the growth rate of the first *Lactobacillus curvatureii* isolate is approximately 0.36 hours.-1 (For example, when grown in a selective medium with an initial pH of 5.2). In some embodiments, the acidification rate of the first *Lactobacillus curvatureii* isolate is approximately -0.006 hours. -1 (For example, when grown in a selective medium with an initial pH of 4.7). In some embodiments, the acidification rate of the first *Lactobacillus curvatureii* isolate is approximately -0.007 hours. -1 (For example, when grown in a selective medium at pH 5.2). In some embodiments, the growth rate of the second *Lactobacillus curvatureii* isolate is approximately 0.38 hours. -1 (For example, when grown in a selective medium at pH 4.7). In some embodiments, the growth rate of the second *Lactobacillus curvatureii* isolate is approximately 0.4 hours. -1 (For example, when grown in a selective medium at pH 5.2). In some embodiments, the acidification rate of the second *Lactobacillus curvatureii* isolate is approximately -0.008 hours. -1 (For example, when grown in a selective medium at pH 4.7). In some embodiments, the acidification rate of the second *Lactobacillus curvatureii* isolate is approximately -0.011 hours. -1 (For example, when growing in a selective medium at pH 5.2).

[0190] In some embodiments, one or more *Lactobacillus curvatureii* isolates include a first, a second, and a third *Lactobacillus curvatureii* isolate. In some embodiments, the first *Lactobacillus curvatureii* isolate has a growth rate of approximately 0.28 hours. -1 (For example, when grown in a selective medium at pH 4.7). In some embodiments, the growth rate of the first *Lactobacillus curvatureii* isolate is approximately 0.36 hours. -1 (For example, when grown in a selective medium with an initial pH of 5.2). In some embodiments, the acidification rate of the first *Lactobacillus curvatureii* isolate is approximately -0.006 hours. -1 (For example, when grown in a selective medium with an initial pH of 4.7). In some embodiments, the acidification rate of the first *Lactobacillus curvatureii* isolate is approximately -0.007 hours. -1 (For example, when grown in a selective medium at pH 5.2). In some embodiments, the growth rate of the second *Lactobacillus curvatureii* isolate is approximately 0.38 hours. -1 (For example, when grown in a selective medium at pH 4.7). In some embodiments, the growth rate of the second *Lactobacillus curvatureii* isolate is approximately 0.4 hours. -1 (For example, when grown in a selective medium at pH 5.2). In some embodiments, the acidification rate of the second *Lactobacillus curvatureii* isolate is approximately -0.008 hours.-1 (For example, when grown in a selective medium at pH 4.7). In some embodiments, the acidification rate of the second *Lactobacillus curvatureii* isolate is approximately -0.011 hours. -1 (For example, when grown in a selective medium at pH 5.2). In some embodiments, the growth rate of the third *Lactobacillus curvatureii* isolate is approximately 0.25 hours. -1 (For example, when grown in a selective medium at pH 4.7). In some embodiments, the growth rate of the third *Lactobacillus curvatureii* isolate is approximately 0.32 hours. -1 (For example, when grown in a selective medium at pH 5.2). In some embodiments, the acidification rate of the third *Lactobacillus curvatureii* isolate is approximately -0.007 hours. -1 (For example, when grown in a selective medium at pH 4.7). In some embodiments, the acidification rate of the third *Lactobacillus curvatureii* isolate is approximately -0.011 hours. -1 (For example, when growing in a selective medium at pH 5.2).

[0191] In some embodiments, the different lactobacilli (e.g., Lactobacillus curvaturei, Lactobacillus janniae) contained in the microbial aggregates of this disclosure differ in their respective growth rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%. For example, the growth rate of Lactobacillus janniae isolates may differ by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25% compared to Lactobacillus curvaturei isolates. In some embodiments, the difference in growth rate between the first lactobacillus isolate (e.g., *Lactobacillus curvatureii* isolate, *Lactobacillus janniae* isolate) and the second lactobacillus isolate is 1-2%, 1-3%, 1-4%, 1-5%, 1-6%, 1-7%, 1-8%, 1-9%, 1-10%, 1-11%, 1-12%, 1-13%, 1-14%, 1-15%, 2-3%, 2-4%, 2-5%, 2-6%, 2-7%, and 2-8%. 2-9%, 2-10%, 2-11%, 2-12%, 2-13%, 2-14%, 2-15%, 3-4%, 3-5%, 3-6%, 3-7%, 3-8%, 3-9%, 3-10%, 3-11%, 3-12%, 3-13%, 3-14%, 3-15%, 4-5%, 4-6%, 4-7%, 4-8%, 4-9%, 4-10%, 4-11%, 4-12%, 4-13%, 4-14%, 4-15% 5-6%, 5-7%, 5-8%, 5-9%, 5-10%, 5-11%, 5-12%, 5-13%, 5-14%, 5-15%, 6-7%, 6-8%, 6-9%, 6-10%, 6-11%, 6-12%, 6-13%, 6-14%, 6-15%, 7-8%, 7-9%, 7-10%, 7-11%, 7-12%, 7-13%, 7-14%, 7-15%, 8-9%, 8-10%, 8-1 1%, 8-12%, 8-13%, 8-14%, 8-15%, 9-10%, 9-11%, 9-12%, 9-13%, 9-14%, 9-15%, 10-11%, 10-12%, 10-13%, 10-14%, 10-15%, 11-12%, 11-13%, 11-14%, 11-15%, 12-13%, 12-14%, 12-15%, 13-14%, 13-15%, or 14-15%.

[0192] In some embodiments, the growth rate of the Lactobacillus isolate refers to its growth rate at a pH of about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, or about 6.5. In some embodiments, the growth rate of the Lactobacillus isolate refers to its growth rate at a pH of 3–6.5, 3–5.5, 3–5, 3–4.5, 3–4, 3.5–5.5, 3.5–5, or 3.5–4.5. In some embodiments, the growth rate of the Lactobacillus isolate refers to its growth rate at a pH of about 4.7 or 5.2. In some embodiments, the growth rate of the Lactobacillus isolate refers to its growth rate at a temperature of about 5°C, about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, about 35°C, about 40°C, about 45°C, about 50°C, or about 55°C. In some embodiments, the growth rate of the Lactobacillus isolate refers to its growth rate at temperatures of 5°C – 15°C, 10°C – 20°C, 15°C – 25°C, 20°C – 30°C, 25°C – 35°C, 30°C – 40°C, 35°C – 44°C, 40°C – 50°C, or 45°C – 55°C. In some embodiments, the growth rate of the Lactobacillus isolate refers to its growth rate at a temperature of approximately 37°C.

[0193] In some embodiments, the lactobacillus isolates of this disclosure (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvature* isolates) are capable of utilizing glycogen. Bacteria capable of utilizing glycogen are those possessing the enzymatic mechanisms required to break down glycogen (e.g., glycogen phosphorylation), enabling the bacteria to utilize glycogen as an energy and carbon source for their metabolic processes. Lactobacilli capable of converting glycogen into glucose can then utilize glucose via fermentation to produce lactic acid, which helps maintain the acidic environment within the vagina (Amabebe E and Anumba DOC, *The Vaginal Microenvironment: The Physiologic Role of lactobacilli*, *Front. Med.*, Vol. 8 (2018)). Methods for identifying glycogen-utilizing bacteria are known to those skilled in the art and may include, for example, culturing bacteria in glycogen-rich agar or broth, performing reducing sugar assays or growth inhibition assays, or evaluating polysaccharide degradation products using electrospray ionization.

[0194] In some embodiments, the Lactobacillus isolates of this disclosure (e.g., Lactobacillus janniae isolate, Lactobacillus curvature isolate) are capable of growing and multiplying on a variety of carbohydrate substrates. Lactobacillus may be able to utilize D-ribose, D-galactose, D-glucose, D-fructose, D-mannose, D-mannitol, methyl α-D-glucopyranoside, N-acetylglucosamine, amygdalin, arbutin, ferric aescin citrate, salicin, D-cellobiose, D-maltose, D-lactose, D-saccharose (sucrose), D-trehalose, starch, glycogen, and / or gentiobiose for growth and multiplication. In some embodiments, *Lactobacillus japonicus* can utilize D-ribose, D-galactose, D-glucose, D-fructose, D-mannose, D-mannitol, methyl α-D-glucopyranoside, N-acetylglucosamine, amygdalin, arbutin, ferric aescin citrate, salicin, D-cellobiose, D-maltose, D-lactose, D-sucrose (sucrose), D-trehalose, starch, glycogen, and / or gentiobiose for growth and reproduction. In some embodiments, *Lactobacillus curvature* can utilize D-ribose, D-galactose, D-glucose, D-fructose, D-mannose, D-mannitol, methyl α-D-glucopyranoside, N-acetylglucosamine, amygdalin, arbutin, ferric aescin citrate, salicin, D-cellobiose, D-maltose, D-lactose, D-sucrose (sucrose), D-trehalose, starch, glycogen, and / or gentiobiose for growth and reproduction. Microbial aggregates containing one or more lactobacilli (e.g., Lactobacillus janniae, Lactobacillus crassifolia) can grow and reproduce in the presence of D-ribose, D-galactose, D-glucose, D-fructose, D-mannose, D-mannitol, methyl α-D-glucopyranoside, N-acetylglucosamine, amygdalin, arbutin, ferric aescin citrate, salicin, D-cellobiose, D-maltose, D-lactose, D-sucrose, D-trehalose, starch, glycogen, and / or gentiobiose.

[0195] Lactobacillus may contain one or more genes encoding proteins that allow the utilization of a variety of carbohydrate substrates. For example, Lactobacillus may contain one or more genes encoding proteins that allow the utilization of D-ribose, D-galactose, D-glucose, D-fructose, D-mannose, D-mannitol, methyl α-D-glucopyranoside, N-acetylglucosamine, amygdalin, arbutin, ferric aescin citrate, salicin, D-cellobiose, D-maltose, D-lactose, D-sucrose (sucrose), D-trehalose, starch, glycogen, and / or gentiobiose.

[0196] In some implementations, the lactobacillus (e.g., Lactobacillus curvature) contains pulAThe gene (encoding pullanase) allows glycogen utilization in bacteria. In some embodiments, Lactobacillus (e.g., Lactobacillus curvature) contains the full-length pullanase gene. pulA The gene (encoding pullanase) allows glycogen utilization in bacteria. In some embodiments, Lactobacillus (e.g., Lactobacillus curvature) contains... pulA The gene, which has pulA Deletion or insertion in a gene can cause at least some of the resulting protein to malfunction.

[0197] Bacteria possessing lactate dehydrogenase are capable of producing lactic acid (D-lactic acid and / or L-lactic acid), which leads to acidification of the environment and inhibits the growth of pathogenic bacteria and yeasts in the vagina. Techniques for assessing the rate of lactate production are known to those skilled in the art and may involve measuring the pH of a lactobacillus sample (e.g., a lactobacillus culture) or by using a lactate assay kit (e.g., a colorimetric or fluorescent lactate assay kit) over time. In some embodiments, the lactobacilli of this disclosure (e.g., *Lactobacillus curvatureii*, *Lactobacillus janniae*) produce about 1 g / L, about 2 g / L, about 3 g / L, about 4 g / L, about 5 g / L, about 6 g / L, about 7 g / L, about 8 g / L, about 9 g / L, about 10 g / L, about 11 g / L, about 12 g / L, about 13 g / L, about 14 g / L, or about 15 g / L of lactic acid (D-lactic acid and / or L-lactic acid).In some embodiments, the lactobacilli of this disclosure (e.g., *Lactobacillus curvature*, *Lactobacillus japonicus*) produce concentrations of 1-2 g / L, 1-3 g / L, 1-4 g / L, 1-5 g / L, 1-6 g / L, 1-7 g / L, 1-8 g / L, 1-9 g / L, 1-10 g / L, 1-11 g / L, 1-12 g / L, 1-13 g / L, 1-14 g / L, 1-15 g / L, 2-3 g / L, 2-4 g / L, 2-5 g / L, 2-6 g / L, 2-7 g / L, 2-8 g / L, 2-9 g / L, 2-10 g / L, 21-11 g / L, 2-12 g / L, 1-13 g / L, 2-14 g / L, 2-15 g / L, 3-4 g / L, 3-5 g / L, and 3-6 g / L. g / L, 3-7 g / L, 3-8 g / L, 3-9 g / L, 3-10 g / L, 3-11 g / L, 3-12 g / L, 3-13 g / L, 3-14 g / L, 3-15 g / L, 4-5 g / L, 4-6 g / L, 4-7 g / L, 4-8 g / L, 4-9 g / L, 4-10 g / L, 4-11 g / L, 4-12 g / L, 4-13 g / L, 4-14 g / L, 4-15 g / L, 5-6 g / L, 5-7 g / L, 5-8g / L, 5-9 g / L, 5-10 g / L, 5-11 g / L, 5-12 g / L, 5-13 g / L, 5-14 g / L, 5-15 g / L, 6-7 g / L, 6-8g / L, 6-9 g / L, 6-10 g / L, 6-11 g / L, 6-12 g / L, 6-13 g / L, 6-14 g / L, 6-15 g / L, 7-8 g / L, 7-9g / L, 7-10 g / L, 7-11 g / L, 7-12 g / L, 7-13 g / L, 7-14 g / L, 7-15 g / L, 8-9 g / L, 8-10 g / L, 8-11 g / L, 8-12 g / L, 8-13 g / L, 8-14 g / L, 8-15 g / L, 9-10 g / L, 9-11 g / L, 9-12 g / L, 9-13 g / L, 9-14 g / L, 9-15 g / L, 10-11 g / L, 10-12 Lactic acid (D-lactic acid and / or L-lactic acid) at concentrations of g / L, 10-13 g / L, 10-14 g / L, 10-15 g / L, 11-12 g / L, 11-13 g / L, 11-14 g / L, 11-15 g / L, 12-13 g / L, 12-14 g / L, 12-15 g / L, 13-14 g / L, 13-15 g / L, or 14-15 g / L.

[0198] In some embodiments, the lactobacilli of this disclosure (e.g., Lactobacillus curvature, Lactobacillus janniae) produce lactic acid (D-lactic acid and / or L-lactic acid) at a rate of about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9 or about 1 gram of lactic acid (D-lactic acid and / or L-lactic acid) per gram of biomass per hour (g / g / h). In some embodiments, the lactobacilli disclosed herein (e.g., Lactobacillus curvatureii, Lactobacillus janniae) are present at concentrations of 0.1-0.2 g / g / h, 0.1-0.3 g / g / h, 0.1-0.4 g / g / h, 0.1-0.5 g / g / h, 0.1-0.6 g / g / h, 0.1-0.7 g / g / h, 0.1-0.8 g / g / h, 0.1-0.9 g / g / h, 0.1-1.0 g / g / h, 0.2-0.3 g / g / h, 0.2-0.4 g / g / h, 0.2-0.5 g / g / h, 0.2-0.6 g / g / h, 0.2-0.7 g / g / h, 0.2-0.8 g / g / h, 0.2-0.9 g / g / h, 0.3-0.4 g / g / h, etc. g / g / h, 0.3-0.5 g / g / h, 0.3-0.6 g / g / h, 0.3-0.7 g / g / h, 0.3-0.8 g / g / h, 0.3-0.9 g / g / h, 0.3-1.0 g / g / h, 0.4-0.5 g / g / h, 0.4-0.6g / g / h, 0.4-0.7 g / g / h, 0.4-0.8 g / g / h, 0.4-0.9 g / g / h, 0.4-1.0 g / g / h, 0.5-0.6 g / g / h, 0.5-0.7 g / g / h, 0.5-0.8 g / g / h, 0.5-0.9 g / g / h, 0.5-1.0 g / g / h, 0.6-0.7 Lactic acid (D-lactic acid and / or L-lactic acid) is produced at rates of 0.6-0.8 g / g / h, 0.6-0.9 g / g / h, 0.6-1.0 g / g / h, 0.7-0.8 g / g / h, 0.7-0.9 g / g / h, 0.7-1.0 g / g / h, 0.8-0.9 g / g / h, 0.8-1.0 g / g / h, or 0.9-1.0 g / g / h.

[0199] Lactic acid can be composed of two enantiomers of lactic acid, D-lactic acid and L-lactic acid, and can be quantified using chiral chromatography (e.g., chiral high-performance liquid chromatography). In some embodiments, D-lactic acid accounts for 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of total lactic acid. In some embodiments, D-lactic acid accounts for 10% to 15%, 10% to 20%, 10% to 25%, 10% to 30%, 10% to 35%, 10% to 40%, 10% to 45%, 10% to 50%, 10% to 55%, 10% to 60%, 10% to 65%, 10% to 70%, 10% to 75%, 10% to 80%, 10% to 85%, 10% to 90% of total lactic acid. 0%, 10% to 95%, 10% to 100%, 25% to 30%, 25% to 35%, 50% to 90%, 50% to 95%, 50% to 100%, 55% to 60%, 55% to 65%, 55% to 70%, 55% to 75%, 55% to 80%, 55% to 85%, 55% to 90%, 55% to 95%, 55% to 100%, 60% to 65%, 6 0% to 70%, 60% to 75%, 60% to 80%, 60% to 85%, 60% to 90%, 60% to 95%, 60% to 100%, 65% to 70%, 65% to 75%, 65% to 80%, 65% to 85%, 65% to 90%, 65% to 95%, 65% to 100%, 70% to 75%, 70% to 80%, 70% to 85%, 70% to 90% %, 70% to 95%, 70% to 100%, 75% to 80%, 75% to 85%, 75% to 90%, 75% to 95%, 75% to 100%, 80% to 85%, 80% to 90%, 80% to 95%, 80% to 100%, 85% to 90%, 85% to 95%, 85% to 100%, 90% to 95%, 90% to 100%, 95% to 100%. In some embodiments, L-lactic acid accounts for 0%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of total lactic acid.In some implementation schemes, L-lactic acid accounts for 0%-5%, 0%-10%, 0%-15%, 0%-20%, 0%-25%, 0%-30%, 0%-35%, 0%-40%, 0%-45%, 0%-50%, 5%-10%, 5%-15%, 5%-20%, 5%-25%, 5%-30%, 5%-35%, 5%-40%, 5%-45%, 5%-50%, 10%-15%, 10%-20%, 10%-25%, 10%-30%, 10%-35%, 10%-40%, 10%-45%, 10%-50%, 15%-20%, 15%-25%, 15%-30%, 15%-35%, 15%-35%, 15%- 40%, 15%-45%, 15%-50%, 20%-25%, 20%-30%, 20%-35%, 20%-40%, 20%-45%, 20%-50%, 25%-30%, 25%-35%, 25%-40%, 25%-45%, 25%-50%, 30%-35%, 30%-40%, 30%-45%, 30%-50%, 35%-40%, 35%-45%, 35%-50%, 40%-45%, 40%-50%, or 45%-50%.

[0200] As used herein, the term "acidification rate" refers to the rate at which bacteria (e.g., lactobacilli) lower the pH (acidity) of their surrounding environment, for example, by producing lactic acid. The acidification rate can be monitored by measuring the change in pH over time (e.g., 0–8 hours, 8–24 hours). In some embodiments, the natural logarithm of the acidification rate is approximately -0.020 hours. -1 Approximately -0.015 hours -1 Approximately -0.010 hours -1 Or approximately -0.005 hours -1 In some implementations, the acidification rate is -0.020 to -0.015 hours. -1 -0.020 to -0.010 hours -1 -0.020 to -0.005 hours -1 -0.020 to 0.000 hours -1 -0.015 to -0.010 hours -1 -0.015 to -0.005 hours -1 -0.015 to 0.000 hours -1 -0.010 to -0.005 hours-1 -0.010 to 0.000 hours -1 Or -0.005 to 0.000 hours -1 .

[0201] As used herein, the terms “time of implantation” and “successful implantation within a predetermined time period” refer to the success and efficiency with which transplanted bacteria (e.g., lactobacilli) establish (e.g., colonize and multiply) within the subject’s body (e.g., the subject’s urogenital tract, such as the subject’s cervix, vagina, uterus, and / or fallopian tubes). As used herein, “female urogenital tract” refers to the female reproductive and urinary system, including the ovaries, fallopian tubes, uterus, cervix, vagina, external genitalia, and urinary tract. Implantation can be influenced by a variety of factors, including the health of the subject’s vaginal environment, the quality and diversity of the transplanted bacteria (e.g., lactobacilli), and the specific method used in the transplantation procedure. Time of implantation can be assessed by evaluating the subject’s clinical symptoms, vaginal pH, microbiota composition and diversity (e.g., using sequencing or 16S rRNA analysis) and / or lactobacillus abundance (e.g., using qPCR) over time.

[0202] In some embodiments, the implantation time of the Lactobacillus isolate of this disclosure is approximately 6, 12, 18, 24, 36, 48, or 72 hours. In other words, in some embodiments, the Lactobacillus isolate can be implanted into the urogenital tract of a subject within 6, 12, 18, 24, 36, 48, or 72 hours after administration of the microbial conglomerate. In some embodiments, the implantation time of the Lactobacillus isolate of this disclosure is approximately 1-6, 5-10, 6-12, 10-15, 12-18, 15-20, 18-24, 20-30, 24-36, 30-40, 36-48, or 36-72 hours.

[0203] In some embodiments, at least one lactobacillus isolate from the microbial conglomerate of this disclosure will be successfully implanted into the urogenital tract of a subject within a predetermined time period after administration of the microbial conglomerate. In some embodiments, the predetermined time period is about 6, 12, 18, 24, 36, 48, or 72 hours. In some embodiments, the predetermined time period is about 1-6, 5-10, 6-12, 10-15, 12-18, 15-20, 18-24, 20-30, 24-36, 30-40, 36-48, or 36-72 hours.

[0204] In some embodiments, the microbial aggregates of this disclosure consist of at least two Lactobacillus isolates (e.g., Lactobacillus janniae isolate and Lactobacillus curvature isolate), said isolates differing in various functional characteristics (e.g., growth rate, ability to utilize carbon substrates (e.g., glycogen), lactic acid production rate, acidification rate, and time to implantation in the female urogenital tract).

[0205] In some embodiments, the microbial aggregate of this disclosure comprises at least two lactobacillus isolates with different growth rates (e.g., *Lactobacillus japonicus* isolate and *Lactobacillus curvatureii* isolate). In some embodiments, the microbial aggregate of this disclosure comprises *Lactobacillus japonicus* with different growth rates and at least one *Lactobacillus curvatureii*. In some embodiments, the microbial aggregate of this disclosure comprises at least two *Lactobacillus curvatureii* isolates with different growth rates.

[0206] In some embodiments, at least two types of lactobacilli (e.g., *Lactobacillus curvatureii* isolates and *Lactobacillus janniae* isolates) of this disclosure differ in their acidification rates. In some embodiments, the acidification rate of the first lactobacillus (e.g., *Lactobacillus curvatureii* isolates and *Lactobacillus janniae* isolates) is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 20%, at least 25%, at least 35%, at least 50%, or at least 75% higher than that of the second lactobacillus (e.g., *Lactobacillus curvatureii* isolates and *Lactobacillus janniae* isolates). In some embodiments, the acidification rate of the first type of lactobacillus (e.g., *Lactobacillus curvatureii* isolate, *Lactobacillus japonicus* isolate) is 1-2%, 1-3%, 1-4%, 1-5%, 1-6%, 1-7%, 1-8%, 1-9%, 1-10%, 1-11%, 1-12%, 1-13%, 1-14%, 1-15%, 4-10%, 4-11%, 4-12%, 4-13%, 4-14%, 4-15%, 5-6%, 5-7%, 5-8%, 5-9%, 5 -10%, 5-11%, 5-12%, 5-13%, 5-14%, 5-15%, 7-12%, 7-13%, 7-14%, 7-15%, 8-9%, 8-10%, 8-11%, 8-12%, 8-13%, 8-14%, 8-15%, 9-15%, 10-11%, 10-12%, 10-13%, 10-14%, 10-15%, 11-12%, 11-13%, 11-14%, 11-15%, 12-13%, 12-14%, 12-15%, 13-14%, 13-15%, or 10-40%.

[0207] In some implementations, the acidification rate is the acidification rate in vitro (e.g., in a culture) and / or in vivo.

[0208] In some embodiments, at least two types of lactobacilli (e.g., *Lactobacillus curlis* isolate and *Lactobacillus jansii* isolate) of this disclosure differ in their ability to utilize glycogen. In some embodiments, the at least two types of lactobacilli (e.g., *Lactobacillus curlis* isolate and *Lactobacillus jansii* isolate) differ in their ability to utilize glycogen by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%. In some embodiments, the at least two types of lactobacilli (e.g., *Lactobacillus jansii* isolate and *Lactobacillus curlis* isolate) differ in their ability to utilize glycogen by 1-2%, 1-3%, 1-4%, 1-5%, 1-6%, 1-7%, 1-8%, 1-9%, 1-10%, 1-11%, 1-12%, 1-13%, 1-14%, 1-15%, 2-3%, 2-4%, 2-5%, 2-6%, 2-7%, 2-8%, 7-15%, 8-9%, 8-10%. %, 8-11%, 8-12%, 8-13%, 8-14%, 8-15%, 9-10%, 9-11%, 9-12%, 9-13%, 9-14%, 9-15%, 10-11%, 10-12%, 10-13%, 10-14%, 10-15%, 11-12%, 11-13%, 11-14%, 11-15%, 12-13%, 12-14%, 12-15%, 13-14%, 13-15%, or 10-40%.

[0209] In some embodiments, at least two lactobacilli of this disclosure (e.g., *Lactobacillus curlis* isolate and *Lactobacillus janniae* isolate) have different carbon utilization profiles. In some embodiments, the carbon utilization profiles are selected from: glycogen utilization profiles; glucose utilization profiles; fructose utilization profiles; mannose utilization profiles; maltodextrin utilization profiles; and mannitol utilization profiles.

[0210] In some implementations, the ability to utilize glycogen refers to the ability to utilize glycogen in vitro (e.g., in a culture) and / or in vivo.

[0211] In some implementations, the ability to utilize mannitol and glucose refers to the ability to utilize mannitol and glucose in vitro (e.g., in a culture) and / or in vivo.

[0212] In some implementations, the ability to utilize glycogen, glucose, fructose, mannose, maltodextrin, or mannitol refers to the ability to utilize glycogen, glucose, fructose, mannose, maltodextrin, or mannitol in vitro (e.g., in a culture) and / or in vivo.

[0213] In some embodiments, at least two lactobacilli of this disclosure (e.g., *Lactobacillus curvatureii* isolate and *Lactobacillus janniae* isolate) differ in their lactic acid production rates. In some embodiments, at least two lactobacilli (e.g., *Lactobacillus curvatureii* isolate and *Lactobacillus janniae* isolate) differ in their lactic acid production rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%. In some embodiments, at least two lactobacilli (e.g., *Lactobacillus curlis* isolate and *Lactobacillus janniae* isolate) differ in their lactic acid production rates by 1-2%, 1-3%, 1-4%, 1-5%, 1-6%, 1-7%, 1-8%, 1-9%, 1-10%, 1-11%, 1-12%, 1-13%, 1-14%, 1-15%, 2-3%, 2-4%, 2-5%, 2-6%, 2-7%, 2-8%, 2-9%, 2-10%, 2-11%, 2-12%, 2-13%, 2-14%, 2-15%, 3-4%, 3-5%, 3-6%, 7- 10%, 7-11%, 7-12%, 7-13%, 7-14%, 7-15%, 8-9%, 8-10%, 8-11%, 8-12%, 8-13%, 8-14%, 8-15%, 9-10%, 9-11%, 9-12%, 9-13%, 9-14%, 9-15%, 10-11%, 10-12%, 10-13%, 10-14%, 10-15%, 11-12%, 11-13%, 11-14%, 11-15%, 12-13%, 12-14%, 12-15%, 13-14%, 13-15%, or 14-15%.

[0214] In some embodiments, at least two types of *Lactobacillus curvatureii* of this disclosure differ in their lactic acid production rates. In some embodiments, the difference in lactic acid production rates between the at least two *Lactobacillus curvatureii* strains is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%. In some embodiments, the difference in lactic acid production rates between the at least two *Lactobacillus curvatureii* strains is 1-2%, 1-3%, 1-4%, 1-5%, 1-6%, 1-7%, 1-8%, 1-9%, 1-10%, 1-11%, 1-12%, 1-13%, 1-14%, 1-15%, 2-3%, 2-4%, 2-5%, 2-6%, 2-7%, 2-8%, 2-9%, 2-10%, 2-11%, 2-12%, 6-13%, 6-14%, 6-15%, 7-8%, 7-9%, 7-10%, 7-11%, 7-12%. Between %, 7-13%, 7-14%, 7-15%, 8-9%, 8-10%, 8-11%, 8-12%, 8-13%, 8-14%, 8-15%, 9-10%, 9-11%, 9-12%, 9-13%, 9-14%, 9-15%, 10-11%, 10-12%, 10-13%, 10-14%, 10-15%, 11-12%, 11-13%, 11-14%, 11-15%, 12-13%, 12-14%, 12-15%, 13-14%, 13-15%, or 14-15%.

[0215] In some implementations, the lactate production rate is the lactate production rate in vitro (e.g., in a culture) and / or in vivo.

[0216] In some embodiments, the lactate production rate (e.g., D-lactic acid production rate, L-lactic acid production rate) is an in vitro rate calculated after 24 hours of bacterial growth in a culture. In some embodiments, the lactate production rate of a specific bacterium or polymer is determined after inoculating MRS broth at 37°C with 5 million CFU / mL. The D-lactic acid production rate is determined according to the following formula: The D-lactic acid production rate equals the natural logarithm (Ln) of (the final concentration of D-lactic acid divided by the initial concentration of D-lactic acid) divided by (the final time minus the initial time). The L-lactic acid production rate is determined according to the following formula: The L-lactic acid production rate equals the natural logarithm (Ln) of (the final concentration of L-lactic acid divided by the initial concentration of L-lactic acid) divided by (the final time minus the initial time).

[0217] In some embodiments, at least two types of lactobacilli (e.g., *Lactobacillus curvatureii* isolates and *Lactobacillus janniae* isolates) of this disclosure differ in the time it takes for them to implant into the female urogenital tract. In some embodiments, the difference in the time it takes for at least two types of lactobacilli (e.g., *Lactobacillus curvatureii* isolates and *Lactobacillus janniae* isolates) to implant into the female urogenital tract is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, or 24 hours. In some embodiments, the difference in the time it takes for at least two types of lactobacilli (e.g., *Lactobacillus curvatureii* isolates and *Lactobacillus janniae* isolates) to implant into the female urogenital tract is 1–6, 5–10, 6–12, 10–15, 12–18, 15–20, 18–24, 20–30, or 24–36 hours.

[0218] In some embodiments, the *Lactobacillus japonicus* and at least one *Lactobacillus curvaturei* of this disclosure differ in the time it takes for them to implant into the female urogenital tract. In some embodiments, the difference in the time it takes for *Lactobacillus curvaturei* and at least one *Lactobacillus japonicus* to implant into the female urogenital tract is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, or 24 hours. In some embodiments, the difference in the time it takes for *Lactobacillus curvaturei* and at least one *Lactobacillus japonicus* to implant into the female urogenital tract is 1-6, 5-10, 6-12, 10-15, 12-18, 15-20, 18-24, 20-30, or 24-36 hours.

[0219] In some embodiments, the at least two types of *Lactobacillus curvatureii* disclosed herein differ in the time it takes for them to implant into the female urogenital tract. In some embodiments, the difference in the time for the at least two types of *Lactobacillus curvatureii* to implant into the female urogenital tract is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, or 24 hours. In some embodiments, the difference in the time for the at least two types of *Lactobacillus curvatureii* to implant into the female urogenital tract is 1-6, 5-10, 6-12, 10-15, 12-18, 15-20, 18-24, 20-30, or 24-36 hours.

[0220] In some implementations, the implantation time within the female urogenital tract is determined in vivo.

[0221] In some embodiments, each lactobacillus isolate in the aggregate is obtained from a healthy human donor. The lactobacilli included in the defined population may be obtained from at least two different healthy human donors (e.g., 2, 3, 4, 5 or more healthy human donors). In some embodiments, the lactobacilli included in the defined population are obtained from three different healthy human donors.

[0222] Lactobacillus isolates in microbial aggregates can be obtained from the vaginal environment of a healthy human donor (e.g., a female donor) with a balanced vaginal microbiota, such as a lactobacillus-dominated microbiota. This can be used... Figure 1 The steps provided are for obtaining Lactobacillus isolates from microbial aggregates. For example, in some embodiments, Lactobacillus isolates from microbial aggregates are obtained by: (1) administering a vaginal microbiota transplant (VMT) (comprising a substantially complete vaginal microbiota preparation (SCVMP) derived from a single healthy female donor) to the female urogenital tract of a recipient subject; (2) collecting a sample from the recipient's urogenital tract and culturing the sample; and (3) collecting isolates from the cultured sample. In some embodiments, VMTs such as those used by DeLong, K. et al., Front Cell Infect Microbiol. The content described in the document dated August 28, 2019, at 9:306, is incorporated herein by reference. In some implementations, VMTs, such as those described by Lev-Sagie, A., et al., Nat Med The contents of this paper are incorporated herein by reference in October 2019; 25(10):1500-1504. In some implementations, VMT is described in Bosma, EF et al. Antibiotic-free vaginal microbiota transplantation (VMT) changes vaginal microbiota and immune profile in women with asymptomatic dysbiosis: reporting of a randomized, placebo-controlled trial. medRxiv ( Cold Spring Harbor Laboratory The content of ) (2024) is incorporated into this paper by reference.

[0223] In some implementations, Lactobacillus isolates in microbial aggregates are obtained by: (1) administering a substantially complete vaginal microbiota preparation derived from a single healthy female donor to the female urogenital tract of the recipient subject; (2) collecting and culturing a sample from the recipient's urogenital tract; and (3) collecting isolates from the cultured sample.

[0224] Microbial aggregates Various aspects of this disclosure provide microbial aggregates comprising a defined population of isolated lactobacilli (e.g., *Lactobacillus curvaturei*, *Lactobacillus jansii*), configured to promote implantation into the female urogenital tract of a subject. In some embodiments, the defined population of isolated lactobacilli (e.g., *Lactobacillus curvaturei*, *Lactobacillus jansii*) configured to promote implantation into the female urogenital tract of a subject includes *Lactobacillus jansii*, *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus jansii*, and at least one additional *Lactobacillus curvaturei* that grows well in the absence of *Lactobacillus jansii*. In some embodiments, at least one *Lactobacillus curvaturei* that grows well in the absence of *Lactobacillus jansii* is capable of implantation into the female urogenital tract of a subject for at least a predetermined time.

[0225] In some embodiments, the microbial conglomerates of this disclosure are designed to include specific Lactobacillus isolates with different functional and genomic characteristics. As described herein, microbial conglomerates with different functional and genomic characteristics can be implanted into the female urogenital tract of different groups of subjects, each with a different vaginal environment. For example, the microbial conglomerates of this disclosure may include two or more Lactobacillus isolates, each with different functional properties (e.g., different growth rates, different acidification rates, different carbohydrate utilization profiles, different implantation rates). The microbial conglomerates of this disclosure may include two or more Lactobacillus isolates, each with different genomic characteristics. For example, in determining a group of two or more Lactobacillus isolates to be included in the microbial conglomerate, computer simulation analysis can be used to identify a species-level pangenome containing implantation-related genes (and beneficial effects on the subject, such as reduced (local) inflammation, e.g., within the urogenital tract). In some embodiments, computer simulation analysis can be used to identify a *Lactobacillus curvatureii* pangenome containing implantation-related genes (and beneficial effects on the subject, such as reduced (local) inflammation, e.g., within the urogenital tract). Isolates can be selected for inclusion in microbial conglomerates such that the combination of isolates provides maximum coverage of a pre-selected portion (or all) of the pan-genome (e.g., implantation-associated pan-genome genes). In other words, combinations of isolates can be assembled into microbial conglomerates such that the conglomerate covers a pre-selected portion (or all) of the pan-genome (e.g., implantation-associated pan-genome genes), although any single isolate may not cover the pre-selected portion on its own. In some embodiments, microbial conglomerates are generated to cover the largest possible portion of the pan-genome with a minimum number of necessary Lactobacillus isolates. Maximizing pan-genome coverage within the microbial conglomerate (e.g., Lactobacillus curvature implantation into the pan-genome) enables the conglomerate to be successfully implanted into the vaginal environment of different groups (e.g., subjects belonging to different groups).

[0226] In some embodiments, the exemplary microbial aggregates of this disclosure consist of: Lactobacillus janniae isolates obtained from a bacterial sample deposited with DSM accession number 34770; Lactobacillus curvature isolates obtained from a bacterial sample deposited with DSM accession number 34771; Lactobacillus curvature isolates obtained from a bacterial sample deposited with DSM accession number 34772; and Lactobacillus curvature isolates obtained from a bacterial sample deposited with DSM accession number 34773.

[0227] In some implementations, the exemplary microbial aggregates of this disclosure consist of the following: (a) Lactobacillus johnsonii isolates whose genomes have a percentage of identity greater than or equal to a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%) when compared with the genomes of bacterial samples deposited in DSM 34770. (b) Lactobacillus curlis isolates whose genomes have a percentage of identity greater than or equal to a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%) when compared with the genomes of bacterial samples deposited in DSM 34771. (c) A percentage of genome identity of an *Lactobacillus curlis* isolate when compared with the genome of a bacterial sample deposited under DSM 34772, which is greater than or equal to a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%); and (d) Lactobacillus curlis isolates whose genomes have a percentage of identity greater than or equal to a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%) when compared with the genomes of bacterial samples preserved in DSM 34773.

[0228] In some embodiments, a microbial aggregate is an n-member aggregate containing n bacterial isolates, where n is an integer reflecting the number of different bacterial isolates in the aggregate. In some embodiments, n is at least 2, at least 3, or at least 4. In some embodiments, n ranges from 2 to 10, 2 to 6, or 2 to 4. In some embodiments, n is 2, 3, 4, 5, 6, 7, 8, 9, 10, or greater. In some embodiments, a microbial aggregate is a 2-member aggregate containing two bacterial isolates. In some embodiments, a microbial aggregate is a 3-member aggregate containing three bacterial isolates. In some embodiments, a microbial aggregate is a 4-member aggregate containing four bacterial isolates.

[0229] In some embodiments, the defined population of isolated lactobacilli consists of: *Lactobacillus japonicus*, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and additional *Lactobacillus curvatureii* that grows well in the absence of *Lactobacillus japonicus*, wherein the relative abundance of *Lactobacillus japonicus* is about 15%, about 20%, about 25%, about 30%, or about 35% of the total viable cells; the relative abundance of *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus* is about 15%, about 20%, about 25%, about 30%, or about 35% of the total viable cells; and the additional *Lactobacillus curvatureii* that grows well in the absence of *Lactobacillus japonicus* is about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, or about 70% of the total viable cells. In some embodiments, the defined population of isolated lactobacilli consists of: *Lactobacillus japonicus*, *Lactobacillus curlifi* rolls that grow well in the presence of *Lactobacillus japonicus*, and additional *Lactobacillus curlifi* that grow well in the absence of *Lactobacillus japonicus*, wherein the relative abundance of *Lactobacillus japonicus* is 15%-20%, 15%-25%, 15%-30%, 15%-35%, 20%-25%, 20%-30%, 20%-35%, or 30%-35% of the total viable cells; the relative abundance of *Lactobacillus curlifi* that grows well in the presence of *Lactobacillus japonicus* is 15%-20%, 15%-25%, 15%-30%, 15%-35%, 20%-25%, 20%-30%, 20%-35%, or 30%-35% of the total viable cells; and the additional *Lactobacillus curlifi* that grows well in the absence of *Lactobacillus japonicus* is 30%-35%, 30%-35% of the total viable cells. 40%, 30% - 45%, 30% - 50%, 30% - 55%, 30% - 60%, 30% - 65%, 30% - 70%, 35% - 40%, 35% - 45%, 35% - 50%, 35% - 55%, 35% - 60%, 35% - 65%, 35% - 70%, 40% - 45%, 40% - 50%, 40% - 55%, 40% - 60%, 40% - 65%, 40% - 70%, 45% - 50%, 45% - 55%, 45% - 60%, 45% - 65%, 45% - 70%, 50% - 55%, 50% - 60%, 50% - 65%, 50% - 70%, 55% - 60%, 55% - 65%, 55% - 70%, 60% - 65%, 60% - 70%, or 65% - 75%.

[0230] In some embodiments, the defined population of isolated lactobacilli consists of *Lactobacillus japonicus*, *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus japonicus*, and additional *Lactobacillus curvaturei* that grows well in the absence of *Lactobacillus japonicus*, wherein the relative abundance of *Lactobacillus japonicus* is about 25% of the total viable cells, the relative abundance of *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus japonicus* is about 25% of the total viable cells, and the additional *Lactobacillus curvaturei* that grows well in the absence of *Lactobacillus japonicus* constitutes about 50% of the total viable cells.

[0231] The relative abundance of Lactobacillus isolates in a defined population can be determined using absorbance measurements (e.g., OD600 measurement of isolates in a culture), live cell counting methods, or by weight (e.g., weight of lyophilized isolates).

[0232] In some embodiments, the defined population of isolated lactobacilli consists of: *Lactobacillus japonicus*, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and additional *Lactobacillus curvatureii* that grows well in the absence of *Lactobacillus japonicus*, *Lactobacillus japonicus* that grows well in the presence of ... absence of *Lactobacillus japonicus* that grows well in the absence of *Lactobacillus japonicus* that grows well in the absence of *Lactobacillus japonicus* that grows well in the

[0233] In some aspects, this disclosure provides a microbial aggregate comprising a defined population of isolated lactobacilli configured to facilitate implantation into the female urogenital tract of a subject. In some embodiments, the defined population comprises *Lactobacillus japonicus*, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvatureii* species, wherein the at least two *Lactobacillus curvatureii* species have different growth rates (e.g., different in vitro growth rates).

[0234] In some implementations, at least two of the *Lactobacillus curvature* species differ in their growth rate, glycogen utilization capacity, lactic acid production rate, acidification rate, and / or the time it takes for them to be implanted in the female urethra.

[0235] In some embodiments, the defined population comprises *Lactobacillus japonicus*, *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvaturei* species, wherein the at least two *Lactobacillus curvaturei* species have different growth rates, wherein the relative abundance of *Lactobacillus japonicus* is about 15%, about 20%, about 25%, about 30%, or about 35% of the total viable cells, the relative abundance of *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus japonicus* is about 15%, about 20%, about 25%, about 30%, or about 35% of the total viable cells, and the relative abundance of the at least two additional *Lactobacillus curvaturei* species is about 15%, about 20%, about 25%, about 30%, or about 35% of the total viable cells. In some embodiments, the defined population comprises one *Lactobacillus japonicus*, one *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvatureii* species, wherein the at least two *Lactobacillus curvatureii* species have different growth rates, wherein the relative abundance of *Lactobacillus japonicus* is 15%-20%, 15%-25%, 15%-30%, 15%-35%, 20%-25%, 20%-30%, 20%-35%, 25%-30%, 25%-35%, or 30%-35% of the total viable cells, and the relative abundance of the *Lactobacillus curvatureii* species that grows well in the presence of *Lactobacillus japonicus* is 15%-20%, 15%-25%, 15%-30%, 15%-35%, 20%-25%, 20%-30%, 20%-35%, 25%-30%, 25%-35%, or 30%-35% of the total viable cells. 35%, and the relative abundance of the at least two additional *Lactobacillus curvatureii* species is 15%-20%, 15%-25%, 15%-30%, 15%-35%, 20%-25%, 20%-30%, 20%-35%, 25%-30%, 25%-35%, or 30%-35% of the total viable cells. In some embodiments, the defined population comprises *Lactobacillus japonicus*, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvatureii* species, wherein the at least two *Lactobacillus curvatureii* species have different growth rates, wherein the relative abundance of *Lactobacillus japonicus* is about 25% of the total viable cells, the relative abundance of *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus* is about 25% of the total viable cells, and the relative abundance of the at least two additional *Lactobacillus curvatureii* species is about 50% of the total viable cells.

[0236] In some embodiments, the defined population comprises *Lactobacillus japonicus*, *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvaturei* species, wherein the at least two *Lactobacillus curvaturei* species have different growth rates, *Lactobacillus japonicus* comprises multiple *Lactobacillus japonicus* species, *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus japonicus* comprises multiple *Lactobacillus curvaturei* species that grow well in the presence of *Lactobacillus japonicus*, and each of the at least two additional *Lactobacillus curvaturei* species comprises multiple *Lactobacillus curvaturei* species.

[0237] Various aspects of this disclosure provide a microbial aggregate comprising a defined population of isolated lactobacilli (e.g., *Lactobacillus jenny*, *Lactobacillus curvaturei*) configured to facilitate implantation into a female urogenital tract (e.g., cervix, vagina, uterus, and / or fallopian tubes). In some embodiments, the defined population of isolated lactobacilli (e.g., *Lactobacillus jenny*, *Lactobacillus curvaturei*) configured to facilitate implantation into the female urogenital tract consists of: *Lactobacillus jenny*, *Lactobacillus curvaturei* that grows well in the presence of *Lactobacillus jenny*, and at least two additional *Lactobacillus curvaturei* species, wherein the at least two additional *Lactobacillus curvaturei* species have different acidification rates. In some embodiments, the difference in acidification rates between the at least two additional *Lactobacillus curvaturei* species is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%. In some implementations, the acidification rate difference between at least two additional Lactobacillus curvature is 1-10%, 1-15%, 1-20%, 5-10%, 5-15%, 5-20%, 10-20%, 10-30%, 10-40%, or 10-50%.

[0238] In some embodiments, the defined population consists of: Lactobacillus janniae, Lactobacillus curvaturei that grows well in the presence of Lactobacillus janniae, and at least two additional Lactobacillus curvaturei, wherein the at least two additional Lactobacillus curvaturei have different acidification rates and differ in their growth rate, glycogen utilization capacity, lactic acid production rate, and / or time of implantation in the female urogenital tract.

[0239] In some embodiments, the defined population comprises: *Lactobacillus japonicus*, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvatureii* species, wherein the at least two additional *Lactobacillus curvatureii* species have different acidification rates, the relative abundance of *Lactobacillus japonicus* is about 15%, about 20%, about 25%, about 30%, or about 35% of the total viable cells, the relative abundance of *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus* is about 15%, about 20%, about 25%, about 30%, or about 35% of the total viable cells, and the relative abundance of the at least two additional *Lactobacillus curvatureii* species is about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, or about 70% of the total viable cells. In some embodiments, the defined population consists of: *Lactobacillus japonicus*, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvatureii* species, wherein the at least two additional *Lactobacillus curvatureii* species have different acidification rates, and the relative abundance of *Lactobacillus japonicus* is 15%-20%, 15%-25%, 15%-30%, 15%-35%, 20%-25%, 20%-30%, 20%-35%, 25%-30%, 25%-35%, or 30%-35% of the total viable cells; the relative abundance of *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus* is 15%-20%, 15%-25%, 15%-30%, 15%-35%, 20%-25%, 20%-30%, 20%-35%, 25%-30%, 25%-35%, or 30%-35% of the total viable cells. 35%, and the relative abundance of at least two additional *Lactobacillus curvature* species is 30%-35%, 30%-40%, 30%-45%, 30%-50%, 30%-55%, 30%-60%, 30%-65%, 30%-70%, 35%-40%, 35%-45%, 35%-50%, 35%-55%, 35%-60%, 35%-65%, 35%-70%, 40%-45%, 40%-50%, 40%-55%, 40%-60%, 40%-65%, 40%-70%, 45%-50%, 45%-55%, 45%-60%, 45%-65%, 45%-70%, 50%-55%, 50%-60 ... 65%, 50% - 70%, 55% - 60%, 55% - 65%, 55% - 70%, 60% - 65%, 60% - 70%, or 65% - 70%.In some embodiments, the defined population consists of: *Lactobacillus japonicus*, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvatureii* species, wherein the at least two additional *Lactobacillus curvatureii* species have different acidification rates, wherein the relative abundance of *Lactobacillus japonicus* is about 25% of the total viable cells, the relative abundance of *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus* is about 25% of the total viable cells, and the relative abundance of the at least two additional *Lactobacillus curvatureii* species is about 50% of the total viable cells.

[0240] In some embodiments, the defined population consists of: *Lactobacillus japonicus*, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus*, and at least two additional *Lactobacillus curvatureii* species, wherein the at least two additional *Lactobacillus curvatureii* species have different acidification rates, *Lactobacillus japonicus* comprises multiple *Lactobacillus japonicus* species, *Lactobacillus curvatureii* that grows well in the presence of *Lactobacillus japonicus* comprises multiple *Lactobacillus curvatureii* species that grow well in the presence of *Lactobacillus japonicus*, and each of the at least two additional *Lactobacillus curvatureii* species comprises multiple *Lactobacillus curvatureii* species.

[0241] In some embodiments, at least two types of lactobacilli (e.g., *Lactobacillus curvatureii*, *Lactobacillus japonicus*) in the microbial aggregate described herein differ in their growth rates. In some embodiments, the at least two types of lactobacilli (e.g., *Lactobacillus curvatureii*, *Lactobacillus japonicus*) in the microbial aggregate described herein differ in their growth rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0242] In some embodiments, the *Lactobacillus japonicus* and at least one *Lactobacillus curvature* in the microbial aggregate described herein differ in their growth rates. In some embodiments, the *Lactobacillus japonicus* and at least one *Lactobacillus curvature* in the microbial aggregate described herein differ in their growth rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0243] In some embodiments, at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ in their growth rates. In some embodiments, the at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ in their growth rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0244] In some embodiments, at least two types of lactobacilli (e.g., *Lactobacillus curvatureii*, *Lactobacillus jansei*) in the microbial aggregate described herein differ in their acidification rates. In some embodiments, the at least two types of lactobacilli (e.g., *Lactobacillus curvatureii*, *Lactobacillus jansei*) in the microbial aggregate described herein differ in their acidification rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0245] In some embodiments, the *Lactobacillus japonicus* and at least one *Lactobacillus curvature* in the microbial aggregate described herein differ in their acidification rates. In some embodiments, the *Lactobacillus japonicus* and at least one *Lactobacillus curvature* in the microbial aggregate described herein differ in their acidification rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0246] In some embodiments, at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ in their acidification rates. In some embodiments, the at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ in their acidification rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0247] In some embodiments, at least two types of lactobacilli (e.g., *Lactobacillus curvatureii*, *Lactobacillus jansei*) in the microbial aggregate described herein differ in their ability to utilize glycogen. In some embodiments, the at least two types of lactobacilli (e.g., *Lactobacillus curvatureii*, *Lactobacillus jansei*) in the microbial aggregate described herein differ in their ability to utilize glycogen by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0248] In some embodiments, the *Lactobacillus japonicus* and at least one *Lactobacillus curvature* in the microbial aggregate described herein differ in their ability to utilize glycogen. In some embodiments, the *Lactobacillus japonicus* and at least one *Lactobacillus curvature* in the microbial aggregate described herein differ in their ability to utilize glycogen by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0249] In some embodiments, at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ in their glycogen utilization rates. In some embodiments, the at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ in their glycogen utilization rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0250] In some embodiments, at least two types of lactobacilli (e.g., *Lactobacillus curvatureii*, *Lactobacillus japonicus*) in the microbial aggregate described herein differ in their lactic acid production rates. In some embodiments, the at least two types of lactobacilli (e.g., *Lactobacillus curvatureii*, *Lactobacillus japonicus*) in the microbial aggregate described herein differ in their lactic acid production rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0251] In some embodiments, *Lactobacillus japonicus* and at least one *Lactobacillus curvatureii* in the microbial aggregate described herein differ in their lactic acid production rates. In some embodiments, the *Lactobacillus japonicus* and at least one *Lactobacillus curvatureii* in the microbial aggregate described herein differ in their lactic acid production rates by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0252] In some embodiments, at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ in their lactic acid production rates. In some embodiments, the at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ in their lactic acid production rate capacity by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, or at least 25%.

[0253] In some embodiments, the implantation times of at least two types of lactobacilli (e.g., *Lactobacillus curvaturei*, *Lactobacillus jansii*) in the microbial aggregates described herein differ at approximately 1-6, 5-10, 6-12, 10-15, 12-18, 15-20, 18-24, 20-30, or 24-36 hours.

[0254] In some embodiments, the time it takes for *Lactobacillus japonicus* and at least one *Lactobacillus curvature* in the microbial aggregate described herein to implant into the female urogenital tract differs. In some embodiments, the time difference between the implantation of *Lactobacillus japonicus* and at least one *Lactobacillus curvature* in the microbial aggregate described herein into the female urogenital tract is approximately 1 day, approximately 2 days, approximately 3 days, approximately 4 days, approximately 5 days, approximately 6 days, or approximately 7 days.

[0255] In some embodiments, the at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein have different implantation times into the female urogenital tract. In some embodiments, the implantation times of the at least two types of *Lactobacillus curvaturei* in the microbial aggregate described herein differ by approximately 1 day, approximately 2 days, approximately 3 days, approximately 4 days, approximately 5 days, approximately 6 days, or approximately 7 days.

[0256] In some embodiments, isolates of the microbial conglomerate are implanted en bloc into the female urogenital tract of the subject. In some embodiments, each isolate of the microbial conglomerate is implanted into the female urogenital tract of the subject. In some embodiments, one, two, three, or four isolates of the microbial conglomerate are implanted into the female urogenital tract of the subject. In some embodiments, *Lactobacillus japonicus* of the microbial conglomerate is the first bacterium of the conglomerate implanted into the female urogenital tract of the subject.

[0257] In some embodiments, at least one of the lactobacilli in the microbial aggregate is capable of implanting into the female urogenital tract of a subject within 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 24, 36, or 48 hours after the aggregate is administered to the subject. In some embodiments, at least two or at least three of the lactobacilli in the microbial aggregate are capable of implanting into the female urogenital tract of a subject within 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 24, 36, or 48 hours after the aggregate is administered to the subject.

[0258] Transplantation of the female urogenital tract can be quantified, for example, by counting colony-forming units (CFU) / gram and / or by nucleic acid sequencing of the microorganisms contained in one or more samples of the female urogenital tract. In some embodiments, implantation of the female urogenital tract is considered successful if at least one (at least two or at least three) of lactobacilli are detected in the female urogenital tract after a specific time period (e.g., 6, 12, 24, 36, 48, or 72 hours). In some embodiments, implantation of the female urogenital tract is considered successful if the relative abundance of at least one lactobacillus is at least 1%, at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, or at least 40% of the total abundance of microorganisms in the urogenital tract. In some embodiments, integration of the transplanted bacteria (e.g., microbial aggregates or individual lactobacillus isolates) into the subject's existing microbiome constitutes implantation. Success of implantation can be assessed by microbiome analysis (e.g., 16S rRNA sequencing, metagenomic sequencing, or qPCR) or laboratory tests (e.g., culture).

[0259] In some embodiments, at least one of the lactobacilli in the exemplary microbial aggregates described herein is capable of persisting in the female urogenital tract of a subject for at least 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 20, 25, 30, or 35 days after administration to the female urogenital tract of a subject. In some embodiments, at least one of the lactobacilli in the exemplary microbial aggregates described herein is capable of persisting in the female urogenital tract of a subject for at least 1, 2, 3, 4, 5, 6, or 8 weeks after administration to the female urogenital tract of a subject.

[0260] In some embodiments, one, two, three, or four species of lactobacilli in the exemplary microbial aggregates described herein are able to persist in the female urogenital tract of a subject for at least 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 20, 25, 30, or 35 days after administration to the female urogenital tract of a subject. In some embodiments, one, two, three, or four species of lactobacilli in the exemplary microbial aggregates described herein are able to persist in the female urogenital tract of a subject for at least 1, 2, 3, 4, 5, 6, or 8 weeks after administration to the female urogenital tract of a subject.

[0261] In some embodiments, the lactobacilli in the aggregate are able to compete with the resident microbiota (e.g., resident lactobacilli and resident non-lactobacilli) in the subject's female urogenital tract, and have been successfully implanted in the embodiments. In some embodiments, the lactobacilli in the aggregate are able to compete with the resident microbiota (e.g., resident lactobacilli and resident non-lactobacilli) in the subject's female urogenital tract for nutrients (e.g., carbohydrates, vitamins), space within the urogenital tract, and / or growth, and have been successfully implanted in the embodiments.

[0262] In some embodiments, the resident microbiota (e.g., resident lactobacilli and resident non-lactobacilli) in the subject's female urogenital tract is at least partially removed by treatment with a local disinfectant or antibiotic, for example, 1, 2, 3, 4, 5, or 6 days, or 1, 2, or 3 weeks prior to the application of the microbial conglomerate, for example, to provide space within the urogenital tract for implantation. In some embodiments, the disinfectant is a disinfectant solution. The disinfectant solution may contain chlorhexidine and / or povidone-iodine. In some embodiments, the disinfectant solution contains about 10% or 5-10% povidone-iodine. In some embodiments, the disinfectant solution contains about 0.5% chlorhexidine. In some embodiments, the antibiotic is metronidazole or clindamycin.

[0263] Microbial aggregates may contain at least 1 million colony-forming units (CFU), at least 5 million CFU, at least 6 million CFU, at least 7 million CFU, at least 8 million CFU, or at least 10 million CFU of total bacteria. Microbial aggregates may contain at least 1 million CFU / mL, at least 5 million CFU / mL, at least 6 million CFU / mL, at least 7 million CFU / mL, at least 8 million CFU / mL, at least 9 million CFU / mL, or at least 10 million CFU / mL of total bacteria. In some embodiments, microbial aggregates include 1 million to 100 million colony-forming units (CFU), 20 million to 100 million CFU, 50 million to 100 million CFU, or 50 million to 200 million CFU. In some embodiments, microbial aggregates contain at least 10 7 10 8 10 9 10 10 10 11 Or 10 12 Total bacteria in CFU. In some embodiments, the microbial aggregate contains at least 10 7 10 8 10 9 10 10 10 11 Or 10 12 Total bacteria CFU / mL.

[0264] In some embodiments, at least a subset of lactobacilli contained in the microbial aggregates or related compositions described herein can be implanted into the human vagina. In some embodiments, at least a subset of individual lactobacillus isolates described herein (e.g., *Lactobacillus curvatureii* isolates, *Lactobacillus janniae* isolates) can be implanted into the human vagina. In some embodiments, implantation occurs even during menstrual discharge. In some embodiments, implantation remains substantially stable after one or more menstrual discharges. The lactobacilli contained in the microbial aggregates described herein, individual lactobacillus isolates (e.g., *Lactobacillus curvatureii* isolates, *Lactobacillus janniae* isolates), or related compositions can continue to reside in the vagina for several menstrual cycles after application. In some embodiments, after vaginal application, lactobacilli are implanted into the vaginal microenvironment for one or more (e.g., two, three, four, five, or six) menstrual cycles. Residence time can be determined, for example, using nucleic acid sequencing, for example, for specific lactobacilli, comparing sequencing results before and after administration of microbial conglomerates, individual lactobacillus isolates (e.g., *Lactobacillus curvatureii* isolates, *Lactobacillus janniae* isolates), or the relevant compositions described herein, for example, to identify members (e.g., one or more lactobacilli) newly added to the subject's microbiome, and then determining (e.g., by nucleic acid sequencing) at predetermined time intervals (e.g., before or after a menstrual cycle, optionally, over multiple menstrual cycles) whether all or a subset of the newly added members are still substantially present within the specified time interval. In some embodiments, the residence time of the subject's microbiome can be compared to that of a donor's microbiome. Residence time can vary depending on various factors, including hormone levels (e.g., estrogen), diet, sexual activity, vaginal acidity status, and the presence of genital infections and other microbial disturbances, such as antibiotic treatment.

[0265] Successful implantation of lactobacilli or individual lactobacillus isolates (e.g., *Lactobacillus curvatureii* isolates, *Lactobacillus janniae* isolates) contained in the microbial aggregates or related compositions described herein can be indicated by one or more of the following: decreased pH, increased lactate content, decreased abundance of antibiotic resistance genes, decreased amount of fungal DNA, decreased toxin content, reduced pathogenic factors, decreased inflammatory cytokines and chemokines, decreased immune cell infiltration, decreased total bacterial DNA load, decreased total pathogenic DNA load, increased viscoelasticity, increased sialyl polysaccharide content, decreased relative or absolute abundance of pathogens or pathogens, or any combination thereof in the vaginal cavity and vaginal microbial microenvironment (e.g., when compared to baseline in the same subject (e.g., before administration and implantation) or untreated control subjects).

[0266] In some embodiments, pathogens are undetectable in the microbial aggregates disclosed herein. A pathogen is any microorganism capable of causing disease or illness in a host (e.g., viruses, bacteria, fungi, protozoa). Non-limiting examples of pathogens include Gardnerella vaginalis, Chlamydia trachomatis, herpes simplex virus, human papillomavirus, Candida species, and Trichomonas vaginalis. In some embodiments, other non-lactobacteria are undetectable. As used herein, the term "other non-lactobacteria" refers to microorganisms that may or may not be pathogenic (e.g., may be commensal microorganisms or environmental contaminants) and are not part of the genus Lactobacillus. Non-limiting examples of other non-lactobacteria include species of Bacillus mirabilis, Prevotella, and Streptococcus.

[0267] Lactobacilli in the vaginal microenvironment Lactobacilli are the dominant microorganisms in the vaginal microbiota, playing a crucial role in maintaining a healthy urogenital tract microenvironment, including the vaginal and / or endometrial microenvironment. Lactobacilli prevent the adhesion and growth of pathogenic microorganisms and / or the overgrowth of pathogens through mechanisms involving the secretion of anti-adhesion factors, hydrogen peroxide, bacteriocins, and the fermentation of glycogen into lactic acid, thereby creating an acidic environment unfavorable to the survival of pathogens and pathogens. The genus *Lactobacillus* comprises a phenotypic heterogeneous group of Gram-positive, aerobic, lactic acid-producing bacteria. Other typical characteristics include being catalase-negative, rod-shaped, and typically possessing low guanine (G) and cytosine (I) DNA content, less than approximately 50%. They belong to the phylum Firmicutes, class Bacilli, and species *Lactobacillus*. (Lactobacillales) Lactobacillus (Lactobacillaceae) Members of the family. Those skilled in the art will be able to use standard techniques to identify Lactobacillus species.

[0268] Lactobacillus species can be identified phenotypically and genetically, for example, based on 16S rRNA (ribosomal RNA) sequences (or DNA encoding 16S rRNA, commonly referred to as 16S rDNA). Genetic analysis can be performed using standard techniques, such as whole-genome sequencing analysis, and widely used typing methods based on nucleotide variations of hundreds of DNA sequences and several gene fragments: multi-site sequence typing (MLST), multi-site variable tandem repeat analysis (MLVA), rMLST, and cgMLST, as discussed, for example, in Marcos Pérez-Losada, M. et al., “Microbial sequence typing in thegenomic era”, Infection, Genetics and Evolution, Vol. 63, September 2018, pp. 346-359.

[0269] Other identification techniques include: vaginal pH, Nugent score, amine test, gas-liquid chromatography analysis of glucose fermentation products, total anaerobic bacteria concentration, total aerobic bacteria concentration, and enzyme activity (e.g., lipase, phospholipase A2 and phospholipase C, hydrogen peroxide production).

[0270] stability Lactobacilli contained in microbial aggregates or related compositions thereof typically survive for up to one month when stored in a refrigerator at 4°C, and for several months (e.g., 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, or 24 months, or longer) when frozen at about -18°C, or preferably in solution or on agar plates at about -80°C. Individual Lactobacillus isolates described herein (e.g., Lactobacillus janniae isolates, Lactobacillus curvature isolates) typically survive for up to one month when stored in a refrigerator at 4°C, and for several months (e.g., 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, or 24 months, or longer) when frozen at about -18°C, or preferably in solution or on agar plates at about -80°C.

[0271] Lactobacilli contained in microbial aggregates or related compositions thereof, if stored in lyophilized or freeze-dried form, typically survive for up to several months (e.g., 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, or 24 months or longer) or several years (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years). Individual Lactobacillus isolates described herein (e.g., Lactobacillus janniae isolates, Lactobacillus curvature isolates), if stored in lyophilized or freeze-dried form, typically survive for up to several months (e.g., 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, or 24 months or longer) or several years (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years). Viability decreases over time. Microbial aggregates or related compositions are suitable for application if they retain at least 30%, 40%, 50%, 60%, 70%, or at least 80% viable bacteria prior to use. If the individual lactobacillus isolates described herein (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates) retain at least 30%, 40%, 50%, 60%, 70%, or at least 80% viable bacteria prior to use, they are suitable for administration. Viable cells are generally capable of colonization and implantation. Viability percentage refers to the percentage of viable bacteria in the population. In some embodiments, the microbial aggregates, individual lactobacillus isolates (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates), or other related compositions are further processed by adding a diluent (such as, for example, physiological saline) for formulation into pharmaceutical compositions. In some embodiments, the microbial aggregates described herein, individual lactobacillus isolates (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates), one or more lactobacillus isolates identified by the methods of the present invention (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates), or compositions thereof, are further processed to be lyophilized (e.g., by freeze-drying, spray drying, or other techniques known in the art), for example, to facilitate storage, packaging, formulation into, for example, compositions, and transportation, and can be rehydrated prior to administration.

[0272] Acidifier The microbial aggregates, individual lactobacillus isolates (e.g., *Lactobacillus curvatureii* isolates, *Lactobacillus janniae* isolates), one or more lactobacillus isolates identified by the methods of this invention, or related compositions may optionally contain one or more acidifying agents, such as, for example, organic acids or salts thereof. In some embodiments, the acidifying agent may be used to lower the pH of the composition, for example, to below pH 5.5 or 5.0, for example, to pH 3.5 to 4.5, or pH 3.0 to 4.5. In lowering the pH, such acidifying agents may act as antimicrobial agents (e.g., for inhibiting *Candida* or pathogenic bacteria). Acidifying agents include, for example, lactic acid, acetic acid, ascorbic acid, citric acid, folic acid, sorbic acid, or boric acid. In other embodiments, the acidifier is applied separately from a composition comprising one or more lactobacillus isolates identified by the methods of the present invention, microbial aggregates, individual lactobacillus isolates described herein (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates), or related compositions; for example, applied before, simultaneously with, or after the application of the composition (e.g., using different dosage forms, such as suppositories, creams, gels, powders, rinses, or similar dosage forms), for example, for one to seven days or one to ten days. In these embodiments, the acidifier can be used to promote the survival and implantation of one or more lactobacillus isolates identified by the methods of the present invention, lactobacilli contained in microbial aggregates, individual lactobacillus isolates described herein (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates), or related compositions. The acidifier can also be used as a spermicide, for example, to kill or inactivate residual sperm that may be present in the preparation. In one embodiment, spermicidal activity is promoted by adding lactic acid. In one embodiment, lactic acid may be provided as a racemic mixture of D- and L-isomers, or in different suitable proportions, including, for example, D-lactic acid only or L-lactic acid only.

[0273] In some embodiments, microbial aggregates, compositions comprising individual lactobacillus isolates (e.g., Lactobacillus janniae isolate, Lactobacillus curvature isolate), or related compositions may be acidified by adding 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, or 5% of an acidifier (e.g., lactic acid). In a preferred embodiment, the concentration of the acidifier added is 0.5% to 1.5%, or 0.2% to 2% (w / w), or a similar concentration matching that of a healthy vagina.

[0274] Viscosity In some embodiments, the microbial aggregates described herein, compositions comprising individual lactobacillus isolates (e.g., Lactobacillus japonicus isolates, Lactobacillus curvatureis isolates), or related compositions may contain one or more pharmaceutically acceptable buffers or diluents or other excipients. In embodiments, the composition is formulated into different dosage forms, such as, for example, suppositories, creams, or dissolving films or tablets, using one or more excipients.

[0275] In some embodiments, the dosage form is liquid, solid, or semi-solid. Solid dosage forms preferably include tablets, capsules, or films. Semi-solid dosage forms preferably include suppositories, ointments, gels, creams, or rigid foams. In a preferred embodiment, the dosage form is a gel.

[0276] prebiotics As used herein, a "prebiotic" is a growth substrate that can increase the growth of bacteria (such as lactobacilli) contained in microbial aggregates, individual lactobacillus isolates described herein (e.g., Lactobacillus janniae isolates, Lactobacillus curvature isolates), in compositions containing one or more (isolated) bacterial isolates identified according to the method of the present invention, or related compositions, such as those measured in vitro. If desired, although not usually necessary, a prebiotic may be added to the compositions described herein, for example, to form a symbiotic mixture, for example, to increase bacterial growth after administration to the urogenital tract of a female subject. In some cases, this may increase successful colonization and implantation. In other embodiments, the prebiotic may be used to maintain implanted preparations and / or general vaginal health.

[0277] If prebiotics are required, they should be carefully selected to minimize their susceptibility to metabolism by any yeasts (e.g., Candida species), pathogens, or pathogens (e.g., Escherichia coli and other Gram-negative bacteria) that can reside in the female urogenital tract (e.g., to avoid promoting their growth). Prebiotics include, for example, lactitol and lactulose, and in some cases, other oligosaccharides and soluble fibers such as fructooligosaccharides (FOS), glucose oligosaccharides (GOS), and inulin.

[0278] Other surfactants If necessary, other active agents, such as antimicrobial agents, antifungal agents, antibacterial agents, antiviral agents, antibiotics, antiparasitic agents (e.g., active against Trichomonas vaginalis), anti-inflammatory agents, etc., may be added to the microbial aggregates, for example, to treat bacterial or fungal infections and / or sexually transmitted diseases in female subjects. When formulating these agents into pharmaceutical compositions, care must be taken not to substantially interfere with the activity and efficacy of the lactobacilli contained in the preparations and compositions described herein.

[0279] In some implementations, the microbial aggregate contains a form of estrogen. Adequate estrogen levels contribute to the nutrition of the vaginal mucosa, and estrogen also increases cellular glycogen content.

[0280] In some implementations, the microbial aggregates contain thiosulfate, for example, to enhance the antipathogenic activity of lactobacilli.

[0281] If necessary, the treatment regimen may utilize antibiotics administered to the subject prior to the administration of the microbial conglomerate. Antibiotics may include metronidazole, or one or more of the following classes of antibiotics: macrolides (e.g., azithromycin, clarithromycin, and erythromycin), tetracyclines (e.g., doxycycline, tigecycline), fluoroquinolones (e.g., levofloxacin, ciprofloxacin, and moxifloxacin), cephalosporins (e.g., ceftriaxone, defotaxime, ceftazidime, cefepime), penicillins (e.g., amoxicillin, amoxicillin combined with clavulanate potassium, ampicillin, piperacillin, and ticarcillin), optionally in combination with β-lactamase inhibitors (e.g., sulbactam, tazobactam, and clavulanic acid), such as ampicillin-sulbactam, piperacillin-tazobactam, and ticarcillin-clavulanate potassium. Aminoglycosides (e.g., amikacin, abekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, erythromycin, streptomycin, tobramycin, and apramycin), penems or carbapenems (e.g., doripenum, ertapenum, imipenum, and meropenem), monocyclic lactams (e.g., aztreonam), oxazolidinones (e.g., linezolid), vancomycin, glycopeptide antibiotics (e.g., telavin), etc.

[0282] In some embodiments, the pharmaceutical composition may also comprise an antimicrobial agent (antibiotic or antifungal agent) selected from metronidazole, tinidazole, secnidazole, clindamycin, nystatin, azithromycin, erythromycin, ofloxacin, doxycycline, levofloxacin, amoxicillin, and fluconazole.

[0283] If necessary, microbial conglomerates may contain agents for treating mycobacterial infections. Suitable agents for treating mycobacterial infections include aminoglycosides (e.g., capreomycin, kanamycin, streptomycin), fluoroquinolones (e.g., ciprofloxacin, levofloxacin, moxifloxacin), isoniazid and isoniazid analogs (e.g., ethionamide), aminosalicylate, cycloserine, diarylquinoline, ethambutol, pyrazinamide, prothionamide, rifampin, etc.

[0284] If needed, microbial conglomerates may contain suitable antiviral agents such as remdesivir, foscavir, Cytogam® (cytomegalovirus immunoglobulin), pucolamide, rupintravir, palizumab, movizumab, cytarabine, digoxin, denotivir, cidofovir, and acyclovir.

[0285] If desired, microbial aggregates may contain suitable antifungal agents, such as polyenes (e.g., nystatin and natamycin) and imidazoles (e.g., fluconazole and clotrimazole).

[0286] If desired, the donor sample or composition identified by the method of the present invention, containing one or more bacterial isolates, may contain one or more suitable steroids. For example, the donor sample or composition may include androgens / synthetic steroids, estrogens, progestins, corticosteroids, neurosteroids, estradiol, piperazine estrone sulfate, drospirenone, noresthisterone, levonorgestrel, testosterone, fluoromethesterone, methylesterosterone, oxandrolone, and hydroxymethylbenzyl ether.

[0287] Dosage form and formulation Microbial aggregates, individual lactobacillus isolates (e.g., Lactobacillus janniae isolates, Lactobacillus curvature isolates), or related compositions can be formulated into isolate preparations and (pharmaceutical) compositions, as well as various dosage forms. Preferred dosage forms are provided below, all of which are equally suitable for microbial aggregates or individual lactobacillus isolates (e.g., Lactobacillus janniae isolates, Lactobacillus curvature isolates).

[0288] This document considers a variety of dosage forms, including suspensions, sprays, gels, creams, ointments, powders, (gelatin or plant cellulose) capsules, rinsing or douching solutions, foams, films, vaginal suppositories, vaginal inserts (e.g., tampons), tablets, discs, wafters (e.g., dried on a film by vaporization), or microencapsulated products employing excipients and formulation techniques known to those skilled in the art. Particularly preferred dosage forms include molded gels, lyophilized gels, tablets, cryopreserved formulations, and films. In one embodiment, the dosage form is a capsule.

[0289] A variety of suitable excipients can be used to formulate microbial aggregates, compositions containing individual lactobacillus isolates (e.g., Lactobacillus janniae isolate, Lactobacillus curvature isolate), or related compositions, such as fillers, polymers, carbon substrates, mucosal adhesives, or pH adjusters and / or buffers.

[0290] Carbon substrate excipients can serve as carbon substrates for microbial aggregates, compositions containing individual Lactobacillus isolates (e.g., Lactobacillus janniae isolate, Lactobacillus curvature isolate), or microbial communities contained in related compositions. Such carbon processes include mannitol and guar gum. Some excipients can also be used as mucosal adhesives or viscosity modifiers. Fillers may include one or more of mannitol, microcrystalline cellulose, guar gum, inulin, or alginate (e.g., sodium alginate). Polymers may include structural polymers. In some embodiments, the polymer comprises one or more of mucin, hyaluronic acid, polyvinyl alcohol, sodium CMC, polyvinylpyrrolidone, hydroxypropyl methylcellulose (e.g., Carbopol 934), and poloxamer (e.g., poloxamer 407). Mucosal adhesives include, for example, alginate (sodium alginate) and sodium CMC. Viscosities include, for example, guar gum and Carbopol 934.

[0291] Some excipients are used as pH adjusters and / or buffers, such as lactate and acetate buffers.

[0292] A suitable formulation exhibits little or no flowability on a suitable vertical surface and maintains high bacterial viability (e.g., CFU count) during formulation and (long-term) storage.

[0293] Required formulation selection parameters include, for example, water activity / moisture content (e.g., moisture content of the dried formulation), for example, between 0.5% and 3% (e.g., for long-term stability of the dried formulation); microbial diversity, for example, the absence of microorganisms such as Pseudomonas aeruginosa, Candida albicans, Staphylococcus aureus, European Pharmacopoeia standards 5.1.4, 2.6.12 and 2.6.13).

[0294] Suitable testing methods include standard assays such as plate counting (e.g., MRS agar), for example, for viable bacterial counts, dosing determination, and shelf life; rheometers, for example, for mucosal adhesion and viscosity; pH ​​meters; Karl Fischer / water activity meters; and European Pharmacopoeia tests, for example, for microbial load.

[0295] One or more bacterial isolates, microbial aggregates, single lactobacillus isolates (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates), or related compositions identified by the methods of this invention can be lyophilized and formulated into, for example, gels and tablets, as well as other dosage forms that can fill lyophilized products, such as, for example, capsules. Microbial aggregates, single lactobacillus isolates (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates), or related compositions can also be formulated into freeze-compatible gels and freeze-compatible liquid culture media (e.g., containing glycerol). Compositions comprising one or more bacterial isolates, microbial aggregates, single lactobacillus isolates (e.g., *Lactobacillus janniae* isolates, *Lactobacillus curvaturei* isolates), or related compositions identified by the methods of this invention can also be formulated into (air-dried) films, for example, which can be formed into discs.

[0296] Lyophilized formulations Microbial aggregates, compositions comprising individual lactobacillus isolates (e.g., *Lactobacillus jenny* isolates, *Lactobacillus curvaturei* isolates) or related components, may be lyophilized. The lyophilized preparations or compositions are stable and can be stored at 2-8°C for extended periods. The lyophilized preparations or compositions comprise lyophilized microbial aggregates or lyophilized individual lactobacillus isolates (e.g., *Lactobacillus jenny* isolates, *Lactobacillus curvaturei* isolates). The lyophilized preparations or compositions may be supplied in vials. The lyophilized preparations or compositions may be reconstituted with a reconstituted solvent prior to administration (e.g., in a clinical or home setting). In some embodiments, the reconstituted solvent includes gels, gelling agents, or liquids. The liquid may contain water, saline, or other liquids suitable for reconstitution and subsequent administration to the subject.

[0297] Sequencing can be performed to assess the microbial community of the donor microbiota sample and to select a suitable female donor.

[0298] Optionally, nucleic acid sequencing may be performed to identify the presence of any antimicrobial resistance (AMR) genes in the donor sample, for example, to determine that the donor sample is substantially free of AMR genes. AMR genes include those that confer resistance to one or more antibiotics (e.g., aminoglycosides, β-lactams, tetracyclines, and sulfonamides) (e.g., as described and cataloged in the NCBI National Antibiotic Resistance Database (NDARO)). It should be understood that the cutoff value is not zero due to the widespread use of antibiotics. Certain reasonable considerations are taken into account regarding the presence of AMR genes. The precise cutoff value can be determined by a person with ordinary skills based on, for example, the nature of the AMR gene (e.g., level of health concern) and public health recommendations.

[0299] Application method Various aspects of this disclosure provide methods for administering microbial aggregates, individual lactobacillus isolates (e.g., Lactobacillus janniae isolates, Lactobacillus curvature isolates), or related compositions described herein into the vagina of a human female subject. Other aspects of the invention provide a method for increasing the relative abundance of lactobacilli (e.g., Lactobacillus curvature, Lactobacillus janniae) in the female urogenital tract of a subject, the method comprising administering microbial aggregates described herein into the subject's urogenital tract.

[0300] In some embodiments, the female urogenital tract is dysbiotic. In some embodiments, the subject's urogenital tract exhibits dysbiosis. Furthermore, the present invention provides microbial aggregates for therapeutic purposes. In one embodiment, the present invention provides a method for treating dysbiosis of the urogenital tract in a female subject using the microbial aggregates described herein, the method comprising applying the microbial aggregates described herein to the subject's urogenital tract.

[0301] In some embodiments, the subject's female urogenital tract contains a bacterial community having a relative abundance of less than 90% of the total bacterial community of lactobacilli prior to application of the microbial aggregate of this disclosure. In some embodiments, the subject's female urogenital tract contains a bacterial community having a relative abundance of less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, or less than 20% of the total bacterial aggregate of lactobacilli prior to application of the microbial aggregate of this disclosure. In some embodiments, the female urogenital tract of the subject contains a bacterial community having the following percentages of total bacterial community prior to application of the microbial aggregate of this disclosure: 20%-25%, 20%-30%, 20%-35%, 20%-40%, 20%-45%, 20%-50%, 20%-55%, 20%-60%, 20%-65%, 20%-70%, 20%-75%, 20%-80%, 20%-85%, 20%-90%, 25%-30%, 25%-35%, 25%-40%, 25%-45%, 25%-50%, 25%-55%, 25%-60%, 25%-65%, 25%-70%, 25%-75%, 25%-80%, 25%-85%, 25%- 90%, 30%-35%, 30%-40%, 30%-45%, 30%-50%, 30%-55%, 30%-60%, 30%-65%, 30%-70%, 30%-75%, 30%-80%, 30%-85%, 30%-90%, 35%-40%, 35%-45%, 35%-50%, 35%-55%, 35%-60%, 35%-65%, 35%-70%, 35%-75%, 35%-80%, 35%-85%, 35%-90%, 60%-65%, 60%-70%, 60%-75%, 60%-80%, 60%-85%, 60%-90%, 65%-70%, 65% The relative abundance of Lactobacillus at -75%, 65%-80%, 65%-85%, 65%-90%, 70%-75%, 70%-80%, 70%-85%, 70%-90%, 75%-80%, 75%-85%, 75%-90%, 80%-85%, 80%-90%, or 85%-95%.

[0302] In some embodiments, the subject's female urogenital tract contains a bacterial community having a relative abundance of more than 70% of the total bacterial community of lactobacilli after application of the microbial aggregate of this disclosure. In some embodiments, the subject's female urogenital tract contains a bacterial community having a relative abundance of more than 75%, more than 80%, more than 85%, more than 90%, more than 95%, or more than 98% of the total bacterial community of lactobacilli after application of the microbial aggregate of this disclosure. In some embodiments, the female urogenital tract of the subject contains a bacterial community having a relative abundance of 70%-75%, 70%-80%, 70%-85%, 70%-90%, 70%-95%, 70%-100%, 75%-80%, 75%-85%, 75%-90%, 75%-95%, 75%-100%, 80%-85%, 80%-90%, 80%-95%, 80%-100%, 85%-90%, 85%-95%, 85%-100%, 90%-95%, 90%-100%, or 95%-100% of the total bacterial community after application of the microbial aggregate of this disclosure.

[0303] In some embodiments, after application of the microbial aggregates of this disclosure, the relative abundance of lactobacilli in the bacterial population of the female urogenital tract of the subject increases by at least 5%. In some embodiments, after application of the microbial aggregates of this disclosure, the relative abundance of lactobacilli in the bacterial population of the female urogenital tract of the subject increases by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, or at least 60%. In some embodiments, after application of the microbial aggregates of this disclosure, the relative abundance of Lactobacillus in the bacterial population of the female urogenital tract of the subjects increased by 5%-10%, 5%-15%, 5%-20%, 5%-25%, 5%-30%, 5%-35%, 5%-40%, 5%-45%, 5%-50%, 5%-55%, 5%-60%, 10%-15%, 10%-20%, 10%-25%, 10%-30%, 10%-35%, 10%-40%, 10%-45%, 10%-50%, 10%-55%, 10%-60%, 15%-20%, 15%-25%, 15%-30%, 15%-35%, 15%-40%, 15%-45%, 15%-50%, and 15%. - 55%, 15% - 60%, 20% - 25%, 20% - 30%, 20% - 35%, 20% - 40%, 20% - 45%, 20% - 50%, 20% - 55%, 20% - 60%, 35% - 60%, 40% - 45%, 40% - 50%, 40% - 55%, 40% - 60%, 45% - 50%, 45% - 55%, 45% - 60%, 50% - 55%, 50% - 60%, or 55% - 60%.

[0304] Vaginal dysbiosis refers to an imbalance or disorder of the normal vaginal microbial community. It is typically characterized by a reduction in the population of lactobacilli and an overgrowth of other microorganisms (which may include pathogens, anaerobic bacteria, or yeasts). This change in the microbial composition can lead to an increase in vaginal pH, a decrease in lactic acid production, and alterations in the overall vaginal ecosystem (Lev-Sagie A et al. The Vaginal Microbiome: II. Vaginal Dysbiotic Conditions, J Low GenitTract Dis 26(1): 79-84 (2022); Saraf VS et al. Vaginal microbiome: normalcy vsdysbiosis, Archives of Microbiology 203: 3793-3802 (2021); van de Wijert JHHM et al. The Vaginal Microbiota: What Have We Learned after a Decade of Molecular Characterization, PLoS One 9(8): e105998 (2014)). Methods for treating vaginal flora imbalance are known in the art and may include the administration of probiotics (e.g., oral supplements or the application of suppositories or creams directly to the vagina), the administration of antibiotics (e.g., when vaginal flora imbalance is associated with a bacterial infection such as bacterial vaginosis), the administration of antifungal medications (e.g., when yeast (e.g., Candida) is the cause of the flora imbalance), hormone replacement therapy or topical estrogen therapy, the administration of vaginal microbiota transplants (e.g., in the form of suppositories or gels), or the administration of acidifiers or gels.

[0305] The methods may include the use of an application device, which is typically performed by a healthcare provider (e.g., in a clinic). Optionally, the methods may include the use of alternative dosage forms described herein, such as suppositories, tablets, capsules, films, creams, etc. If desired, the methods may be performed by the subject themselves, for example, through self-administration (e.g., at home). These methods may also include other healthcare-related activities, such as diagnosing health problems and providing standard treatment, and providing microbial aggregates, compositions consisting of individual lactobacillus isolates (e.g., Lactobacillus janniae isolates, Lactobacillus curvature isolates), or related compositions described herein. These activities may include one or more combination therapies provided herein. For example, the application methods described herein may also include the administration of antimicrobial agents, antifungal agents, antibacterial agents, antiviral agents, antibiotics, antiparasitic agents (e.g., active against Trichomonas vaginalis), anti-inflammatory agents, etc.

[0306] In some embodiments where administration is performed using a device, the device typically includes an open end (e.g., a tip) for insertion into the vaginal cavity and a dispensing end (e.g., a piston or plunger) for discharging the composition through the open end. The administration steps include: a) inserting the open end into the vaginal cavity, b) discharging the composition into the vaginal cavity, and c) removing the device from the vaginal cavity (after administering the desired dose). Administration is preferably performed while the subject is in the lithotomy position, e.g., with a female subject in the lithotomy position. In some embodiments, the subject should remain in the lithotomy position for at least 5 minutes, at least 10 minutes, at least 20 minutes, or at least 30 minutes before returning to an upright position to allow sufficient residence time within the vaginal cavity for the microbial aggregate, individual lactobacillus isolates (e.g., Lactobacillus janniae isolates, Lactobacillus curvature isolates), or the associated composition, e.g., sufficient contact time with the vaginal mucosa or endometrial surface. In some embodiments, administration is targeted to a higher region of the vaginal cavity, e.g., near the vaginal fornix.

[0307] If necessary, the female subject's menstrual cycle should be considered when determining the timing of administration. For example, administration can be avoided during menstruation. In some embodiments, administration is preferably performed at times other than menstruation, including, for example, within the time window before ovulation and before menstrual bleeding.

[0308] Microbial conjugates may be administered to subjects if necessary. In some embodiments, microbial conjugates are administered to subjects once, twice, or three times over 3–21 days. In some embodiments, microbial conjugates are administered to subjects once daily for 3, 5, 10, 15, or 20 days. In some embodiments, microbial conjugates are administered to subjects once daily for 5 days. In some embodiments, microbial conjugates are administered to subjects once daily for 15 days. In some embodiments, microbial conjugates are administered to subjects every one to four weeks for one to six months. In some embodiments, microbial conjugates are administered to subjects twice, three times, or four times a week for 1, 2, 3, 4, 5, 6, 7, or 8 weeks.

[0309] In some implementations, the specific steps, timing, and duration of administration vary from subject to subject (e.g., determined by the healthcare provider) in order to provide optimal conditions for the colonization and establishment (implantation) of the bacteria (e.g., lactobacilli) contained in the microbial aggregate or related composition within the female subject's vagina.

[0310] Health symptoms and biomarker assessment In some embodiments, successful colonization and implantation are associated with changes in: (a) the composition of the microbiota of the female subject's urogenital tract (e.g., the vagina and / or endometrial tract), and / or (b) one or more disease-related health symptoms over a predetermined time period. These desired changes may be included as additional selection criteria for one or more isolates identified as capable of colonization and implantation. In a preferred embodiment, one or more isolates identified by the methods described herein are not only capable of colonizing and implanting into the urogenital tract, but also associated with desired changes in the composition of the female subject's urogenital tract microbiota and / or (b) one or more disease-related health symptoms. Such isolates may be preferentially selected for isolation, propagation, and formulation into preparations and (pharmaceutical) compositions.

[0311] Expected changes in the composition of the urogenital microbiota in female subjects that can be identified include, for example, a decrease in the relative abundance of pathogens and / or pathogens residing in the urogenital tract (e.g., a relative abundance of pathogens and / or pathogens below 10%), and / or an increase in the relative abundance of lactobacilli to above 50% (above 60%, or above 70%).

[0312] One or more expected changes in disease-related health symptoms that can be identified include, for example, (a) a decrease in one or more pro-inflammatory markers (e.g., local or systemic cytokines and chemokines) and / or a decrease in immune cell infiltration; (b) a decrease in vaginal pH (e.g., a decrease in pH by at least 0.3, 0.5, 1.0, or 1.5) and / or an increase in vaginal lactate content; and / or (c) a change in grade (e.g., a change to grade 0 or grade I) according to the Ison-Hay scoring system compared to (a), (b), and / or (c) values ​​determined for the same subject prior to administration of one or more isolates capable of colonization and implantation.

[0313] Other expected changes in health symptoms that can be identified as being associated with one or more diseases include: reduced abundance of antibiotic resistance genes, reduced fungal DNA content, reduced toxin content, and / or reduced pathogenicity and / or virulence factors.

[0314] The vaginal health of female subjects can be assessed at predetermined time intervals before and / or after administration. Tests may include one or more of the following: the Amsel criteria, the Nugent Gram staining scoring system, and the Hay-Ison criteria.

[0315] Amsel's criteria include the presence of three of the following four symptoms: (a) thin, uniform, foul-smelling discharge; (b) vaginal fluid pH > 4.5; (c) vaginal fluid with an amine odor when 10% KOH is added; and (d) presence of "clue" cells (vaginal epithelial cells with attached bacteria that obscure the cell edges) (Amsel et al., Am. J. Med. 74:14-22 (1983)).

[0316] The Nugent Gram staining scoring system involves assessing the relative abundance of the three morphologies of bacteria using a properly prepared Gram stain, and then calculating a so-called Nugent score based on the abundance of large Gram-positive bacilli (Lactobacillus morphology; Lactobacillus reduction score 0 to 4), small Gram-negative and variable bacilli (Bacteroides and Gardnerella morphology; score 0 to 4), and curved Gram-variant bacilli (Amobruccobacillus morphology; score 0 to 2). The Nugent score ranges from 0 to 10, with 0-3 considered normal (non-BV), 4-6 considered moderate, and 7-10 considered BV positive.

[0317] The Hay-Ison criteria (or Ison-Hay scoring system) recommend classifying the vaginal flora into five grades: a) Grade 0, epithelial cells without bacteria; b) Grade I, normal vaginal flora (only lactobacilli morphology); c) Grade II, reduced number of lactobacilli morphology, accompanied by mixed bacterial flora; d) Grade III, only mixed bacterial flora, with very few or no lactobacilli morphology; e) Grade IV, only Gram-positive cocci.

[0318] Grades 0, I, and IV are common in women without BV. Grade II is moderate, as defined by the Amsel criteria, and is not seen in women with BV. Grade III is consistent with BV, as diagnosed by the Amsel criteria. Grade III flora indicates BV (CA Ison and P.E. Hay, Sex Transm. Infect. Dec. 2002; 78(6):413-5).

[0319] Further expected changes in health symptoms that can be identified as being associated with one or more diseases include beneficial immune responses, which can be assessed, for example, by proteomics (e.g., Olink) and transcriptomics (e.g., Fluidigm or RNAseq).

[0320] In some implementations, the expected changes associated with successful colonization and implantation in the urogenital tract of female subjects are assessed at one, two, three, four, six, eight, ten, or twelve weeks, or at six, eight, ten, twelve, eighteen, or twenty-four months after administration of the donor sample.

[0321] In some implementations, the expected changes associated with successful colonization and implantation in the urogenital tract of female subjects are assessed 1, 2, 3, 4, 5, 6, or 7 days after administration of the donor sample.

[0322] In some implementations, expected changes associated with successful colonization and implantation in the female subject's urogenital tract can be detected 1, 2, 3, 4, 5, 6, or 7 days after administration of the donor sample.

[0323] In some implementations, expected changes associated with successful colonization and implantation in the urogenital tract of female subjects can be detected one, two, three, four, six, eight, ten, or twelve weeks after administration of the donor sample, or six, eight, ten, twelve, eighteen, or twenty-four months.

[0324] Nucleic acid sequencing In one embodiment, the method includes sequencing nucleic acids in a sample to identify the bacterial classification present in the sample (e.g., a sample from the urogenital tract of a female subject before and after administration of a donor sample, or a composition containing one or more bacterial isolates). Genetic information of the sample can be obtained by extracting nucleic acids from the sample. Methods for extracting nucleic acids from a sample are known in the art. For sequencing, nucleic acids are extracted from a collected bacterial sample. Various standard DNA extraction protocols exist. Preferably, an extraction protocol specifically enriched for microbial DNA (e.g., a protocol to reduce the amount of human DNA in the sample) is used. Exemplary commercial kits include the MoLysis Complete5 kit and the Qiagen DNAeasy blood and tissue kit. In a preferred embodiment, human DNA is removed prior to sequencing. DNA can be extracted using the Molysis Complete5 kit (MolZym), which employs differential lysis to extract microbial DNA and remove human DNA.

[0325] Nucleic acid sequencing can be performed using any method known in the art, including whole-genome sequencing or other standard nucleic acid techniques such as Southern blotting, sequence analysis, electrophoresis, and PCR (including quantitative PCR (qPCR)). Sequences can be determined using, for example, Maxam-Gilbert sequencing, Sanger sequencing, capillary array DNA sequencing, thermal cycling sequencing, solid-phase sequencing, mass spectrometry sequencing (such as matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF / MS)), and hybridization sequencing. Examples of electrophoretic analysis include slab gel electrophoresis (such as agarose gel electrophoresis or polyacrylamide gel electrophoresis), capillary electrophoresis, and denaturing gradient gel electrophoresis.

[0326] Other exemplary sequencing methods include: dideoxy sequencing reactions using labeled terminators or primers and gel separation in plates or capillaries (Sanger method), shotgun sequencing, polymerase chain reaction (PCR), real-time polymerase chain reaction (qPCR), reverse transcription PCR (RT-PCR), multiplex PCR, ligase chain reaction, pyrosequencing, synthesis sequencing, ligation sequencing, massively parallel characterization sequencing, polymerase cloning sequencing (polony sequencing), SOLiD sequencing, DNA nanosphere sequencing, mass spectrometry sequencing, microfluidic sequencing, high-throughput sequencing, Illumina sequencing, HiSeq sequencing, MiSeq sequencing, 16S ribosomal sequencing, chain termination sequencing, and gel separation (as described in Sanger et al., PNAS, 74(12): 5463 67 (1977)); chemical degradation of nucleic acid fragments. See Maxam et al., PNAS, 74: 560 564 (1977); sequencing by hybridization. For example, see Harris et al. (US Patent Application No. 2009 / 0156412); Illumina (MiSeq and HiSeq), Helicos TrueSingle Molecule Sequencing (tSMS) (Helicos Biosciences).See Harris TD et al. (2008) Science 320:106-109; see also, for example, Lapidus et al. (US Patent No. 7,169,560), Lapidus et al. (US Patent Application No. 2009 / 0191565), Quake et al. (US Patent No. 6,818,395), Harris (US Patent No. 7,282,337), Quake et al. (US Patent Application No. 2002 / 0164629), and Braslaysky et al., PNAS, 100: 3960-3964 (2003); 454 sequencing, such as Roche 454 GS FLX (Roche) (Margulies, M et al., 2005, Nature, 437, 376-380); SOLiD technology, such as the SOLiD 5500 series (Applied Biosystems); Ion Torrent / Ion Proton / Ion Proton sequencing, such as PGM, Proton, S5 series; single-molecule real-time (SMRT) technology (Pacific Biosciences); nanopore sequencing (Oxford Nanopore Technologies) (Soni GV and Meller A. (2007) Clin Chem 53: 1996-2001); Qiagen Gene Reader; chemically sensitive field-effect transistor (chemFET) arrays (see, for example, U.S. Patent Application Publication No. 2009 / 0026082); and the use of electron microscopy (Moudrianakis EN and Beer M. PNAS USA. March 1965; 53:564-71), or combinations thereof, which are incorporated herein by reference. Exemplary next-generation sequencing methods are described, for example, in Muneer Ahmad Malla et al., “Exploring the Human Microbiome: The Potential Future Role of Next-Generation Sequencing in Disease Diagnosis and Treatment”, Front. Immunol., January 7, 2019 (incorporated herein by reference). If necessary, the extracted nucleic acids can be amplified. Suitable amplification methods include polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, immune amplification, nucleic acid sequence amplification (NASBA), self-sustaining sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA).For example, PCR can be real-time PCR. In some implementations, PCR is quantitative real-time PCR (QRT-PCR).

[0327] If needed, nucleic acids synthesized due to gene transcription and / or metagenomic molecules can be detected. For example, in the case of 16S rRNA genes, genomic DNA corresponding to all or part of the 16S rRNA gene region, messenger RNA (mRNA) transcripts of all or part of the 16S rRNA gene, and / or functional 16S rRNA can be detected and used to count the abundance of microbial taxa characterized, for example, by sequence homology of a specific 16S rRNA gene sequence.

[0328] Genetic analysis can be performed using standard techniques, such as whole-genome sequencing analysis, as well as widely used typing methods based on nucleotide variations of hundreds of DNA sequences and a few gene fragments: multi-site sequence typing (MLST), multi-site variable tandem repeat analysis (MLVA), rMLST, and cgMLST (as discussed, for example, in Marcos Pérez-Losada, M. et al., “Microbial sequence typing in the genomic era”, Infection, Genetics and Evolution, Vol. 63, September 2018, pp. 346-359).

[0329] Sequencing using any of the methods described above and those known in the art can produce sequence reads. These reads can be analyzed using any number of methods known in the art to identify microorganisms (including bacterial classification) in a sample, such as a vaginal fluid sample from a healthy donor.

[0330] Microorganisms can also be identified and sorted into taxonomic categories through other methods, such as analyzing the proteome, transcriptome, metabolome, or combinations thereof. For example, microbial RNA transcripts, proteins, and non-16S genes can be analyzed.

[0331] Other methods that can be used to identify microorganisms include microarrays or other oligonucleotide probe-based technologies (based on DNA or RNA) or antibody-based detection methods, including enzyme-linked immunosorbent assay (ELISA), Western blotting, immunohistochemistry, immunocytochemistry, flow cytometry and fluorescence activated cell sorting (FACS), immunoprecipitation, and enzyme-linked immunospot (ELISPOT).

[0332] Isolation and propagation of bacterial isolates Methods for identifying bacterial isolates capable of colonizing and implanting into the female urogenital tract optionally include one or more steps to isolate, test, propagate, and formulate (e.g., dosage forms, preparations, compositions, such as pharmaceutical compositions) one or more isolates identified using the methods described herein. As described herein, one or more isolates capable of colonizing and implanting into the female urogenital tract can be identified after comparing the composition (bacterial classification) of a donor woman with that of a female subject (e.g., by nucleic acid sequencing), after a predetermined time period, and / or after determining a desired outcome (e.g., alteration of dysbiosis or reduction of one or more disease-related symptoms). Isolates identified from a sample that match one or more isolates from a donor sample to a predetermined degree of sequence identity are considered capable of colonizing and implanting, and in some embodiments, are associated with resolution of dysbiosis and / or disease-related health symptoms, or other desired outcomes. After identification of isolates successfully colonizing and implanting into the microbial microenvironment in vivo, such identified isolates are then isolated from a healthy donor sample containing a healthy donor microbial community.

[0333] The isolation and propagation of bacterial isolates are known in the art, and there are various methods to achieve the isolation and propagation of bacteria in vitro.

[0334] For example, lactic acid-producing bacteria (e.g., from a donor sample containing a donor (vaginal) microbiota or a sample containing a subject (vaginal) microbiota) are isolated, for example, from human vaginal fluid / cervical-vaginal secretions, selected, and cultured in vitro in a suitable nutrient medium to provide at least one isolated bacterial isolate. The colonization and implantation capacity of at least one isolated isolate is then optionally tested by administering the isolated isolate to a female subject. The residence time of at least one isolate in the microbial microenvironment of the subject's urogenital tract is then tested, and / or its association with one or more health-related outcomes, such as relief of dysbiosis or reduction of one or more disease-related symptoms exhibited by the female subject prior to administration of one or more isolated isolates.

[0335] Optionally, or additionally, the isolates are tested for the presence of antimicrobial resistance (AMR) genes. Preferably, the isolates contain low abundance (or substantially none) of resistance genes. Antimicrobial resistance (AMR) genes include genes that confer resistance to one or more antibiotics (e.g., aminoglycosides, β-lactams, tetracyclines, and sulfonamides) (e.g., as described and cataloged in the NCBI National Antibiotic Resistance Database (NDARO)). It should be understood that the threshold value is not zero due to the widespread use of antibiotics. Certain reasonable considerations are taken into account for the presence of AMR genes. The precise threshold value can be determined by a person with ordinary skills based on, for example, the nature of the AMR gene (e.g., level of health concern) and public health recommendations.

[0336] Optionally, or additionally, the isolates may be tested for the presence of one or more pathogenic factors / bacterial virulence factors and / or colonization factors.

[0337] In addition, if desired (although not typically necessary for the methods described herein), one or more isolates may be subjected to one or more in vitro functional tests (before, during, or after administration to female subjects), for example, to supplement or refine data obtained from in vivo tests, including: a) growth in culture media, b) antagonism against pathogens (bacteria, viruses, and / or fungi) inhabiting the vaginal mucosa, c) high viability during fermentation, d) sustained colonization of the mucosal surface (e.g., by in vitro adhesion assays, such as VEC determination), e) high lactate production, f) in vivo genetic stability after repeated culture and vaginal administration, and / or g) high viability after final treatment (e.g., preservation in diluent, lyophilization (drying), or (micro)encapsulation and storage). Each distinguishing characteristic described herein can be detected according to standard methods known in the art.

[0338] For example, the antagonistic effect against pathogens can be determined by measuring the hydrogen peroxide produced in vitro by the isolated isolate, for example, by colorimetric assays (e.g., using a medium containing tetramethylbenzidine or using commercially available hydrogen peroxide test strips). Optionally, or additionally, antagonism against pathogens can be determined by measuring a plate assay of the isolated isolate and one or more pathogens, and determining the size (e.g., diameter) and number of inhibition zones around the colonies of the isolated isolate. For example, rapid growth can be measured by determining the growth rate (population doubling) entering the late logarithmic or stationary phase, for example, by comparing it with the known growth rate of a control isolate or other members of the same species. For example, high viability and viability percentage (e.g., after culture or drying) can be measured by determining the growth rate and / or the number of dead / live cells after exposure to influencing factors such as changes in culture temperature, pH (e.g., low pH, high pH), the richness of the growth medium, the concentration of buffers, etc., and exposure to drying (e.g., freeze-drying, lyophilization) and storage (measuring the percentage of live cells at predetermined intervals). The total cell count can be obtained visually (e.g., using a microscope, such as a dark-field condenser and a Petroff-Hausser counting chamber) by counting live / dead cells, or by counting colony-forming units (CFU) on a suitable culture medium plate and calculating the live / dead cell ratio as CFU / total cells per milliliter. For example, lactate levels in the culture medium can be determined using commercially available lactate assays or common chemical separation techniques such as capillary electrophoresis and chromatography (e.g., HPLC). For example, the ability of an isolated isolate to adhere to the vaginal mucosa can be assessed in vitro by determining adhesion values, such as by calculating a vaginal epithelial cell (VEC) adhesion percentage value, defined as the percentage of VECs to which at least one bacterial cell adheres out of the total number of VECs. Optionally, adhesiveness is determined by calculating a vaginal epithelial cell (VEC) adhesion percentage value, defined as the percentage of VECs to which at least one bacterial cell adheres out of the total number of VECs. Another measure of in vitro adhesion is counting the average number of microbial cells that adhere to a predetermined number of epithelial cells. For example, the stability of the bacterial genetic profile of isolated isolates during repeated culturing in large-scale production and during the manufacturing process of, for example, (pharmaceutical) compositions can be tested. In one embodiment, the isolated isolates retain their genetic profiles after at least 10 repeated culturing cycles.

[0339] It is preferable to evaluate and select isolates to determine their in vivo genetic stability after vaginal administration, for example, that they are genetically stable in vivo for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months or at least 12 months.

[0340] Isolates are preferably evaluated and selected to determine their viability during cryopreservation (e.g., freezing) and storage, as well as freeze-drying / lyophilization. Isolates stored at 4°C, frozen at approximately -18°C, or frozen at approximately -80°C are preferably viable for up to several months (e.g., 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, or 24 months, or longer). Viability decreases over time. Isolates are suitable for use if they retain at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or at least 80% viable bacteria before use. In some embodiments, isolates retain at least 30%, 40%, 50%, 60%, 70%, or at least 80% viable bacteria before use. Viable cells are generally capable of colonization and implantation. Viability percentage refers to the percentage of viable bacteria in the population. If necessary, one or more isolated isolates may be further processed into freeze-dried and / or granulated, for example, to facilitate storage, packaging, formulation into, for example, compositions, and transportation, and may be rehydrated before application.

[0341] Bacterial isolates capable of colonizing and implanting in the female urogenital tract (e.g., isolates isolated by the methods described herein) can be propagated using any method known in the art. For example, lactic acid-producing bacterial isolates (including Lactobacillus isolates) can be grown in a variety of different types of culture media in liquid, semi-solid (e.g., agar), or solid form. Culture conditions can be similar to the natural environment in which the bacteria inhabit.

[0342] Standard bacterial culture media typically contain salts, carbohydrate sources, and pH buffers. For Lactobacillus, the pH is usually maintained in the range of about 4.5 to about 7.0 by adding sodium phosphate, arginine, ammonium hydroxide, sodium hydroxide, potassium hydroxide, etc., preferably pH 5.5-6.5. Vitamins and growth promoters, including amino acid preparations, may also be added. Bacterial culture media are known and commercially available (e.g., from Sigma-Aldrich), including, for example, MRS (including Lactobacillus-MRS agar (De Man, J. et al., J. Appl. Bact. 23:130-135, 1960)), Rogosa, NZM, YM, M17, Thayer-Martin, tryptone soybean, CDM (Geshnizgani AM and Onderdonk AB, (J Clin Microbiol. May 1992; 30(5):1323-6)), and brain-heart infusion (BHI) broth. Carbohydrates suitable for the growth of isolates in this invention include D-galactose, D-glucose, D-fructose, D-mannose, D-mannitol, N-acetylglucosamine, amygdalin, arbutin, aescin, salicin, D-cellobiose, D-maltose, sucrose, D-trehalose, amides, and glycogen. Some culture media can be formulated to be selective for lactic acid-producing bacteria such as Lactobacillus, for example, by using a low pH and adding certain additives, such as sodium acetate and ammonium citrate, to inhibit other flora and fungi. In some embodiments, the culture medium contains Brucella blood agar containing heme and vitamin K, which promotes the growth of a wide range of vaginal bacteria.

[0343] Lactobacillus is a highly aerobic organism adapted to fermentation. It naturally colonizes the mucous membranes of mammals and typically grows optimally at approximately body temperature (e.g., 37°C), although it can also grow at lower (e.g., 30°C) and higher (e.g., 40°C) temperatures. The growth rate can be controlled by altering the temperature.

[0344] Once the desired bacterial cell density is reached, the bacterial cells can be harvested using any suitable method to remove them from the culture medium. Non-limiting exemplary methods for harvesting cultured cells include filtration, centrifugation, and precipitation. In some embodiments, the cell biomass is washed at least once with a physiological buffer solution. In some embodiments, the wash solution may contain additional components, such as, for example, glucose. In some embodiments, the wash solution contains a buffer solution or one or more buffers. Exemplary buffers that can be used or added to the wash solution include phosphates (e.g., Na₂HPO₄, NaH₂PO₄, NaHCO₃, and arginine).

[0345] Formulated into preparations and pharmaceutical compositions One or more colonizable and implantable isolates identified by the methods described herein can be formulated into isolate preparations and (pharmaceutical) compositions, as well as various dosage forms, for example, using one or more carriers, excipients, diluents, and / or buffers, which may optionally be pharmaceutically acceptable. In some embodiments, the dosage form may be an applicator or dispenser, such as those commonly used in medicine and science. In some embodiments, the dosage form may be a vaginal suppository that remains in the vaginal cavity until dissolved.

[0346] Other suitable dosage forms include suspensions, sprays, gels, creams, powders, capsules (gelatin or plant cellulose), douches, irrigation solutions, suppositories, vaginal inserts, tablets, discs, rice paper capsules (e.g., film drying, vaporization), or microencapsulated products using excipients and formulation techniques known to those skilled in the art. Suitable dosage forms should be formulated for easy dissolution and / or dispersion within the vaginal cavity.

[0347] Other suitable formulations include absorbent products containing bacterial components, such as feminine hygiene diapers, panty liners, sanitary napkins, tampons, groin protectors, or incontinence prevention products.

[0348] One or more colonizable and implantable isolates identified by the methods described herein can be formulated into a dried form, such as lyophilized or spray-dried, and then optionally formulated into the dosage forms described herein, or reconstituted prior to use, for example, with sterile water, a weakly acidic solution, a gel, or a buffer. If the composition cannot be reconstituted, rehydration can also be achieved in the vaginal cavity, depending on the specific formulation of the dosage form, for example, by means of a resident vaginal fluid. Lyophilization of live bacteria facilitates the long-term preservation of microorganisms. Those skilled in the art can lyophilize bacteria using standard techniques.

[0349] In all these embodiments, standard materials for drug formulation, such as dyes, fragrances, pH buffers, desiccants or suspending agents, or other pharmaceutical formulations, can be incorporated into the composition and dosage form.

[0350] In all these embodiments, the devices and compositions described herein can be packaged in suitable packaging, such as bottles, flacones, blister packs, cartridges, applicators, or dispensers.

[0351] Assembly of microbial aggregates The inventors recognized that assembling microbial colonies for therapeutic purposes may require monitoring the genetic sequences of the bacteria used in the colonies over time. For example, if the bacterial genetic sequence is affected by too many mutations (e.g., SNVs, SNPs, or other genetic sequence variations), genetic drift can cause the bacteria to no longer exhibit the desired therapeutic properties. Therefore, the inventors developed a technique that uses calculations to determine whether two bacterial isolates are substantially similar and thus considered to be the same bacterium. Figure 13 This is a flowchart of an exemplary process 1300 for assembling a microbial aggregate, which includes two or more bacteria belonging to one or more bacterial species.

[0352] Various (e.g., partial or complete) actions of process 1300 can be implemented using any suitable computing device. For example, in some embodiments, one or more steps of exemplary process 1300 can be implemented in a clinical or laboratory environment. For example, one or more actions of process 1300 can be implemented on a computing device located within a clinical or laboratory environment. In some embodiments, the computing device can obtain gene sequencing data directly from sequencing equipment located within a clinical or laboratory environment. For example, computing devices included in a sequencing apparatus can obtain gene sequencing data directly from the sequencing apparatus. In some embodiments, the computing device can obtain gene sequencing data indirectly from sequencing equipment located inside or outside a clinical or laboratory environment. For example, computing devices located within a clinical or laboratory environment can obtain gene sequencing data via a communication network (such as the Internet, cloud computing environment, local area network (LAN), wireless local area network (WLAN), wide area network (WAN), or any other suitable network), as certain aspects of the technology described herein are not limited to any particular communication network.

[0353] Alternatively or concurrently, one or more actions of the exemplary process 1300 may be performed in an environment remote from the clinical or laboratory setting. For example, one or more actions of process 1300 may be performed on a computing device located outside the clinical or laboratory setting. In this case, the computing device may indirectly obtain gene sequencing data generated using sequencing equipment located inside or outside the clinical or laboratory setting. For example, the gene sequencing data may be provided to the computing device via a communication network, such as the Internet, a cloud computing environment, a wide area network, or any other suitable network.

[0354] It should be understood that in some implementation schemes, such as Figure 13 As shown, not all actions in process 1300 can be performed using one or more computing devices. For example, the action 1312 of assembling microbial aggregates can be performed manually (e.g., by a clinician or manufacturer).

[0355] In some implementations, process 1300 can be used to determine whether the claimed bacterial sample is substantially identical to a reference sample of bacteria. If it is determined that the claimed sample is substantially identical to the reference sample, it can also be determined that the claimed sample and the reference sample can be considered to be the same type of bacteria, thus the claimed sample can be considered applicable to a microbial aggregate.

[0356] Process 1300 begins with action 1302, in which gene sequencing data can be obtained from a so-called bacterial sample for the microbial conglomerate. Process 1300 also includes action 1304, which can be performed before, during, or after action 1302, and includes obtaining gene sequencing data from a bacterial reference sample for the microbial conglomerate. In some embodiments, the so-called sample and / or reference sample of bacteria may be a Lactobacillus sample. In some embodiments, the so-called sample and / or reference sample of bacteria may be a Curl Lactobacillus sample.

[0357] In some embodiments, gene sequencing data can be obtained by sequencing a biological sample (e.g., an isolate of the so-called sample and / or an isolate of the reference sample) obtained using any suitable sequencing technology. Gene sequencing data may include sequencing data of any suitable type, from any suitable source, and in any suitable format. In some embodiments, the sequencing device used to sequence the biological sample may be selected from any suitable sequencing device known in the art, including but not limited to Illumina™, SOLid™, Ion Torrent™, PacBio™, nanopore-based sequencing devices, Sanger sequencing devices, or 454™ sequencing devices. In some embodiments, the sequencing device used to sequence the biological sample is an Illumina sequencing device (e.g., NovaSeq™, NextSeq™, HiSeq™, MiSeq™, or MiniSeq™).

[0358] As an illustrative example, in some embodiments, gene sequencing data may include bulk sequencing data. Bulk sequencing data may contain at least 1 million reads, at least 5 million reads, at least 10 million reads, at least 20 million reads, at least 50 million reads, or at least 100 million reads. In some embodiments, sequencing data includes bulk RNA sequencing (RNA-seq) data, single-cell RNA sequencing (scRNA-seq) data, or next-generation sequencing (NGS) data. In some embodiments, sequencing data includes microarray data.

[0359] In some implementations, gene sequencing data can be obtained by accessing and / or receiving gene sequencing data obtained after sequencing a biological sample. For example, gene sequencing data can be obtained by accessing gene sequencing data stored in a computer-readable storage medium (e.g., locally stored and / or remotely stored gene sequencing data). For example, gene sequencing data can be obtained by receiving transmitted gene sequencing data from a remote computer (e.g., via network transmission including but not limited to the Internet, cloud computing environments, and / or local area networks or wide area networks).

[0360] In some implementations, after obtaining the gene sequencing data of the so-called sample and reference sample, process 1300 can proceed to action 1306, where the gene sequencing data of the two samples can be compared. Any suitable comparative alignment method can be used to compare the obtained gene sequencing data. For example, the NUCmer command with the –maxmatch flag implemented in MUMmer v3.23 or later can be used to perform comparative alignment of the obtained gene sequencing data. Further aspects of the MUMmer software package are described in S. Kurtz et al. Versatile and open software for comparing large genomes , Genome Biology 5:R12 (2004).

[0361] After comparing the obtained gene sequencing data, process 1300 can proceed to action 1308, whereby the aligned gene sequencing data can be used to calculate the percentage of identity. The percentage of identity describes the percentage of aligned gene sequencing data that are identical between the two sets of gene sequencing data, and can be written as: Where N 比对 It is the total number of identical base pairs, N SNV N is the number of SNVs in the gene sequencing data of a sample relative to a reference sample. Any suitable technique can be used to determine N. 比对 and N SNV The value of N. For example, as mentioned above, the dnadiff command, as implemented in MUMmer v3.23 or later, can be used to determine N. 比对 and N SNV The value of .

[0362] After determining the identity percentage, process 1300 can proceed to action 1310, whereby it can be determined that the claimed sample and the reference sample are samples of the same bacterial species. This determination can be made by determining that the calculated identity percentage value is greater than or equal to a threshold. The threshold defines the distinction between different bacteria of the same bacterial species. For example, a calculated identity percentage less than the threshold may indicate that the claimed sample contains a large number of SNVs relative to the reference sample, making the claimed sample and the reference sample potentially not considered to be the same bacterial species. Therefore, a calculated identity percentage greater than or equal to the threshold may indicate that the claimed sample contains an acceptable number of SNVs relative to the reference sample, making the claimed sample and the reference sample acceptable to be considered to be the same bacterial species.

[0363] In some implementations, process 1300 may optionally include determining a threshold. For example, the threshold may be determined using gene sequencing data obtained from two or more known samples of the same bacteria. The obtained gene sequencing data can then be used to calculate the percentage of identity between the two or more sample pairs, as described herein (e.g., by comparing gene sequencing data pairs to determine N). 比对 and N SNV The value of the percentage identity is calculated, and the percentage of identity for each pair is determined. The maximum value of the calculated percentage identity can then be used to determine the threshold, since this maximum value represents the minimum difference between gene sequences of the same bacteria (e.g., due to genetic drift or other factors that can introduce SNVs).

[0364] In some implementations, the threshold may be 99.81%. In some implementations, the threshold may be 99.90%. In some implementations, the threshold may be 99.96%. Other aspects of threshold determination are described herein in conjunction with Figure 3.

[0365] After determining that the claimed sample and the reference sample are samples of the same bacteria, process 1300 can proceed to action 1312, in which a microbial aggregate can be assembled using the claimed sample. The microbial aggregate can be assembled by combining multiple lactobacilli (including the claimed sample) together. Identification of lactobacilli inclusion in the microbial aggregate can be determined using several different in vitro, in vivo, and computer simulation characteristics of the potential bacteria, such as implantation capacity, in vitro growth and acidification rates, and species-level pangenome coverage (see, for example, Examples 2-5).

[0366] The assembly of the so-called sample can be compared with one or more publicly available Lactobacillus curli RefSeq assemblies, which are known to those skilled in the art and include GCF_000091765, GCF_000160515, GCF_000161915, GCF_000162255, GCF_000162315, GCF_000165885, GCF_000176975, GCF_000301115, GCF_000301135, GCF_000466885, GCF_001434005, GCF_001541515, GCF_001546025, GCF_001563615, and GCF_002088015. GCF_002218645, GCF_002218695, GCF_002218815, GCF_002218845, GCF_002218855, GCF_002218885, GCF_002218895, GCF_002218945, GCF_002218965 , GCF_002218975, GCF_002219005, GCF_002219015, GCF_002219045, GCF_00 2219055, GCF_002219085, GCF_002811165, GCF_002861765, GCF_002861775GCF_002861815、GCF_002863245、GCF_002863485、GCF_002863505、GCF_003795065、GCF_003971565、GCF_004361125、GCF_004361175、GCF_004361185、GCF_004361195、GCF_004361245、GCF_004361295、GCF_004361345、GCF_004361375、GCF_004361445、GCF_004361465、GCF_004361515、GCF_004361555、GCF_004361565、GCF_004361575、GCF_008694745、GCF_009730275、GCF_009769205、GCF_009933525、GCF_013456995、GCF_013487905、GCF_013778545、GCF_015669875、GCF_016767795、GCF_018885325、GCF_019537355、GCF_020042005、GCF_020042225、GCF_020887095、GCF_021278925、GCF_021278945GCF_022453955、GCF_022453975、GCF_022454015、GCF_022454025、GCF_022454055、GCF_022454075、GCF_022454115、GCF_022454135、GCF_022454155、GCF_022454175、GCF_022454205、GCF_022454275、GCF_022454315、GCF_022454335、GCF_022454355、GCF_022454375、GCF_022454385、GCF_022454395、GCF_022454435、GCF_022454495、GCF_022454535、GCF_022454555、GCF_022454565、GCF_022454615、GCF_022454695、GCF_022454705、GCF_022454735、GCF_022454755、GCF_022454765、GCF_022454795、GCF_022454815、GCF_022454845、GCF_022454895、GCF_022454915、GCF_022454935、GCF_022454955GCF_022454965、GCF_022455005、GCF_022455035、GCF_022455065、GCF_022455155、GCF_022455175、GCF_022455185、GCF_022455205、GCF_022455255、GCF_022455295、GCF_022455315、GCF_022455325、GCF_022455375、GCF_022455395、GCF_022455455、GCF_022455475、GCF_022455485、GCF_022455515、GCF_022455535、GCF_022455555、GCF_022455575、GCF_022455595、GCF_022455615、GCF_022455635、GCF_022455655、GCF_022455675、GCF_022455695、GCF_022455705、GCF_022455755、GCF_022455855、GCF_022455875、GCF_022455915、GCF_022455955、GCF_022455975、GCF_022455985、GCF_022456015 GCF_022456035、GCF_022456175、GCF_022456215、GCF_022456295、GCF_022456575、GCF_022456595、GCF_022456605、GCF_022456655、GCF_022456695、GCF_022456705、GCF_022456755、GCF_022456795、GCF_022456805、GCF_022456835、GCF_022456855、GCF_022456875、GCF_022456895、GCF_022456935GCF_022456975, GCF_022456995, GCF_022457275, GCF_022457405, GCF_022457425, GCF_022457445, GCF _022457465, GCF_022457495, GCF_022457545, GCF_022458295, GCF_022458335, GCF_022458395, GCF_022 458415, GCF_022458425, GCF_025194045, GCF_026740115, GCF_027680585, GCF_027682305, GCF_027695 305, GCF_029011155, GCF_029011475, GCF_029011495, GCF_029011595, GCF_029011765 and GCF_904382375.

[0367] Figure 14 This is a schematic diagram of an exemplary computer system, and the embodiments described herein (e.g., such as...) Figure 13 The method can be implemented on this system. Computer system 1400 may include one or more processors 1410 and one or more articles of manufacture, including tangible (e.g., non-transitory) computer-readable storage media (e.g., memory 1420 and one or more non-volatile storage media 1430). Processor 1410 can control the writing and reading of data to and from memory 1420 and non-volatile storage devices 1430 in any suitable manner, as aspects of the techniques described herein are not limited to any particular data writing or reading technique. To perform any of the functions described herein, processor 1410 can execute one or more processor-executable instructions stored in one or more non-transitory computer-readable storage media (e.g., memory 1420), which can be used as non-transitory computer-readable storage media storing processor-executable instructions executable by processor 1410.

[0368] The computing device 1400 may also include a network input / output (I / O) interface 1440 through which the computing device can communicate with other computing devices (e.g., via a network), and may also include one or more user I / O interfaces 1450 through which the computing device can provide output to a user and receive input from a user. User I / O interfaces may include devices such as a keyboard, mouse, microphone, display device (e.g., a monitor or touchscreen), speaker, camera, and / or other various types of I / O devices.

[0369] The above embodiments can be performed in any of a variety of ways. One or more aspects and embodiments of this disclosure relate to the execution of a process or method, which can be performed or controlled using program instructions executable by an apparatus (e.g., a computer, processor, or other device). In this regard, various inventive concepts can be implemented as a computer-readable storage medium (or multiple computer-readable storage media) (e.g., a computer memory, one or more floppy disks, compact disks, optical disks, magnetic tapes, flash memory, field-programmable gate arrays, or other semiconductor devices, or other tangible computer storage media) encoded with one or more programs that, when executed on one or more computers or other processors, perform the methods implementing the various embodiments described above. One or more computer-readable media may be removable, such that one or more programs stored thereon can be loaded onto one or more different computers or other processors to implement one of the aspects described above. In some embodiments, the computer-readable medium may be a tangible (e.g., non-transitory) computer-readable medium. In some embodiments, the computer-readable medium may include permanent storage.

[0370] In this regard, it should be understood that one implementation of the embodiments described herein includes at least one computer-readable storage medium (e.g., RAM, ROM, EEPROM, flash memory or other storage technologies, CD-ROM, digital versatile optical disc (DVD) or other optical disc storage devices, magnetic tape, magnetic tape, disk storage devices or other magnetic storage devices, or other tangible, non-transitory computer-readable storage media) encoded with a computer program (i.e., a plurality of executable instructions) that, when executed on one or more processors, performs the functions of one or more of the embodiments described above. The computer-readable medium may be removable, such that the program stored thereon can be loaded onto any computing device to implement the various aspects of the techniques discussed herein. Furthermore, it should be understood that referring to a computer program that performs or implements any of the functions described above is not limited to applications running on a host computer. Rather, the terms "computer program" and "software" as used herein generally refer to any type of computer code (e.g., application software, firmware, microcode, or any other form of computer instructions) that can be used to program one or more processors to implement the various aspects of the techniques discussed herein.

[0371] Clearly, the example aspects described above can be implemented in a variety of different forms of software, firmware, and hardware in the implementation shown in the figure. Furthermore, certain parts of the implementation can be implemented as "modules" that perform one or more functions. These modules may include hardware such as processors, application-specific integrated circuits (ASICs), or field-programmable gate arrays (FPGAs), or a combination of hardware and software.

[0372] The terms “program” or “software” are used in a general sense herein to refer to any type of computer code or set of computer-executable instructions that can be used to program a computer or other processor to implement the various aspects described above. Furthermore, it should be understood that, according to one aspect, one or more computer programs that, when executed, perform the methods of this disclosure do not need to reside on a single computer or processor, but can be distributed in a modular form across multiple different computers or processors to implement the various aspects of this disclosure.

[0373] Computer-executable instructions can take many forms, such as program modules that are executed by one or more computers or other devices. Typically, program modules include routines, programs, objects, components, data structures, etc., that perform specific tasks or implement specific abstract data types. In various implementation schemes, the functionality of program modules can be combined or distributed as needed.

[0374] When executed as software, the software code can be executed on any suitable processor or set of processors, whether provided on a single computer or distributed across multiple computers.

[0375] Furthermore, it should be understood that a computer can be presented in any of many forms, such as rack-mounted computers, desktop computers, laptop computers, tablet computers, quantum computers, or optical computers as non-limiting examples. Additionally, a computer can be embodied in a device that is not generally considered a computer but has suitable processing capabilities, including personal digital assistants (PDAs), smartphones, or any other suitable portable or fixed electronic device.

[0376] In addition, a computer may have one or more input and output devices. These devices are particularly useful for presenting a user interface. Examples of output devices that can be used to provide a user interface include printers or displays for visual presentation and speakers or other sound-generating devices for auditory presentation. Examples of input devices that can be used for a user interface include keyboards and positioning devices such as mice, touchpads, and numeric panels. As another example, a computer may receive input information via speech recognition or in other auditory formats.

[0377] These computers can be interconnected via one or more networks of any suitable form, including local area networks (LANs) or wide area networks (WANs), such as enterprise networks and intelligent networks (INs) or the Internet. Such networks can be based on any suitable technology and operate according to any suitable protocol, and may include wireless networks, wired networks, or fiber optic networks.

[0378] Furthermore, as described, some aspects can be embodied as one or more methods. Actions performed as part of a method can be ordered in any suitable manner. Therefore, implementations can be constructed in which actions are performed in a different order than those shown, and these implementations can include the simultaneous performance of some actions, even if they are shown as sequential actions in the exemplary implementation.

[0379] definition The following definitions apply to all aspects and embodiments disclosed herein. Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Furthermore, it should be understood that similar or equivalent methods and materials to those described herein may be used in the practice or testing of this disclosure. The materials, methods, and examples described are illustrative only and not intended to be limiting. Other features of this disclosure will become apparent from the following detailed description and claims.

[0380] In a preferred embodiment, the term "about" should be allowed to differ from the indicated numerical value. + A 10% deviation, or even better, allow for + A 5% tolerance is allowed. Unless otherwise stated, all numerical values ​​representing the amount of components, time, etc., as used in the specification or claims should be understood to be modified by the term "about". Therefore, unless otherwise expressly or implicitly stated, or unless a person skilled in the art correctly understands that the context has a clearer interpretation, the listed numerical parameters are approximate values ​​and may depend on the desired characteristic sought and / or the detection limit under standard test conditions / methods known to a person skilled in the art.

[0381] The terms “contact,” “application,” or “experience,” and more specifically, “vaginal application” or “vaginal administration” are used interchangeably herein to refer to a subject (e.g., a female subject) or a specific organ or other physiological site (e.g., the urogenital tract or vaginal cavity or its sub-parts, such as sites involving the vaginal wall (mucosa or endometrial surface) or the vaginal fornix) and the dosage form, preparation, or (pharmaceutical) composition provided to the subject or site, such as a bacterial community required for colonization and implantation. In one embodiment, application is performed topically. In another embodiment, application is performed topically (e.g., in the vagina).

[0382] The term "bacterial isolate" or "isolated strain" refers to bacteria isolated from the same species that share defined functional and / or genotypic characteristics. In some embodiments, the bacterial isolate is *Lactobacillus curlis* isolate. In some embodiments, the bacterial isolate is *Lactobacillus japonicus* isolate. In some embodiments, the bacterial isolate has been isolated from other materials (e.g., from vaginal bacterial communities, such as samples derived from cervical vaginal secretions or vaginal fluid). In some embodiments, the bacterial isolate can be propagated in vitro. In some embodiments, the bacterial isolate is substantially free of contaminants or components (e.g., such as vaginal mucus and epithelial cells) that are present in the source material in its natural state. In some embodiments, the bacterial isolate is characterized by a genomic haplotype. In some embodiments, two different bacterial isolates have sequence identity in their paired genomes that is no greater than a threshold (e.g., a threshold of 99.81%, 99.90%, or 99.96%). In some embodiments, functional characteristics include growth rate, acidification rate, and carbohydrate utilization rate, etc. In some implementations, two or more different bacterial isolates (e.g., obtained from different sources, such as different donors) can be combined to generate microbial aggregates.

[0383] As used herein, the terms “bacterial sample” or “microbial sample” refer to a sample containing bacteria. For example, a sample could be vaginal fluid / secretions.

[0384] The term "carbon substrate utilization profile" or "carbon utilization profile" is an indicator (such as a comprehensive measurement or a set of measurements) that reflects the extent to which a bacterial isolate grows or consumes different carbon substrates selected from a set of one or more (or two or more) carbon substrates (such as mannitol and glucose). In some embodiments, a carbon substrate utilization profile includes one or more measurements of growth rate and / or acidification rate during the logarithmic growth phase on two or more carbon substrates.

[0385] The term "comprising" should be understood to also disclose the term "consisting of" as a preferred option. For example, if the composition is stated to contain three components, this also discloses a composition consisting of these three components as a preferred embodiment.

[0386] When the term "comprising" is used to refer to (a) a pharmaceutically active compound, bacteria, etc., it should be understood that the pharmaceutically active compound, bacteria, etc., is preferably the only pharmaceutically active compound, bacteria, etc. is also disclosed. For example, if a microbial aggregate is said to contain *Lactobacillus curlis* and *Lactobacillus janniae*, this simultaneously and preferably indicates that the donor sample contains *Lactobacillus curlis* and *Lactobacillus janniae* as the only bacterial species.

[0387] The term "aggregate" or "microbial aggregate" refers to a mixture of bacteria that does not exist in nature, i.e., it is not naturally occurring and / or synthetic, and possesses novel characteristics that none of the constituent bacteria possesses alone. ("Non-naturally occurring" aggregate).

[0388] "Non-culture method" means a method that does not involve, for example, the isolation and / or in vitro propagation of bacterial isolates in a culture.

[0389] The term "different" or "phenotypic" refers to isolates with different phenotypes. In some embodiments, different or phenotypic isolates have different growth rates. In some embodiments, different or phenotypic isolates have different acidification rates. In some embodiments, different or phenotypic isolates have different carbon substrate utilization profiles. In some embodiments, different or phenotypic isolates have different carbon substrate utilization capabilities.

[0390] The terms “dosage” and “prescription” are used interchangeably herein. A dosage refers to the amount of active ingredient given to an individual at each administration. Dosages will vary depending on a number of factors, including frequency of administration (e.g., once daily, once weekly or more, once monthly or every 3 months); individual size and tolerability; severity of the condition; expected outcome (e.g., treatment, prevention, modulation or restoration of the vaginal microbiota); and route of administration. A baseline dose may be administered first, and then adjusted based on the subject’s initial response. For example, a single dose of the composition described herein, comprising a substantially complete vaginal microbiota preparation, may be available in 10 4 Up to 10 10 Within the range of colony-forming units (per dose). In other embodiments, the single-dose range of the composition may be 10. 3 Up to 10 12 10 4 Up to 10 9 10 5 Up to 10 9 10 5 Up to 10 8 10 6 Up to 10 9 10 7 Up to 10 9 Or 10 7 Up to 10 10 One colony-forming unit (per dose).

[0391] "Dosage form" refers to the specific physical form of a composition or preparation, for example, depending on the required amount of the substance to be applied and the route of administration, such as oral or topical application (e.g., vaginal application). For example, a dosage form can be a suppository, tablet, capsule, film, cream, etc., or a device, such as, for example, an applicator or dispenser, for example, for vaginal application. Dosage forms can be single-use or multiple-use dosage forms.

[0392] As used herein, “dysbiosis” refers to a microbial imbalance, i.e., an abnormality in health where the abundance of a dominant species is reduced, while less dominant species are enriched and / or become dominant. Vaginal dysbiosis refers to an imbalance of the microbiota within the vagina, where, in some embodiments, this imbalance may extend to the endometrium. Dysbiosis is generally associated with one or more of the following: (a) qualitative and quantitative changes in the content or quantity of the microbiota itself; (b) changes in its metabolic activity; and / or (c) changes in its local distribution (e.g., within the microenvironment). The human microbiota (or microbiome) refers to a community of microorganisms that promote inflammation of urogenital tissues (e.g., the vagina) and / or facilitate or establish an environment that allows or promotes the colonization or growth of one or more pathogenic microorganisms. Dysbiosis also refers to a disturbance of homeostasis within the urogenital system (e.g., the vagina). In some implementations, vaginal microbiota dysbiosis typically results in an elevated pH relative to a healthy microbiota, such as a pH above 4.5, or a pH of 5.0, 5.5, 6.0, 6.5, 7.0, or higher. In some implementations, vaginal microbiota dysbiosis is characterized by a reduction in Lactobacillus species and an increase in the diversity of vaginal anaerobic bacteria. In some implementations, vaginal microbiota dysbiosis is associated with an increased risk of infection, inflammation, and sexually transmitted diseases. Microbiota dysbiosis may be characterized by a relative abundance of selected pathogens, such as >20% of selected pathogens, and a relatively low abundance of vaginal lactobacilli, such as <10% of vaginal lactobacilli (Lactobacillus curvatureii, Lactobacillus indolentus, Lactobacillus jansii, Lactobacillus gasseri).

[0393] As used in this article, “dysbiosis subjects” include subjects with vaginal symptoms (symptomatic subjects) and subjects without any vaginal symptoms (asymptomatic subjects), where symptoms are characterized by the Amsel criteria, Nugent score and / or Hay / Ison score.

[0394] Therefore, “expected alterations” to dysbiosis may include prevention and / or treatment of any of the aforementioned symptoms associated with dysbiosis, such as reducing inflammation or infection of the urogenital tract, or restoring and / or rebalancing the vaginal microbiota (e.g., for achieving homeostasis). Expected alterations to dysbiosis may alleviate at least one or more symptoms, delay symptom progression, alter symptom course (e.g., slow symptom progression), or reverse symptoms, wherein symptoms may include an increase in beneficial lactobacilli, a decrease in infection, a reduction in the relative number of specific pathogens, or a reduction in (local) inflammation.

[0395] As used herein, the term "effective dose" means an amount administered to a typical subject (e.g., a female subject) sufficient to produce the desired beneficial or therapeutic effect in that subject (e.g., a microbial aggregate, a single lactobacillus isolate (e.g., Lactobacillus janniae isolate, Lactobacillus curvature isolate), or a related combination). Desired beneficial or therapeutic effects include, for example, prevention and / or treatment of urogenital dysbiosis, inflammation, or infection, and also include restoration and / or rebalancing of the vaginal microbiota (e.g., achieving homeostasis), such as anti-inflammatory and / or antipathogenic status of the urogenital and vaginal microbiota. For example, an effective dose is a dose sufficient to relieve at least one or more symptoms, delay symptom development, alter symptom progression (e.g., slow symptom progression), or reverse symptoms (e.g., at the necessary dose and time). Effective doses typically cause statistically significant, measurable changes.

[0396] As used herein, the terms “implantation” or “colonization” refer to the colonization of a microorganism, such as bacteria (e.g., lactobacilli), in an environment (e.g., a microbial microenvironment or microbial community), such as in the female urogenital tract of a subject, such that a live population of the microorganism continues to reside in the microenvironment or community for a certain period of time (e.g., a predetermined period of time). Microbial implantation can be transient or stable, depending on the duration of the microorganism's residence in the microenvironment. For example, implantation can be quantified by counting colony-forming units (CFU) / gram and / or by nucleic acid sequencing of microorganisms contained in one or more vaginal samples collected over a certain period of time. In some embodiments, successful microbial implantation means that the microorganism colonizes in the environment such that it can be detected in the environment after a specific period of time. In some embodiments, successful microbial implantation means that the microorganism colonizes in the environment such that its relative abundance represents at least 5% or 10% of the total microbial abundance in the environment (e.g., the relative abundance of lactobacilli in the female urogenital tract of a subject represents at least 5% or 10% of the total microbial abundance). In some embodiments, the microbial aggregates of this disclosure facilitate the implantation of at least a subset of a defined population (e.g., at least one lactobacillus isolate) into the female urogenital tract of a subject. In some embodiments, the microbial aggregates of this disclosure facilitate the implantation of a defined population of lactobacilli into the female urogenital tract of a subject. The defined population may include *Lactobacillus japonicus* isolates, *Lactobacillus curvatureii* isolates that grow well in the presence of *Lactobacillus japonicus*, and at least one additional *Lactobacillus curvatureii* isolate that grows well in the absence of *Lactobacillus japonicus*.

[0397] In one embodiment, the term "facilitated implantation" refers to the implantation of *Lactobacillus japonicus* isolates. In one embodiment, the term "facilitated implantation" refers to the implantation of *Lactobacillus curvaturei* isolates that grow well in the presence of *Lactobacillus japonicus*. In one embodiment, the term "facilitated implantation" refers to the implantation of *Lactobacillus curvaturei* isolates that grow well in the absence of *Lactobacillus japonicus*. In one embodiment, the term "facilitated implantation" refers to the implantation of both *Lactobacillus curvaturei* isolates that grow well in the presence of *Lactobacillus japonicus* and *Lactobacillus curvaturei* isolates. In one embodiment, the term "facilitated implantation" refers to the implantation of both *Lactobacillus japonicus* isolates and *Lactobacillus curvaturei* isolates that grow well in the absence of *Lactobacillus japonicus*. In one embodiment, the term "facilitated implantation" refers to the implantation of a defined population (e.g., *Lactobacillus japonicus* isolates, *Lactobacillus curvaturei* isolates that grow well in the presence of *Lactobacillus japonicus*, and *Lactobacillus curvaturei* isolates that grow well in the absence of *Lactobacillus japonicus*).

[0398] As a non-limiting example, *Lactobacillus curvatureensis* that grows well in the presence of *Lactobacillus janniae* can be implanted in the female urogenital tract of a subject in the presence of *Lactobacillus janniae* for at least a predetermined period of time (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 days).

[0399] The term "implantation potential" refers to the potential for implantation in a recipient. In some embodiments, implantation potential refers to the quality of an isolate isolated from a donor SCVMP that has demonstrated successful implantation in a recipient subject. In some embodiments, FBS-003 has implantation potential. In some embodiments, FBS-004 has implantation potential. In some embodiments, FBS-005 has implantation potential. In some embodiments, FBS-006 has implantation potential.

[0400] The terms "balanced microbiota," "microbiota-balanced," and "microbiota-balanced" refer to a healthy vaginal environment in which resident bacteria comprise a high relative abundance of lactobacillus species. A balanced vaginal microbiota is characterized by a relatively high abundance (e.g., greater than 70%, 80%, 90%, or 95%) of healthy vaginal lactobacillus species (Lactobacillus curvularia, Lactobacillus indolentus, Lactobacillus janniae, Lactobacillus gasseri) and a relatively low abundance of selected pathogens. In some embodiments, a balanced microbiota is characterized by a "lactobacillus-dominated" vaginal microbiota. In some embodiments, a balanced microbiota is stable, meaning that the microbiota persists in the vaginal environment for a period of time (e.g., 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or 12 months). In some implementations, the balanced microbial community is stable, meaning that the microbial community persists in the vaginal environment across the menstrual cycle (e.g., 1 menstrual cycle, 2 menstrual cycles, 3 menstrual cycles, 4 menstrual cycles, 5 menstrual cycles, 6 menstrual cycles, or 12 menstrual cycles).

[0401] As used herein, the terms “excipient,” “pharmaceuticalally acceptable carrier,” “diluent,” or “buffer” refer to inactive, pharmaceutically acceptable materials, ingredients, compositions, or mediators that are added to form part of a final formulation and / or to maintain a drug or other agent in the form delivered to the subject. Each carrier is preferably compatible with other components of the formulation, for example, the carrier does not diminish the therapeutic effect of the active ingredient or agent; for example, the carrier is pharmaceutically inert. In some embodiments, a pharmaceutically acceptable carrier may be a carrier other than water (including, for example, creams, lotions, gels, liposomes, nanoparticles, films, ointments, and / or vaginal devices). In some embodiments, a pharmaceutical composition is provided comprising a substantially complete vaginal microbiota preparation and a pharmaceutically acceptable carrier and / or diluent (e.g., physiological saline). These compositions facilitate easy administration of the preparation in a manner known to those skilled in the art. In some embodiments, a buffer, such as a weak acid or weak base, is added to maintain acidity at a selected level (e.g., pH 3.5 to 4.5) and prevent rapid changes in acidity.

[0402] The term "haplotype" refers to a set of heritable DNA variations or polymorphisms, such as single nucleotide polymorphisms (SNPs) or single nucleotide variants (SNVs), located on the same chromosome or within a defined genetic region. In some implementations, haplotypes can be used as a defining indicator for a particular bacterium or isolate.

[0403] The terms “increase,” “enhance,” “enhance,” or “activate” can mean an increase of at least 10% compared to a reference level, such as an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including 100% increase, or any increase between 10 and 100% compared to a reference level, or at least about 2 times, or at least about 3 times, or at least about 4 times, or at least about 5 times, or at least about 10 times, or any increase between 2 and 10 times or greater compared to a reference level.

[0404] As used herein, the term "isolated nucleic acid" refers to nucleic acid purified from one or more cellular components. Isolated nucleic acids can be prepared from a sample using any acceptable method known in the art. For example, cells can be lysed using known lysis agents, and nucleic acids can be purified or partially purified from other cellular components.

[0405] As used in this article, the term "lactic acid-producing bacteria" refers to bacteria that produce lactic acid through fermentation.

[0406] The terms “decline,” “reduction,” “lowering,” “reducing,” “downsizing,” or “inhibition” mean a reduction of at least 10% compared to a reference level, such as at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including 100% (i.e., zero content (or below the detection limit) compared to the reference sample), or any reduction between 10% and 100% compared to the reference level.

[0407] "Freeze-dried," "spray-dried," or "lyophilized" compositions refer to compositions that have had moisture removed, for example, for ease of storage and transport. Such compositions may be rehydrated before use (e.g., application). Freeze-dried, spray-dried, or lyophilized compositions may be further formulated into granules or packages for ease of storage and transport.

[0408] The term “microorganism” is used synonymously with the term “microbe” and includes bacteria (archaea, eubacteria), yeasts, fungi, and viruses. As used herein, the term “species” refers to a taxonomically and / or genetically distinct group of microorganisms. A species may include one or more distinguishable isolates (e.g., by sequencing).

[0409] The term "microbiota" refers to a community of microorganisms residing in different shared environments ("microbial microenvironments"). For example, "vaginal microbiota" refers to a community of one or more microbial species residing in or found within the vagina. The terms "microbial community" or "flora" are used synonymously with the term "microbiota." A healthy or normal microbiota is a symbiotic community of microorganisms that colonizes (inhabits) a specific microbial microenvironment of a host, such as the vagina. Bacteria are the most numerous microbial component of the normal flora. "Microbiota" refers to the sum of microorganisms (bacteria, archaea, yeasts, fungi, and bacteriophages) and their genomes.

[0410] A “microbial atlas” refers to a group of microbial species and / or isolates present in a microbial sample. With respect to microbial samples obtained from species discovered in a shared environment, a microbial atlas provides a detailed description of the species present in a microbial community. As used herein, the term “atlas” can refer to either a single atlas or a summary atlas of multiple single atlases, depending on the context of its use. In some embodiments, a summary atlas may include, for example, a pan-genome (sequence), such as all genes (or genomes) of all individual members (e.g., isolates) within a specific group (e.g., clade).

[0411] As used in this article, "mucosa" refers to the mucous membrane. Mucus is a secretion produced by and covering the mucous membrane. Mucus is viscous and is typically produced by mucous cells (such as goblet cells) found in the mucous membrane and submucosal glands. It is rich in antimicrobial enzymes (such as lysozyme), immunoglobulins, inorganic salts, proteins such as lactoferrin, and glycoproteins (mucins). The mucosal surface includes the epithelial layer of the reproductive tract (vaginum), for example, lactobacilli can colonize the vaginal mucosal surface.

[0412] In contrast, terms like "normal" or "healthy," "vaginal flora" or "vaginal microenvironment," "microbiota," "urogenital tract" or "community status," or similar terms, refer to a woman who has no vaginal discomfort and does not exhibit vaginal lesions (e.g., no signs or symptoms corresponding to or caused by vaginal lesions), whose vaginal condition is relatively low in susceptibility to sexually transmitted diseases and pathogens, and who typically has a low pH, such as a pH below or equal to 4.5, for example, between 3.2 and 4.5; and who is typically dominated by lactic acid-producing bacteria (e.g., Lactobacillus). Normal vaginal flora or normal flora refers to the microbial community located in the vagina in a normal, healthy state (i.e., non-pathological, non-pathogenic, and / or non-dysbiosis state).

[0413] "Cervical and vaginal secretions" or "vaginal fluid" refers to a mixture of cervical mucus, shed epithelial cells, vaginal exudate, and bacteria found in the female vagina.

[0414] "Endometrial fluid" refers to the fluid that accumulates within the uterine cavity, containing bacterial cells, host cells, and proteins, nucleotides, and metabolites of microbial and host origin. Endometrial fluid is typically obtained by aspiration for further analysis.

[0415] As used herein, “nucleic acid” includes DNA and RNA (e.g., mRNA, rRNA, or tRNA) and their analogues, including nucleic acids containing conventional nitrogenous bases (e.g., A, G, C, T, U), base analogues (e.g., inosine), purine or pyrimidine base derivatives, and any substituents.

[0416] "Proportionally equal" means a combination of isolates in which the proportion of each isolate is approximately equal, or the relative abundance of each isolate is approximately the same as that of the other isolates. The proportion of isolates in a polymer can be determined by measuring CFU, qPCR, dry weight, or volume. In some embodiments, a polymer containing two isolates will contain approximately 50% of each isolate. In some embodiments, a polymer containing three isolates will contain approximately 33% of each isolate. In some embodiments, a polymer containing four isolates will contain approximately 25% of each isolate.

[0417] As used herein, "sequence identity" or "identity percentage" when applied to nucleic acid molecules refers to the percentage of nucleic acid residues in a candidate nucleic acid molecule sequence that are identical to the target nucleic acid molecule sequence after sequence alignment to achieve the maximum identity percentage, and any substitution of nucleic acid residues is not considered part of sequence identity. Nucleic acid sequence identity can be determined using any method known in the art, such as CLUSTALW, T-COFFEE, BLASTN.

[0418] As used herein, the “sequence identity percentage” is a value determined by comparing two optimally aligned sequences on a comparison window, where a portion of the polynucleotide sequence in the comparison window may contain additions or deletions (i.e., vacancies) compared to a reference sequence (which does not contain additions or deletions) for optimal alignment of the two sequences. This percentage is calculated as follows: the number of identical nucleic acid bases or amino acid residues in the two sequences is determined to produce a number of matching positions; this number of matching positions is divided by the total number of positions in the comparison window, and the result is multiplied by 100 to obtain the sequence identity percentage.

[0419] As used herein, the term “substantial identity” of a polynucleotide sequence means that the polynucleotide contains a sequence having at least about 95% identity with a given reference sequence. The identity percentage can be any value from 90% to 100%. Most embodiments include at least: using the procedure described herein (e.g., BLAST, using standard parameters), achieving 95%, 96%, 97%, 98%, 99%, or 99.9% identity with the reference sequence.

[0420] The term "subject" refers to a person (e.g., a human female). In one embodiment, the subject is a person aged 18 years or older. In one embodiment, the subject is in puberty. In one embodiment, the subject is pregnant. In one embodiment, the subject is of reproductive age. In one embodiment, the subject is premenopausal. In one embodiment, the subject is postmenopausal. In one embodiment, the subject is administered the microbial conglomerate described herein, a single lactobacillus isolate (e.g., Lactobacillus janniae isolate, Lactobacillus curvature isolate), or a related composition. In some embodiments, the subject is a human female exhibiting a clinical condition associated with microbial imbalance (e.g., dysbiosis).

[0421] The term "substantially" means to a great extent or significantly. For example, in the case of a sample that is "substantially free" of pathogens, the term means that the sample is mostly or substantially free of pathogens, but may not be completely free. A sample that is substantially free of selected pathogens can mean a sample containing about 5%, <5%, <4%, <3%, <2%, or <1% of the selected pathogens. In a specific implementation, the term "substantially free" means containing <5%.

[0422] As used in this article, “suitable nutrient medium” refers to a culture medium in which bacteria can be cultured.

[0423] As used herein, the terms “treatment,” “care,” and “treatment” refer to preventative and therapeutic care aimed at preventing, reversing, alleviating, improving, suppressing, slowing, or stopping the progression or severity of a condition or symptom associated with a disease or illness. Treatment includes improving symptoms or indicators of a disease or illness, and stopping or at least slowing the progression or worsening of symptoms that would be expected without treatment. The effectiveness of treatment can be measured by monitoring one or more symptoms or clinical markers, for example, by comparing the subject’s condition and symptoms before administration, or by comparing them to untreated control subjects. In one instance, treating a vaginal infection means reducing the amount of infectious agents (e.g., the number of cells or viral particles), reducing the severity of symptoms, and / or reducing the frequency of symptom occurrence. Treatment that reduces pathogen levels to levels controlled by the immune system or a healthy vaginal microbiota (e.g., the infection is no longer detectable, for example, by symptoms or general diagnostic techniques) is considered effective, as used herein.

[0424] As used herein, the term "urogenital tract" or "urogenital system" includes the uterus, fallopian tubes, ovaries, vagina, cervix, vulva, and urethra. In some cases, the teachings and examples used herein specifically refer to "vaginal tract," "vaginal cavity," "vaginal canal," or "vagina." Those skilled in the art will understand that these examples and teachings are exemplary only and not limiting, and therefore, where appropriate, apply to other anatomical locations of the urogenital tract or urogenital system, not just the vagina.

[0425] As used herein, the term "live" refers to cells (e.g., bacterial cells) that are capable of surviving under given conditions (e.g., storage under specific storage conditions for a period of time, including temperature and humidity) and are generally capable of colonizing and multiplying (e.g., within the urogenital tract) upon exposure to those conditions. Viability percentage refers to the percentage of live cells in a population. For example, viability percentage could refer to the percentage of viable (e.g., refrigerated, frozen, and / or stored) lactobacilli in a pharmaceutical composition that colonize after application to the vaginal mucosa. Viability can be assessed using methods such as CFU, VCC, or Bactobox. In the CFU method, a series of dilutions of the sample are plated onto a suitable culture medium for the target microorganism and then incubated at an appropriate temperature for a period of time before the number of colonies is counted. In the VCC method, the sample is stained with a live / dead staining agent and then counted, for example, in a counting chamber. The live / dead staining agent can be a fluorescent dye that stains cells with damaged cell membranes (and therefore reduced or lost viability) red and intact (live) cells green. In the Bactobox method, total particles / ml and viable intact cell concentration (ICC) were counted using impedance flow cytometry, with culture initiated at approximately 5 million CFU / ml using only ICC.

[0426] The abbreviation "CFU" stands for "colony forming unit".

[0427] The abbreviation "VCC" refers to a live cell count (as determined by live cell staining).

[0428] Example This technology is further illustrated by the following embodiments, which should not be construed as limiting in any way. The embodiments provided herein are intended to illustrate the advantages of this technology and further assist those skilled in the art in preparing or using compositions and systems based on this technology. The embodiments should in no way be construed as limiting the scope of this technology, which is defined by the appended claims. These embodiments may include or combine any variations, aspects, or embodiments of the technology described above. The variations, aspects, or embodiments described above may further each include or incorporate any and all other variations, aspects, or embodiments of the technology.

[0429] On one hand, the following embodiments describe the inventors' development and characterization of a previously unknown bacterial aggregate that can be administered to women as a live biotherapy product to address and / or treat vaginal flora imbalance, thereby improving overall vaginal health. As described and demonstrated in the various embodiments presented herein, a microbial aggregate was developed using three phylogenetically distinct *Lactobacillus curvaturei* isolates and one *Lactobacillus janniae* isolate, each isolate being identified from a healthy donor vaginal environment dominated by stable *Lactobacillus* and stably implanted in subjects presenting with vaginal flora imbalance via vaginal microbiota transplantation (VMT). As discussed in the embodiments, the isolates are phenotypically characterized by various properties, including growth rate, acidification rate, and carbohydrate utilization at one or more pH characteristics associated with an dysbiotic vaginal environment, and were compared with the characteristics of a four-member aggregate and two- and three-isolated versions of the four-member aggregate. Overall, the data show that these isolates work synergistically to exhibit the characteristics and colonization activity required for successful and robust implantation in the host vagina with dysbiosis, making them effective as in vivo biotherapy products to help women treat vaginal dysbiosis and related conditions.

[0430] Example 1. Isolating bacterial isolates from the vaginal environment of a healthy donor with a balanced flora for the construction of therapeutic multi-functional... Microbial aggregates of isolated strains This embodiment describes how to isolate a single lactobacillus isolate from a substantially complete vaginal microbiota preparation (SCVMP) derived from a healthy female donor. Figure 1 A diagram is provided.

[0431] SCVMP derived from a single healthy female donor was administered into the female urogenital tract of the recipient subject.

[0432] To initiate the isolation process, the microbial composition of the SCVMP was analyzed at the species and haplotype levels. The isolation procedure aimed to maximize the number of isolated lactobacilli, excluding inert lactobacilli. MRS medium was used for all lactobacillus species. The minimum number of colonies was selected based on the haplotypes found in the microbial community: three colonies were selected for each major haplotype (relatively abundant), and five colonies were selected for each minor haplotype (relatively less abundant). This method ensures that the number of colonies selected reflects the diversity in the preparation, thus maximizing the number of isolated lactobacilli. Typically, three colonies were selected for each morphology. If the number of morphologies was less than the number of haplotypes, more colonies were selected.

[0433] The starting point for isolation is a 50 µL aliquot of SCVMP. A series of SCVMP dilutions are plated onto selected media (chosen based on species present in the sequencing analysis) and incubated for 3 days at 37°C in an anaerobic chamber with a gas pack. All plates are counted and closely observed to identify distinct colony morphologies. All work is performed under aseptic conditions. Individual colonies are described, picked, and transferred to new plates of the same medium and incubated under the same conditions until pickable colonies are observed (usually 1–3 days). After growth on a second plate, colonies are described again and transferred to a third plate in the same manner. If colony morphology is impure, a new lineage is established. After growth on a third plate, individual colonies are transferred to a liquid medium of the same type as the plate. The liquid culture is incubated at 37°C in an anaerobic chamber with a gas pack. After growth is complete (usually 1–5 days), a glycerol stock solution is prepared, pH is measured, and aliquots are taken for DNA extraction and sequencing.

[0434] The genome of a single isolate is compared to the original metagenomic genome of the donor sample from which the isolate originated. If this indicates th...

Claims

1. A microbial aggregate comprising a defined population of isolated lactobacilli, said defined population comprising: (a) An isolate of Lactobacillus janniae obtained from a bacterial sample deposited under DSM accession number 34770; (b) Lactobacillus curlis isolate obtained from a bacterial sample deposited under DSM accession number 34772; (c) *Lactobacillus curvatureii* isolates obtained from a bacterial sample deposited under DSM accession number 34771, and (d) Lactobacillus curlis isolate obtained from a bacterial sample deposited under DSM accession number 34773.

2. A microbial aggregate comprising a defined population of isolated lactobacilli, said defined population comprising: (a) The percentage of Lactobacillus janniae isolates whose genomes are greater than or equal to a threshold when compared with the genomes of bacterial samples deposited in DSM 34770. (b) The percentage of Lactobacillus curlis isolates whose genomes are identical to the genomes of bacterial samples deposited in DSM 34771 when compared with a threshold. (c) The percentage of genome identity of Lactobacillus curlis isolates when compared with the genome of bacterial samples deposited in DSM 34772 that is greater than or equal to a threshold; and (d) The percentage of Lactobacillus curlis isolates whose genomes are identical to the genomes of bacterial samples preserved in DSM 34773 with a threshold greater than or equal to the threshold.

3. The microbial aggregate as claimed in claim 2, wherein the threshold values ​​of (a), (b), (c) and / or (d) are 99.81%.

4. The microbial aggregate of claim 2, wherein the threshold values ​​of (a), (b), (c) and / or (d) are 99.90%.

5. The microbial aggregate of claim 2, wherein the threshold values ​​of (a), (b), (c) and / or (d) are 99.96%.

6. The microbial aggregate as claimed in any of the preceding claims, wherein the isolate of (a) is derived from or propagated from a bacterial sample preserved in DSM 34770.

7. The microbial aggregate as claimed in any of the preceding claims, wherein the isolate of (b) is derived from or propagated from a bacterial sample preserved in DSM 34771.

8. The microbial aggregate as claimed in any of the preceding claims, wherein the isolate in (c) is derived from or propagated from a bacterial sample preserved in DSM 34772.

9. The microbial aggregate as claimed in any of the preceding claims, wherein the isolate in (d) is derived from or propagated from a bacterial sample preserved in DSM 34773.

10. The microbial community as described in any of the preceding claims, wherein the defined community is configured to facilitate implantation into the female urogenital tract of the subject.

11. The microbial aggregate of claim 10, wherein at least one of the lactobacilli is capable of implanting into the female urogenital tract of the subject for at least a predetermined period of time.

12. The microbial aggregate as described in any of the preceding claims, wherein the defined population of isolated lactobacilli comprises: The relative abundance of the total live cells is 15% to 35% of the bacteria of the Lactobacillus janniae isolate (a); The relative abundance of the total live cells is 15% to 35% of the bacteria in (b) the Lactobacillus curvature isolate; The relative abundance of the total viable cells is 15% to 35% of the bacteria in (c) of the *Lactobacillus curvatureii* isolate; and The relative abundance of the total live cells is 15% to 35% of the bacteria of the *Lactobacillus curvatureii* isolate (d).

13. The microbial aggregate as described in any of the preceding claims, wherein the defined population of isolated lactobacilli comprises: The relative abundance of the total live cells is approximately 25% of the bacteria in (a) of the Lactobacillus janniae isolate; The relative abundance of the total live cells is approximately 25% of the bacteria in (b) of the Lactobacillus curvature isolate; The relative abundance of the total viable cells is approximately 25% of the bacteria in (c) of the *Lactobacillus curvatureii* isolate; and The relative abundance of the total live cells is approximately 25% of the bacteria in the *Lactobacillus curvatureii* isolate (d).

14. The microbial aggregate as described in any of the preceding claims, wherein: (a) The Lactobacillus janus isolates described herein contain multiple Lactobacillus janus strains; (b) The *Lactobacillus curvaturei* isolates contain a variety of *Lactobacillus curvaturei*; (c) The *Lactobacillus curvaturei* isolates contain a variety of *Lactobacillus curvaturei*; and (d) The *Lactobacillus curvaturei* isolates contain a variety of *Lactobacillus curvaturei*.

15. The microbial aggregate as claimed in any of the preceding claims, wherein the *Lactobacillus curvaturei* isolate of (b) grows well in the presence of *Lactobacillus janniae*.

16. The microbial aggregate as described in any of the preceding claims, wherein the *Lactobacillus curvaturei* isolates of (c) and / or (d) grow well independently of the presence of *Lactobacillus janniae*.

17. The microbial aggregate as claimed in any of the preceding claims, wherein at least two of the lactobacilli differ in their growth rates.

18. The microbial aggregate of claim 17, wherein the Lactobacillus janniae and at least one Lactobacillus curvature differ in their growth rates.

19. The microbial aggregate of claim 17 or 18, wherein at least two types of *Lactobacillus curvatureii* differ in their growth rates.

20. The microbial aggregate of any one of claims 17-19, wherein the growth rate is an in vitro (e.g., in a culture) and / or in vivo growth rate.

21. The microbial aggregate as described in any of the preceding claims, wherein the *Lactobacillus janniae* grows at an initial pH of 4.7 for 0.32-0.36 hours. -1 Or at an initial pH of 5.2, for 0.41–0.43 hours. -1 .

22. The microbial aggregate as claimed in any of the preceding claims, wherein the growth rate of the *Lactobacillus curvatureii* isolate of (b) is 0.35-0.41 hours at an initial pH of 4.

7. -1 Or at an initial pH of 5.2, for 0.39–0.41 hours. -1 .

23. The microbial aggregate as claimed in any of the preceding claims, wherein the growth rate of the *Lactobacillus curvatureii* isolate in (c) is 0.27-0.29 hours at an initial pH of 4.

7. -1 Or at an initial pH of 5.2, for 0.35–0.37 hours. -1 .

24. The microbial aggregate as claimed in any of the preceding claims, wherein the growth rate of the *Lactobacillus curvatureii* isolate in (d) is 0.24-0.26 hours at an initial pH of 4.

7. -1 Or at an initial pH of 5.2, for 0.31–0.33 hours. -1 .

25. The microbial aggregate as claimed in any of the preceding claims, wherein at least two of the lactobacilli differ in their acidification rates.

26. The microbial aggregate of claim 25, wherein the Lactobacillus janniae and at least one Lactobacillus curvature differ in their acidification rates.

27. The microbial aggregate of claim 25 or 26, wherein at least two types of *Lactobacillus curvature* differ in their acidification rates.

28. The microbial aggregate of any one of claims 25-27, wherein the acidification rate is an in vitro (e.g., in a culture) and / or in vivo acidification rate.

29. The microbial aggregate as claimed in any of the preceding claims, wherein the acidification rate of said *Lactobacillus janniae* is -0.005 to -0.003 at an initial pH of 4.7, or -0.009 to -0.007 at an initial pH of 5.

2.

30. The microbial aggregate as claimed in any of the preceding claims, wherein the acidification rate of the Lactobacillus curvature isolate of (b) is -0.009 to -0.007 at an initial pH of 4.7, or -0.012 to -0.010 at an initial pH of 5.

2.

31. The microbial aggregate as claimed in any of the preceding claims, wherein the acidification rate of the *Lactobacillus curvatureii* isolate in (c) is -0.007 to -0.005 hours at an initial pH of 4.

7. -1 Or at an initial pH of 5.2, for -0.008 to -0.006 hours. -1 .

32. The microbial aggregate as claimed in any of the preceding claims, wherein the acidification rate of the *Lactobacillus curvatureii* isolate in (d) is -0.008 to -0.006 hours at an initial pH of 4.

7. -1 Or at an initial pH of 5.2, for -0.012 to -0.010 hours. -1 .

33. The microbial aggregate as claimed in any of the preceding claims, wherein at least two of the lactobacilli differ in their ability to degrade glycogen.

34. The microbial aggregate of claim 33, wherein the Lactobacillus janniae and at least one Lactobacillus curvature differ in their ability to degrade glycogen.

35. The microbial aggregate of claim 33 or 34, wherein at least two types of *Lactobacillus curvatureii* differ in their ability to degrade glycogen.

36. The microbial aggregate of any one of claims 33-35, wherein the ability to degrade glycogen is the ability to degrade glycogen in vitro (e.g., in a culture) and / or in vivo.

37. The microbial aggregate as claimed in any of the preceding claims, wherein at least two of the lactobacilli differ in their lactic acid production rates.

38. The microbial aggregate of claim 37, wherein the Lactobacillus janniae and at least one Lactobacillus curvature differ in their lactic acid production rates.

39. The microbial aggregate of claim 37 or 38, wherein at least two types of *Lactobacillus curvatureii* differ in their lactic acid production rates.

40. The microbial aggregate of any one of claims 37-39, wherein the lactate production rate is the in vitro (e.g., in culture) and / or in vivo lactate production rate.

41. The microbial aggregate as claimed in any of the preceding claims, wherein at least two of the lactobacilli differ in their rate of implantation into the female urogenital tract.

42. The microbial aggregate of claim 41, wherein the Lactobacillus janniae and at least one Lactobacillus curvature differ in their rate of implantation into the female urogenital tract.

43. The microbial aggregate of claim 41 or 42, wherein at least two types of *Lactobacillus curvatureii* differ in their rate of implantation into the female urogenital tract.

44. The microbial aggregate of any one of claims 41-43, wherein the rate of implantation into the female urogenital tract is determined in vivo.

45. The microbial aggregate as claimed in any of the preceding claims, wherein at least one of the lactobacilli is capable of being implanted into the female urogenital tract of the subject within 24 hours after administration to the subject.

46. ​​The microbial aggregate as claimed in any of the preceding claims, wherein at least one of the lactobacilli is capable of persisting in the female urogenital tract of the subject for at least 4 days after administration to the subject.

47. The microbial aggregate of claim 46, wherein two, three, or four of the lactobacilli are capable of persisting in the female urogenital tract of the subject for at least four days after administration to the subject.

48. The microbial aggregate as claimed in any of the preceding claims, wherein the lactobacilli in the aggregate are capable of competing with the resident microbiota in the female urogenital tract of the subject.

49. The microbial aggregate as claimed in any of the preceding claims, wherein each of the lactobacilli in the aggregate is obtained from a healthy human donor.

50. A microbial community as claimed in any of the preceding claims, wherein the lactobacilli included in the defined community are obtained from at least two different healthy human donors.

51. The microbial community as described in any of the preceding claims, wherein the lactobacilli included in the defined community were obtained from three different healthy human donors.

52. The microbial aggregate as claimed in any of the preceding claims, wherein the Lactobacillus janniae isolate and Lactobacillus curvature isolate that grow well in the presence of Lactobacillus janniae are obtained from different healthy human donors.

53. The microbial aggregate as claimed in any of the preceding claims, wherein the Lactobacillus curvature isolate in (c) and the Lactobacillus curvature isolate in (d) are both obtained from the same healthy human donor.

54. A method for increasing the relative abundance of lactobacilli in the female urogenital tract of a subject, the method comprising applying a microbial aggregate as described in any one of claims 1-53 to the urogenital tract of the subject.

55. The method of claim 54, wherein the subject’s female urogenital tract comprises a bacterial community having a relative abundance of less than 90% (e.g., less than 80%, 70%, 60%, 50%, 40%, 30%, or 20%) of the total bacterial community prior to application of the microbial aggregate.

56. The method of claim 54 or 55, wherein the female urogenital tract of the subject comprises a bacterial community having a relative abundance of more than 70% (e.g., more than 80%, 85%, 90%, 95%, or 98%) of the total bacterial community after administration of the microbial aggregate.

57. The method of claim 54 or 55, wherein after administration of the microbial aggregate, the relative abundance of lactobacilli in the bacterial population of the female urogenital tract of the subject increases by at least 5 percentage points (e.g., at least 10, 15, 20, 25, 30, 40, 50, or 60 percentage points).

58. The microbial aggregate as described in any one of claims 1-53, for use in therapy.

59. The microbial aggregate of any one of claims 1-53, a method for treating dysbiosis of the female urogenital tract of a subject, the method comprising applying the microbial aggregate to the urogenital tract of the subject, optionally wherein the subject is asymptomatic.

60. The microbial conglomerate of claim 59, wherein the subject’s female urogenital tract comprises a bacterial community having a relative abundance of less than 90% (e.g., less than 80%, 70%, 60%, 50%, 40%, 30%, or 20%) of the total bacterial community prior to application of the microbial conglomerate.

61. The microbial conglomerate used as described in claim 59 or 60, wherein the female urogenital tract of the subject comprises a bacterial population having a relative abundance of more than 70% (e.g., more than 80%, 85%, 90%, 95%, or 98%) of the total bacterial population after application of the microbial conglomerate.

62. The microbial aggregate used as described in claim 59 or 60, wherein after application of the microbial aggregate, the relative abundance of lactobacilli in the bacterial population of the female urogenital tract of the subject increases by at least 5 percentage points (e.g., at least 10, 15, 20, 25, 30, 40, 50, or 60 percentage points).

63. A composition comprising an isolate of *Lactobacillus japonicus* obtained from a bacterial sample deposited under DSM accession number 34770.

64. A composition comprising an isolate of Lactobacillus curvature obtained from a bacterial sample deposited under DSM accession number 34772.

65. A composition comprising an isolate of Lactobacillus curvature obtained from a bacterial sample deposited under DSM accession number 34771.

66. A composition comprising an isolate of Lactobacillus curvature obtained from a bacterial sample deposited under DSM accession number 34773.

67. A composition comprising two or more lactobacilli selected from: (a) An isolate of Lactobacillus janniae obtained from a bacterial sample deposited under DSM accession number 34770; (b) Lactobacillus curlis isolate obtained from a bacterial sample deposited under DSM accession number 34772; (c) *Lactobacillus curvatureii* isolates obtained from a bacterial sample deposited under DSM accession number 34771, and (d) Lactobacillus curlis isolate obtained from a bacterial sample deposited under DSM accession number 34773.

68. A composition comprising an isolate of *Lactobacillus janniae*, the genome of which has a percentage of identity greater than or equal to a threshold when compared with the genome of a bacterial sample deposited in DSM34770.

69. A composition comprising a *Lactobacillus curlis* isolate, wherein the genome of the *Lactobacillus janniae* isolate has a percentage of identity greater than or equal to a threshold when compared with the genome of a bacterial sample deposited in DSM34771.

70. A composition comprising a *Lactobacillus curlis* isolate, wherein the genome of the *Lactobacillus janniae* isolate has a percentage of identity greater than or equal to a threshold when compared with the genome of a bacterial sample deposited in DSM34772.

71. A composition comprising a *Lactobacillus curlis* isolate, wherein the genome of the *Lactobacillus janniae* isolate has a percentage of identity greater than or equal to a threshold when compared with the genome of a bacterial sample deposited in DSM34773.

72. A composition comprising two or more lactobacilli selected from the following: (a) The percentage of Lactobacillus janniae isolates whose genomes are greater than or equal to a threshold when compared with the genomes of bacterial samples deposited in DSM 34770. (b) The percentage of Lactobacillus curlis isolates whose genomes are identical to the genomes of bacterial samples deposited in DSM 34771 when compared with a threshold. (c) The percentage of genome identity of Lactobacillus curlis isolates when compared with the genome of bacterial samples deposited in DSM 34772 that is greater than or equal to a threshold; and (d) The percentage of Lactobacillus curlis isolates whose genomes are identical to the genomes of bacterial samples preserved in DSM 34773 with a threshold greater than or equal to the threshold.

73. The composition of any one of claims 68-72, wherein the threshold is 99.81%, 99.90%, or 99.96%.

74. A pharmaceutical composition comprising a microbial aggregate as claimed in any one of claims 1-53 or a composition as claimed in any one of claims 63-73, and a pharmaceutically acceptable buffer, diluent, or excipient.

75. A method for increasing the relative abundance of lactobacilli in the female urogenital tract of a subject, the method comprising administering to the subject's urogenital tract a microbial aggregate as described in any one of claims 1-53, a composition as described in any one of claims 63-73, or a pharmaceutical composition as described in claim 74.

76. The method of claim 75, wherein the female urogenital tract of the subject comprises a bacterial community having a relative abundance of less than 90% (e.g., less than 80%, 70%, 60%, 50%, 40%, 30%, or 20%) of the total bacterial community prior to application of the microbial aggregate.

77. The method of claim 75 or 76, wherein the female urogenital tract of the subject comprises a bacterial community having a relative abundance of more than 70% (e.g., more than 80%, 85%, 90%, 95%, or 98%) of the total bacterial community after administration of the microbial aggregate.

78. The method of any one of claims 75-77, wherein after administration of the microbial aggregate, the relative abundance of lactobacilli in the bacterial population of the female urogenital tract of the subject increases by at least 5 percentage points (e.g., at least 10, 15, 20, 25, 30, 40, 50, or 60 percentage points).

79. The microbial aggregate of any one of claims 1-53, the composition of any one of claims 63-73, or the pharmaceutical composition of claim 74, for use in therapy.

80. A method of treating female urogenital dysbiosis in a subject, comprising applying the microbial aggregate to the urogenital tract of the subject, optionally wherein the subject is asymptomatic.

81. A method of treating inflammation of a female urogenital tract in a subject using a microbial aggregate as described in any one of claims 1-53, a composition as described in any one of claims 63-73, or a pharmaceutical composition as described in claim 74, the method comprising applying the microbial aggregate to the urogenital tract of the subject, optionally wherein the subject is asymptomatic.

82. The microbial aggregate, composition, or pharmaceutical composition used as described in claim 80 or 81, wherein the female urogenital tract of the subject comprises a bacterial population having a relative abundance of less than 90% (e.g., less than 80%, 70%, 60%, 50%, 40%, 30%, or 20%) of the total bacterial population prior to administration of the microbial aggregate.

83. The microbial aggregate, composition, or pharmaceutical composition used as described in any one of claims 80-82, wherein: The female urogenital tract of the subject contained a bacterial community having a relative abundance of more than 70% (e.g., more than 80%, 85%, 90%, 95%, or 98%) of lactobacilli after administration of the microbial conglomerate; or After administration of the microbial aggregate, the relative abundance of lactobacilli in the bacterial population of the female urogenital tract of the subject increased by at least 5 percentage points (e.g., at least 10, 15, 20, 25, 30, 40, 50 or 60 percentage points).

Citation Information

Patent Citations

  • Lactobacillus crispatus composition for use in pregnant subjects

    EP4294417A1

  • Improved support for tables

    US106109A

  • Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension

    US20020164629A1

  • Methods and apparatus for measuring analytes using large scale FET arrays

    US20090026082A1

  • Surface-capture of target nucleic acids

    US20090156412A1